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Sophie Grace Scrivener 
B-cell chronic lymphocytic leukaemia (B-CLL) is characterized by an accumulation of 
clonal malignant B cells within lymphoid tissue, the bone marrow and the peripheral 
blood. Whilst abnormalities of these B cells are the essential cause of this disease, the aim 
of this research project was to investigate whether the T cell compartment may play a role 
in the aetiology of this disease by evaluating the expression of key surface antigens 
involved in both activation of and interaction with B cells and other antigen presenting 
cells of the immune system. There were marked abnormalities in the expression of certain 
key activation and interaction antigens on the peripheral blood T cells of patients with B-
CLL, in particular, compared to normal controls, there was a significant reduction in the 
number of circulating T cells expressing CD25, CD28, CD 152, CD4, CD5 and CD 11 a. 
There was no difference in expression of TCRap, CD8, CD54 and CD154. Significantly 
more T cells from CLL patients expressed HLA-DR. Removal of the malignant clone of 
cells prior to short-term T cell culture did not affect expression of these markers. Numbers 
ofT cells expressing intracellular CD25 and CD 152 were not decreased after activation 
and a significantly greater number of resting T cells expressed both antigens 
intracellularly. There was also evidence of a soluble factor present in CLL AB serum 
which caused increased numbers of normal and CLL T cells to express CD25 and CD 152 
after culture. Initial results suggest that this may be IFN-y, levels of which were 
significantly higher, as measured by ELISA, from resting CLL T cells compared to 
normals. By studying the expression of these antigens using cell culture, flow cytometric 
and ELISA techniques, the results suggest a functional state of anergy in these T cells. This 
anergic state may contribute to the pathogenesis of B-CLL and its related phenomena of 
immu~osuppression and autoimmunity. This was further reflected in the results of the T 
Ill 
cell functional studies and reduced IL-2 expression in the mixed lymphocyte reaction 
(MLR). 
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CHAPTER ONE: INTRODUCTION 
1.0 Leukaemia 
Leukaemia arises when a single cell in the bone marrow or lymphoid tissue undergoes 
neoplastic change and starts to proliferate and accumulate. Leukaemia can be classified in 
two different ways, depending on the type of precursor cell that becomes malignant (either 
lymphoid or myeloid) and how quickly the disease develops (acute or chronic). Cellular 
origins of the leukaemias are shown in figure 1. Acute leukaemias consist predominantly of 
immature cells, usually blast forms and the clinical features of the disease worsen as the 
number of blasts rapidly increases. Acute leukaemias include acute lymphoblastic 
leukaemia, the most common type of leukaemia in young children and acute myeloblastic 
leukaemia, affecting both adults and children. The chronic leukaemias consist of more 
mature cells, some of which are able to perform some normal functions. Chronic 
leukaemias include chronic lymphocytic leukaemia which is predominantly found in the 
elderly, sometimes in younger adults but very rarely in children, and chronic myeloid 
leukaemia which occurs mainly in adults, but does affect a small number of children. 
Classifications of the different forms ofleukaemia are shown in table I. 
1.1 B-cell Chronic Lymphocytic Leukaemia (B-CLL) 
In 1967, William Dameshek wrote of the "immunoproliferative disorder" B-CLL as " ... an 
accumulative disease of immunologically incompetent lymphocytes" (Dameshek W 1967). 
This was a more detailed description that followed from Turk's initial identification of the 
disease in 1903 and Minot and Isaacs clinical explanations in 1924. 
TABLE 1: Classification of Leukaemia 
TYPE OF POSSIBLE CELLULAR 
LEUKAEMIA ORIGIN 
common acute lymphoblastic leukaemia lymphoid progenitor cell 
(cALL) 
pre-B acute lymphoblastic leukaemia pre-B cell 
(pre-B ALL) 
B-cell acute lymphoblastic leukaemia B cell 
(B-ALL) 
acute myeloblastic leukaemia myeloid precursor cells 
(AML) 
chronic lymphocytic leukaemia mantle zone/follicular 
(CLL) mature B cell 
chronic myeloid leukaemia pluripotent stem cell 
(CML) 
multiple myeloma plasma cell 
(MM) 
hairy cell leukaemia mature B cell 
(HCL) 
Table showing the classification of the different forms of leukaemia and the possible origin of the "nonnal" 
cellular counterpart from which the leukaemic cell may have arisen 
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Fig. 1 Cellular origins of Leukaemia 
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Figure showing the cellular origin of each 
different type of leukaem ia. Normal cellular 
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Many ofthe clinical and haematological features ofB-CLL described by these physicians 
remain pertinent. 
1.1.1 Aetiology 
B-cell Chronic Lymphocytic Leukaemia (B-CLL) is characteristically a disease of the 
elderly, with approximately 90% of all patients over the age of SO at diagnosis (Whittaker 
JA 1992; Montserrat E 2001). This does not rule out younger cases, which have been 
reported in patients less than twenty years of age and even in childhood (Casey TP 1968). 
The male: female ratio is highest in this form of leukaemia with two males affected for every 
one female (Zaknoen SL and Kay NE 1990). B-CLL is the most common form of 
leukaemia seen in Western countries 
(Kipps TJ 1997; Thompson AA et al 1999; Sakai A et al 2000), with 30 - 40% of all 
leukaemias diagnosed being B-CLL (Dierlamm J et al 1997). There are dramatic differences 
between ethnic groups; B-CLL is virtually absent in Japan and Africa, whilst those of Jewish 
origin display a two-fold greater risk than other western countries (Caligaris-Cappio F 
1997). 
There has also been much speculation as to a link between certain occupations and the risk 
of developing B-CLL. In stark contrast to other types of leukaemia, B-CLL is the only one 
that has not been related to exposure to radiation (Caligaris-Cappio F and Hamblin T J 
1999). For reasons that remain unclear, B-CLL has been associated with farmers who work 
with high levels of soybean production, cattle raising, dairy produce and herbicides. A 
greater risk is also associated with those individuals who work in rubber manufacturing and 
asbestos production (Dighiero G et al 1991 ). However, there is no clear link established 
between CLL and exposure to known environmental agents (Caligaris-Cappio F et al2001). 
Familial CLL, where relatives of patients with CLL have an increased risk of developing the 
disease, suggests that a subset of CLL cases may have an inherited basis. In familial cases of 
4 
CLL, the mean age at diagnosis was shown to be approximately I 0 years younger than that 
seen in sporadic cases (Ishibe N et al 2001 ). The genetic predisposition towards familial 
CLL is poorly understood. Familial CLL and sporadic CLL are indistinguishable in their 
morphology, immunophenotype and VH gene mutations from non-familial cases (Sakai A et 
a12000). 
1.1.2 Clinical diagnosis 
Patients may have the disease for many years before it is diagnosed. As the name suggests, 
it is a chronic condition, which is slowly progressive until symptoms become noticeable, or, 
as with many asymptomatic elderly patients, it becomes apparent during a routine blood 
test. Symptoms of B-CLL vary amongst individuals, with at least 20% of patients displaying 
few or none at diagnosis. The commonest symptoms at presentation include anaemia, 
lymphadenopathy, splenomegaly, hepatomegaly and thrombocytopenia (Montserrat E et al 
1997). 
Haematologically, the disease is distinguishable from other forms of leukaemia. The 
expression of the aberrant surface marker CDS aUows for a diagnosis of B-CLL, setting it 
aside from prolymphocytic leukaemia, hairy ceU leukaemia, follicular centre ceU lymphoma 
in leukaemic phase, splenic lymphoma with villous lymphocytes and lymphoplasmacytoid 
lymphoma which do not express COS (DiGiuseppe JA and Borowitz MJ 1998). Whilst 
mantle cell leukaemia is known to express COS, it is also CD23 negative. 
1.1.3 Laboratory diagnosis ofCLL 
The NCI-sponsored Working Group on CLL (Cheson BD et al 1996) has published 
guidelines for the diagnosis of B-CLL using the foUowing criteria: an absolute lymphocyte 
count of S x I 09 /L or more, morphologicaUy mature lymphocytes and an immunophenotype 
of monoclonal B-ceUs as described below: 
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i) surface immunoglobulin (usually IgM or !gM and lgD) of low intensity with either 
kappa or lambda light chain, 
ii) expression of the pan-B cell antigens CDI9, CD20 and C023, 
ill) eo-expression of COS on the leukaemic B cells. 
The first line in identification of CLL is a full blood count, measuring not only the total and 
differential white cell and absolute lymphocyte counts, but also haemoglobin (Hb) 
concentration and platelet count (fig. 2). The presence of a lymphocytosis and low Hb and 
platelets requires a blood film, for a more detailed examination of these findings. CLL cells 
often produce "smudge" or "smear" cells, due to their fragility. Intact clonal cells can be 
identified more clearly by their morphology. Blood will then be sent for 
immunophenotyping, which involves the staining of mononuclear white cells for surface 
markers C02, COS, C022, C023, FMC7 and a kappa/lambda ratio. A CLL diagnosis can 
be made at this stage and depending on the type of diagnosis (typical or atypical), the 
patient may require either a bone marrow biopsy or cytogenetic testing or both. A typical 
panel for CLL is shown in table 2. 
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Table 2: Laboratory diagnosis of CLL using monoclonal antibodies 
Monoclonal antibody CeU population identified 
CD2 gives an absolute T ceU comrt 
CD5 common to all T cells: positive in B cells in CLL 
CD22 B ceU marker: CD22...., and CD23-..: indicative ofNHL 
CD23 B ceU marker: CD22-ve and CD23..., indicative ofCLL 
FMC7 FM eT"" indicative ofNHL, FMCr"' indicative of CLL 
KiA. ratio normal ratio 2:1, an imbaJance in tbis ratio indicative of 
CLL and normally monoclonal 
Table showing monoclonal antibodies used to diagnose CLL in the laboratory at Derriford Hospital and 
how they can be used to differentiate between CLL and other forms of leukaemia and lymphoma. 
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Figure 2: Laboratory diagnosis of CLL 
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..l. 
Blood film 
smear cells +ve 
pleiomorphic lymphocytes +ve 
..l. 
lmmunophenotyping 
CD2-ve 
CDS+ve 
CD22+ve 
CD23+ve 
FMC7-ve 
1C I A. ratio not 2:1 
CLL diagnosis made Typical 
..l. 
Atypical 
..l. 
Bone marrow Cytogenetics 
biopsy 
~ ..l. 
CLL diagnosis made 
Figure showing the a typical laboratory diagnosis of CLL from blood count to immunophenotyping and bone 
marrow biopsy 
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After a clear diagnosis ofCLL at this stage, patients with typical morphology may not need 
any further investigation if no treatment is required. Patients with atypical morphology or 
those with typical morphology who require treatment may need cytogenetic testing for 
cyclin DJ to distinguish mantle cell lymphoma (MCL), and a bone marrow biopsy. The 
biopsy allows for the degree of marrow infiltration to be assessed. Bone marrow infiltration 
is seen in one of four patterns, interstitial, nodular, mixed interstitial/nodular and diffuse 
(Rozman C et a! 1980; Zwiebel JA and Cheson BD 1998) (Table 3). 
Table 3: Bone marrow infiltration patterns 
Pattern of infiltration Degree of marrow infiltration 
Interstitial 33% of patients: normal haemopoietic cells are replaced in small quantities 
by mature lyrnphocytes, but fat cells and bone marrow structure are 
preserved 
Nodular I 0% of patients: nodules of mature lyrnphocytes are present in the bone 
marrow in greater quantities than normal lymphoid follicles and they lack 
clear centres. Fat cells are still present. 
mixed 25% of patients: a combination of both interstitial and nodular patterns of 
interstitial/nodular infiltration 
diffuse 25% of patients: a diffuse lymphoid infiltration is seen with massive 
replacement of normal haemopoietic cells and fat cells. There is more 
disease progression in patients at stage A and B with this marrow infiltration 
Table showing the types of bone marrow infiltration identified in CLL patients and the proportion of patients 
with that type of infiltration 
Attempts have been made to use bone marrow infiltration as an indicator of survival and 
disease progression. It has been suggested that those patients who present with diffuse 
marrow infiltration have a shorter survival time than those with non-diffuse infiltration 
(Rozman C et a! 1984). However, it has not been possible to correlate bone marrow 
infiltration with disease progression and survival and patterns of bone marrow involvement 
probably do not clearly contribute prognostic information beyond what is available from 
other staging systems (Pangalis GA et al 1987; Desablens B et a! 1989; Mauro FR et a! 
1994; Geisler CH et all996; Zwiebel JA and Cheson BD 1998). 
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1.1.4 Genetic changes 
1.1.4.1 Trisomy 12 
Clonal chromosome abnormalities can be detected in 50% - 80% of patients with CLL 
(Dierlamm J et al 1997). The two most common non-random chromosomal alterations 
specifically associated with B-CLL are trisomy 12 and 13ql4 deletion (Matutes E et al 
1996). Approximately I 0-20% of CLL patients are diagnosed with this aberration using 
conventional chromosomal analysis (Oscier DG 1994), whilst the use of fluorescent in situ 
hybridisation (FISH) will detect trisomy 12 in up to 30% of all patients (Jurlander J 1997; 
Hamblin TJ et al 1997; Zwiebel JA et al 1998). Trisomy 12 is only found in 21 - 37% of 
the clonal population of B cells and not in the T cells or non-clonal B cells, suggesting that 
it may be a genetic abnormality secondary to the leukaemic process (Garcia-Marco J et al 
1994; Crossen PE 1997; Dierlamm J et al 1997; Navarro B et al 1998; Juliusson G et al 
1998). However, Gahn et al have shown that of 7 patients who expressed the trisomy 12 
mutation, 3 had the mutation on CD34+ve stem cells, implying that while trisomy 12 is not 
primarily involved in the leukaemic process, its expression may not in fact be secondary to 
the formation of the malignant clone (Gahn B et al 1997). 
Studies have shown that the presence of trisomy 12 in CLL patients is linked to a higher 
frequency of stronger expression of surface membrane immunoglobulin (Smlg) and FMC7 
expression (Matutes E et al 1996). It also implies a possibly worse prognosis (Geisler CH 
et al 1997; Criel A et al 1997; Juliusson G et al 1998; Hogan WJ et al 1999; Dohner H et al 
1999). Three genes involved in cell-cycle activation, cyclin D2, CDK4 and MDM2, are all 
located on chromosome 12. Each is over-expressed in CLL clonal B cells (Jurlander J et al 
1998). 
A possible association between trisomy 12 and atypical morphology, such as a cleaved 
nucleus and an increase in the total number of prolymphocytes, has been postulated in 
several studies (Criel A et al 1994; Matutes E et al 1996; Woessner S et al 1996). However, 
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the presence of this genetic abnormality has not been linked to the stage of the disease or 
with patients' responses to treatment. In contrast, disease progression and treatment free 
survival (TFS) time have been linked to trisomy 12. In a group of 54 untreated patients, 
each of the seven patients found to have trisomy 12 had a median TFS time significantly 
less than those patients with a normal chromosome 12 (Hogan WJ et all999). 
1.1.4.2 13q14 
Deletion at 13q14 is indicative of the loss or inactivation of a tumour suppressor gene. 
Using Fluorescence In-Situ Hybridisation (FISH), approximately 30% of CLL patients 
show a deletion of chromosome 13 at region q14 (Avet-Loiseau Het al1996; Starostik Pet 
al 1999). As with trisomy 12, this aberration is only seen in a proportion of the clonal B 
cells, again suggesting a possible secondary involvement in the leukaemic process (Jabbar 
SA et a! 1995; Navaho B et al 1998). In contrast to other haematological malignancies, 
13q 14 has been shown to represent a loss of genetic material rather than over-expression 
(Gardiner AC et al 1996; Dohner H et al 1999). The retinoblastoma (Rb) tumour 
suppressor gene is located at region 13q14 and while it was thought that this gene might be 
an important candidate in the biology of CLL, CLL B cells with Rb loss will still express 
retinoblastoma protein (Oscier DG et al 1990; Liu Y et a! 1993). 
In addition to this gene, it has been speculated that a novel gene exists close to the RB 
gene, named DBM (deleted in I! cell malignancy) (Brown AG et al 1993). Molecular 
analysis has shown that 80 to 90% of patients with a 13q 14 deletion have a monoallelic 
loss of this region, whilst 34 to 46% of patients who were previously shown to have a 
cytogenetically normal chromosome at 13ql4 actually have the same loss ofDBM (Oscier 
DG et al 1994). At present, the role of this deletion in disease pathogenesis and prognosis 
remains to be determined. 
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In contrast to the poorer prognosis associated with trisomy 12, 13q 14 deletions are not 
linked to morphological changes or a worsening prognosis (Finn WG et a! 1996; Kroft SH 
et a! 1997; Juliusson Get al1998; Hogan WJ et all999; Dohner Het al1999). 
In addition to the 13q14 deletion, which incorporates the span 13q12-ql4, there is also a 
common deletion found at the region 13q14-q22. 
1.1.4.3 p53 
A p53 gene abnormality is present in approximately I 0 to 25% of patients with 8-CLL 
(Oscier DG 1994; Jurlander J 1998) and its presence has been linked to more aggressive 
forms of CLL as well as increased chemotherapy resistance and a higher chance of 
transformation from CLL to Richter's syndrome (El Rouby S et a! 1993). p53 is a tumour 
suppressor gene located on chromosome 17, which induces apoptosis in response to DNA 
damage (Parham P 2000). It acts as a growth suppressor, either by causing cell cycle arrest 
at the G1 stage of the cell cycle or by causing apoptosis (Zwiebel JA and Cheson BD 1998). 
A mutation in this gene could possibly prevent apoptosis and lead to the accumulation of 
cells characteristic of CLL. The presence of p53 in CLL cases has also been linked to a 
poorer prognosis and disease progression (Cano I et al 1996; Amiel A et al 1997). 
1.1.4.4 ImmUiwglobulilr getre mutatiotrs 
In normal 8 cell development, the variable regions of the immunoglobulin heavy (V H) and 
light (VL) chains undergo somatic hypermutation as they pass through germinal centres. 
Early studies on the V H genes in CLL suggested that most malignant 8 cells had unmutated 
V H genes, leading to the hypothesis that the 8 cell clone could have arisen from a naive 8 
cell such as CDS+ mantle cells which had not passed through the germinal centre (Oscier 
DG 1999). As larger studies were carried out however, up to SO% of CLL patients VH 
genes were shown to have mutations, indicating that they would have passed through the 
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germinal centre (Hamblin TJ et at 1999). The finding of unmutated V H genes was 
associated with atypical morphology, isolated trisomy 12, advanced stage and progressive 
disease. 
1.1.4.5 Additional genetic changes 
Although the main chromosomal and genetic changes of CLL are described above, there 
are other important alterations in the B-CLL genome. 
Bc/-2 re-arrangements: a translocation at the region of the Bcl-2 gene can lead to over 
expression of the Bcl-2 protein. The gene coding for immunoglobulin can translocate 
with the Bcl-2 gene, leading to over-expression of the protein, which normally 
functions to prevent premature apoptosis in B cells (Oscier DG 1994). A continual 
over-expression of this protein could promote an accumulation of B cells unable to 
undergo programmed cell death. Although the Bcl-2 re-arrangement is rare in CLL, 
Bcl-2 is over-expressed in approximately 90% of patients (Kipps TJ 1997) and the 
reason for this is not clear (Gottardi D et a1 1995; Osorio L et at 1998). Differences 
have been observed in expression of Bcl-2 at different stages of the disease. Expression 
was lower at stage A and B of the disease (33% and 29% respectively), whilst 
expression at stage C was 80%, suggesting that more advanced cases have a greater 
involvement of Bcl-2 as the disease progresses (Aviram A et at 2000). 
Chromosome 6: in CLL, deletions in chromosome 6 have been reported which 
incorporate the regions 6q15 and 6q23, in approximately 12% of patients with clonal 
abnormalities (Dierlamm J et al, 1997). 
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Chromosome 11: approximately 16% ofB-CLL patients with a clonal abnormality have 
structural changes in chromosome 11 and 37% of those have this abnormality as a 
single aberration. In addition, a translocation at 11:14 has also been demonstrated. 
Changes at chromosome 11q are most frequent in typical CLL and are associated with 
progressive disease (Dierlamm J et al 1997; Neilson JR et al 1997). llq21-q23 
deletions involving the ataxia telangeictasia mutated (ATM), radixin (RDX) and FDX 
genes are also frequently observed using FISH techniques in CLL patients (Stankovic T 
et al 1999; Oscier DG 1999). This leads to a reduced expression of the A TM protein. 
The presence of these mutations signifies a very poor prognosis. 
Chromosome 14: Changes seen at chromosome 14 involve the immunoglobulin heavy-
chain locus at 14q32 and have been observed in 16% of all CLL cases. (Dierlamm J et 
al 1997). Translocations which result in rearrangement and upregulation of the bcl-3 
gene are observed at t(14; 19)(q32;q13). This change is often associated with trisomy 
12, young age and aggressive disease. 
Chromosome abnormalities and surface antigen expression: recent work has 
investigated the possible relationship between chromosome abnormalities and the 
expression of surface antigens (Hulkkonen J et al 2002). In particular, deletion of 
chromosome arm 1lq was linked to a reduced expression of the splicing variant 
CD45RA, but an enhanced expression of CD45RO. Cases of trisomy 12 were 
associated with increased CD45RA and reduced CD45RO expression, in addition to an 
increased expression ofCD27 and membrane lgkappa. It is possible that these observed 
links between genetic aberrations and cell surface antigen expression may have an 
effect on the progression of the disease and the individual patient response to drug 
treatment. 
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The finding of chromosomal and genetic changes may provide important information, 
which increases understanding of the aetiology of CLL and other related 
lymphoproliferative disorders. Some abnormalities improve the assessment of prognosis 
and can also contribute to decisions of treatment. 
1.1.5 Telomerase activity 
When a eukaryotic cell undergoes replication, telomere length is reduced as genetic 
material is reproduced and divided between the two new cells (Berendes HD and Meyer 
GF 1968). Somatic cells are able to maintain unlimited replicative potential through the 
activity of telomerase, an enzyme which prevents telomere shortening and permits 
continued replication (Ballon G et a! 2001; Helder MN et a! 2002). Normal peripheral 
blood cells express low but detectable levels of telomerase activity, which can be up-
regulated in T and B lymphocytes after in vitro stimulation. Approximately 90% of all 
solid tumours have telomerase activity that is significantly higher than normal cells (Lubbe 
J et a! 1997), yet levels of telomerase activity in CLL are only significantly higher in 
patients with progressive disease (Bechter OE et al 1998). However, compared to normal 
controls, telomerase has a significantly higher activity in CLL B cells .. The lower levels of 
telomerase observed in CLL compared to solid tumours and other haematological 
malignancies, such as hairy cell leukaemia, might reflect the lower number of proliferating 
cells, the higher degree of cell differentiation and the theory that B-CLL cells may originate 
from resting B lymphocytes. 
1.1.6 Classification of disease stage and prognosis 
Whilst detection of genetic aberrations is important in the study of B-CLL, a means of 
classifYing the stage of disease in each individual patient is still more relevant to the 
identification of those subgroups of patients who require immediate treatment, those who 
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will need treatment in the near future and those who are able to continue without treatment 
for some time. In current use today are two methods of staging, which may be used alone 
or in combination, the Rai staging system and the Binet staging system. There have been 
many clinical studies that have involved assessing the importance of both systems (Rai KR 
et al 1975; Binet JL et al 1981) and clinical staging remains the most important prognostic 
tool (Catovsky D 1997). The staging system described by Rai incorporates a grading of 
clinical signs and laboratory findings at the time of diagnosis, which segregates patients 
into five stages from stage 0 through to stage IV. These are detailed in table 4. 
Table 4: Rai's staging criteria for CLL 
CLINICAL CLASSIFICATION SURVIVAL 
STAGING (MONTHS) 
Blood and marrow lymphocytosis (absolute 
STAGEO blood lymph count ~15 x 109/L, 40% or >120 
more lymph's in the marrow) 
Blood and marrow lymphocytosis with 
STAGE I lymph node enlargement 95 
Blood and marrow lymphocytosis with 
STAGE 11 splenomegaly and/or hepatomegaly (with or 72 without lymph node enlargement) 
Blood and marrow lymphocytosis with Hb 
STAGE Ill lower than 11 g/dL (excluding auto immune 30 haemolytic anaemia, with or without lymph 
node, snleen or liver enlargement) 
Blood and marrow lymphocytosis with 
STAGE IV platelet count lower than 100 x 10
9/L (with 30 
or without lymph node, spleen and liver 
enlargement and independently of Hb) 
Table showing the clinical stage of CLL and classification of the symptoms at each stage as defined by Rai 
(Rai K.R et al 1975). 
Rai's staging system indicates that patients who can be categorised in stage 0 of the disease 
need not receive treatment in the form of radiotherapy or chemotherapy and in whom 
progression of their disease should be monitored regularly. In stages I and ll, treatment is 
16 
not usually required unless there are significant symptoms relating to more advanced 
disease and, if so, a reduction in tumour mass may be advantageous clinically. In stages m 
and IV, the objective of treatment is to achieve a complete remission or, if that is not 
possible, a good partial remission. Rai has shown in his studies that patients who present 
with more severe symptoms and a higher lymphocyte count at the time of diagnosis tend to 
have poorer prognosis. Those patients diagnosed at stages 0, I and II lived longer than those 
presenting at stages m and IV (Rai KR et al1975). Patients may progress from one stage to 
another but survival times remain specific to the stage at which a prognosis is made. The 
staging system as indicated by Binet is shown in table 5. 
Table 5: Binet's staging criteria for CLL. 
CLINICAL CLASSIFICATION SURVIVAL 
STAGING (MONTHS) 
Hb equal or greater than I 0. Platelets equal or 
STAGE A greater than 100,000 mm
3
. Less than three enlarged >120 
areas* 
Hb equal or greater than I 0. Platelets equal or 
STAGEB greater than 100,000 mm
3
• Three or more enlarged 61 
areas* 
Hb less than I 0 and /or platelets less than I 00,000 
STAGEC mm
3
• Any number of enlarged areas* 32 
• =Enlarged areas incorporate cervical, axillary, inguinal, spleen and liver 
Table showing the clinical stage of CLL and classification of the symptoms at each stage as defined by Binet 
(Binet JL et al1981). 
In this system, more emphasis is placed on isolating patients defined as high risk by the 
presence of anaemia or thrombocytopenia. It has been postulated by Binet that it is possible 
to combine the two systems of classification. Rai stages 0 and m can be assigned to Binet 
stage A, Rai stage IV is grouped with Binet stage C and the remaining patients from stage 
II can be separated into stage A and B depending on physical signs (Binet JL et al 1981 ). 
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Binet stage A can be further sub-divided into Stage A' and Stage A" (Digheiro G et al 
1991 ). Stage A' is characterised by a lymphocyte count less than 30 x 109 IL and an Hb 
greater than 12g/dL. 80% of stage A patients fall into this category. Stage A" is 
characterised with either a lymphocyte count greater than 30 x 109 IL or Hb less than 
12g/dL. 20% of stage A patients fall into this category. 
The use of these staging systems has helped to simplify the classification of B-CLL 
patients, essentially by separating them into low risk, intermediate risk and high risk (Rai 
KR et al 1990). Whilst both systems undoubtedly remain at the forefront of B-CLL 
staging, there is a degree of controversy surrounding both methods as to their usefulness in 
identifying individual groups of patients who may or may not benefit from therapy (Foon 
KA et al 1987; Zwiebel JA et al 1998). As new methods of detection emerge, it is 
envisaged that factors such as CD38 expression, beta2-microglobulin, soluble serum CD23 
levels and lymphocyte doubling time may play an important role as independent prognostic 
factors and indicators of the need for treatment (Vilpo J 1999; Del Poeta G et al 2001; 
lbrahim S et al 2001 ). Some of these methods are being put into practice today. 
Whilst the Rai and Binet staging systems are important in the diagnosis of CLL, both rely 
heavily on clinical and morphological features. In recent years, there has been an increase 
in the use of current techniques such as immunophenotyping to classify 
Iymphoproliferative disorders. With reference to the classification ofCLL, a scoring 
system has been proposed (Matutes E et al 1994) (table 6). In this system, points are 
allocated to each patient, depending on the expression of key immunological markers 
associated with CLL, the final total score indicating the likelihood of a positive diagnosis. 
In the initial study, the majority of patients (87%) scored the expected total of 4 or 5, 
indicating a clear case for CLL diagnosis. This system allows a clearer definition of CLL 
from other morphologically similar diseases such as splenic lymphoma with villous 
18 
lymphocytes (SLVL), follicular lymphoma, mantle cell lymphoma and lymphoplasmacytic 
lymphomas. 
Table 6: Scoring system for CLL 
Membrane marker 
Smlg 
CD5 
CD23 
FMC7 
CD22 
Score 4-5: cypical CLL 
Score 3-4: atypical CLL 
Score< 3: non-CLL 
1 point 0 points 
weak moderate/strong 
positive negative 
positive negative 
negative positive 
weak/negative moderate/strong 
Table showing the scoring system for CLL. Points are allocated to each patient depending on the presence or 
absence of the surface antigens shown and the total score can aid a diagnosis of typical or atypical CLL or 
another form of leukaemia (Matutes E et al 1994 ). 
1.1.7 Newer prognostic factors 
B-CLL is a heterogeneous disease, which may constantly change, both within the 
individual and amongst the population, although it can stay stable until death. A 
comparison between patients diagnosed in the time span of 1960-1979 against those 
diagnosed during 1980-1989 has shown striking and statistically different results. In the 
latter cohort of patients, diagnosis was made at a later age, more patients were diagnosed in 
low risk groups and survival time was more than double (Rozman C et al 1997). As 
diagnostic tools have become more widely available and their use has increased amongst 
the elderly population, this change is likely to reflect not so much a change in the disease 
itself, but instead more accurate and earlier diagnosis. Today, the median survival time for 
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patients with CLL is approximately 10 years, but prognosis among individuals is highly 
variable, with some patients having no reduction in normal life expectancy and others for 
whom median survival is less than 3 years (Rai Ketal 1975; Binet Jet al 1981; Dierlamm 
J et al 1997; Montserrat E 2001). CD38 expression, beta2-microglobulin, soluble serum 
CD23 levels, CD23 surface expression, interferon-a receptor (lFN-a) expression and 
lymphocyte doubling time may all play an important role as prognostic factors (Dadmarz R 
et al 1998; Vilpo J 1999; Popescu D et al 2001; Del Poeta Get al 2001; lbrahim Setal 
2001). Impairment of immune function as demonstrated by hypogammaglobulinaemia, 
frequent and recurrent infections and neutropenia also suggest a poorer prognosis and 
disease progression. Low levels of serum IgA and IgG, but not lgM, worsen with disease 
progression and are indicative of a poor prognosis (Rozman C et al 1988). 
The expression of adhesion markers in both cellular and soluble form has also been shown 
to play an important role in disease prognosis. High levels of soluble CD44 and CD54 are 
both considered adverse prognostic factors (Angelopolou MK et al 1999). 
The increasing use of molecular techniques has introduced another opportunity to study 
disease prognosis. It has been possible to show that telomerase, an enzyme which mediates 
the repair and preservation of telomeres within chromosomes and thus prevents the ageing 
process normally found in somatic cells, has a significantly higher activity in B cells in 
CLL patients compared to normal controls. This enhances the ability of CLL cells to live 
longer and continually repair DNA, not only by preventing the erosion of telomeres, but by 
actually restoring telomere length (Bechter OE et al 1998). Telomerase activity may 
become an important independent variable in the new generation of prognostic factors. 
CD38 may also prove to be a useful tool for disease prognosis (Caligaris-Cappio F et al 
1999). CD38 expression has been linked to B cells that show no mutation of their 
immunoglobulin variable (IgV) genes (Caligaris-Cappio F 1999). Mutation of IgV genes 
normally occurs when developing B cells encounter antigen in the germinal centres (GC) of 
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secondary follicles. Point mutations occur in the lgV genes and result in the production of 
antibody. Examination of lgV re-arrangement in CLL has shown that approximately half of 
all CLL cases have mutations, implying that the B cell has passed through the GC within 
the secondary follicles and has had exposure to antigen. In contrast, the other half of the 
CLL cases which did not reveal lgV mutations would suggest that the clone originates from 
a naive B cell that may not have previously encountered antigen within the GC (Hamblin 
TJ et al 1999; Oscier DG 1999). B cells with unmutated lgV genes have a much higher 
percentage of CD38-positive cells, so these two features could prove to be useful tool for 
prognosis of the disease (Damle RN et al 1999). The presence of unmutated lgV genes has 
been strongly associated with atypical lymphocyte morphology, progressive disease and 
shorter survival (Oscier D 1999; Caligaris-Cappio F 1999; Damle RN 1999). A more 
recent report has further confirmed these findings, showing that CD38 expression in 
association with a secondary 17p deletion are poor prognostic factors, particularly in early 
stage disease (Chevallier P et a! 2002). There have been suggestions that this dichotomy 
may have clinical implications, as it could provide the basis of why some patients never 
require treatment while others need intensive therapy (Caligaris-Cappio F 1999). However, 
it is still not clear exactly what the role of CD38 is in relation to IgV mutations and 
research is continuing to clarify its role in prognosis ofB-CLL (Jelinek DF et a12001). 
The expression of p53 abnormalities and loss of the retinoblastoma (Rb) gene, which is 
often linked to drug resistance, also indicate a poor prognosis (Morabito F et al 1997; 
Cordone I et al 1998). In contrast, the deletion at site D 13s25, a molecular marker located 
on chromosome 13 band q 14 found in 95% of all clonal CLL cells, gives a more favourable 
prognosis (Jabbar SA et al 1995; Oscier DG 1999). As molecular techniques expand, an 
increasing number of genetic sites will be identified allowing for a better and more accurate 
diagnosis and prognosis for individual CLL patients. 
21 
1.2 Treatment 
B-CLL is a disease that often follows a path of slow progression particularly for patients 
diagnosed at an early stage. As many of these patients are elderly, a policy of "wait and 
see" is often adopted for those who show little or no symptoms or signs related their 
diagnosis. Many patients can continue for a number of years without symptoms 
(Montserrat E 2001) and a delay in treatment reduces the risk of drug resistance if the 
disease should progress. In addition, many of the drugs commonly used for the treatment of 
8-CLL can have adverse side effects and delaying treatment will avoid these for a time. It 
is important that the choice of treatment and management of CLL takes account of the 
patients' age, quality of life and the toxic side-effect of the treatment (Oscier DG 1999). 
From the time of diagnosis, it is important to monitor patients closely for a period to 
observe any noticeable changes indicating progression of disease, such as unexplained 
weight loss, fever, increasing infective episodes, increasing tiredness, lymph node 
enlargement, increasing lymphocyte count, falling normal blood counts and abdominal 
distension or discomfort due to splenomegaly (Whittaker JA 1987; Rai KR et al 1998; 
Montserrat E 2001). 
Once an accurate identification of disease stage has been made, treatment depends on a 
number of factors including symptoms, prognosis and age as treatment that may be suited 
to the younger patient with more aggressive disease could be inappropriate and even 
harmful to the elderly patient with indolent disease (Montserrat E 2001). 
1.1.1 Low risk (modified Rai criteria stage 0), Billet stage A 
Patients diagnosed at this stage have been shown to obtain no benefit from receiving 
treatment with either chemotherapy or radiotherapy (Montserrat E 2001). A recent study by 
the French co-operative group on CLL assigned 609 stage A patients to either no treatment 
or chlorambucil and compared this group to a further 926 stage A patients who received no 
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treatment or chlorambucil plus prednisolone. The study took place over ten years with a 
median follow up of six years and results showed that early intervention with chlorambucil, 
with or without prednisolone, did not affect the overall survival of the patient groups. This 
has helped to validate the previous notion that treatment should be deferred until the 
disease progresses (Catovsky D 1997; Rai KJ 1998; Digherio G et al 1998). If lymphocyte 
counts are low and the patient is relatively free from symptoms, they should simply be seen 
regularly and observed for progression. At this stage, the rate of lymphocyte doubling time 
is the most important factor in the decision to begin treatment. 
1.2.2 Intermediate risk (modified Rai criteria stage I- Il), Binet stage B 
Therapy may be initiated for patients in this staging group if the patient shows disease 
related symptoms such as rapid lymphocyte doubling time or enlarged nodes. At present, 
the aim of therapy within this population is to reduce tumour size and achieve a good level 
of remission. The cornerstone of treatment is usually chlorambucil (see below) (Rai KJ 
1998). 
1.2.3 Higlr risk (modified Rai criteria stage Ill- IV), Binet stage C 
Most patients within this group are treated immediately without the "wait-and-watch" 
phase (Montserrat E 1999; Rai KJ 1999). The aim is to reduce the bulk of the disease and 
then to improve levels of haemoglobin and platelets and to achieve a complete remission or 
a good partial remission. Chemotherapy is used first line and increasingly more aggressive 
regimes are applied in younger patients 
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1.2.4 Treatment regimes for CLL 
C/rlorambucil 
This agent works by alkylating DNA, attacking nucleophilic sites and causing cell death 
(Chabner BA et al 1996). It is one of the most frequently used drugs in the treatment of B-
CLL as it is usually very effective in reducing the white cell count (WCC). Patients may be 
treated either with large doses over a short period of time, or smaller doses over a more 
extended time period (Montserrat E 1999). Continuous, low dose exposure is now 
discouraged for all alkylating agents as this carries a greater risk of second malignancy. 
(Asten P et al 1999). Chlorambucil induces a good partial response with low toxicity in 60 
to 70% of patients, but long-term use invariably leads to drug resistance (Oscier DG, 
1999). 
Fludarabi11e 
This adenosine analogue works by inhibiting DNA polymerase and ribonucleotide 
reductase within rapidly dividing cells, thus preventing the growth of the leukaemic cells. It 
is taken up by the cell and becomes incorporated into new nuclear material and once 
phosphorylated, prevents DNA synthesis. Recently, this drug has become increasingly 
more important as first line treatment for B-CLL after two large multi-centred trials 
showed more complete and overall remissions with fludarabine than with previous 
standard chemotherapy and that the remissions lasted significantly longer (Rai KR et al 
1996; Johnson Set al1996; Bumbea Het al2001). It is also an important drug in patients 
with advanced CLL, which prove unresponsiveness to other agents (Giraldo P et al 1999). 
Toxicities associated with this form of treatment include myelosuppression and a markedly 
decreased CD4 T cell count, which can lead to an increase in opportunistic infections 
(Willams WJ 1996). Fever of unknown origin and pneumonia can also occur (Myint H et al 
1995; Catovsky D 1997). It may be necessary to protect patients on fludarabine against 
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specific infections such as pneumocystis carinii pneumonia with oral septrin for up to six 
months after the last treatment is completed and long-term antibiotic prophylaxis is often 
recommended (Bergmann L et al 1993). Other potential side effects include auto-immune 
haemolytic anaemia (AlliA), transfusion related graft versus host disease and, rarely, 
neurotoxicicty. In addition to fludarabine, the other nucleoside analogues cladribine and 
pentostatin also have activity in CLL. Cladribine can be effective in early stage CLL and 
has had promising results in the treatment of hairy cell leukaemia. However, the literature 
and experience with these drugs are not nearly as extensive as with fludarabine. 
Increasingly, fludarabine is being used in combination with other chemotherapeutic agents 
with good results (Rai KJ et al 1998). A recent study has shown that cyclophosphamide 
given in combination with fludarabine gave a 75% complete response in CLL patients 
(Ferrara F et al2001; Ferrer AFA 2001). The main complications of this form of treatment 
include severe neutropenia, myelosuppression and infection. 
Pentostatin 
This potent inhibitor of adenosine deaminase is an anti-tumour antibiotic, which leads to 
apoptotic death of the leukaemic cells. It has been used successfully in combination with 
cyclophosphamide to produce complete responses without significant myelosuppression in 
previously treated patients (Weiss MA et al 2000). It has also been used successfully in 
combination with theophylline and chlorambucil to down-regulate the anti-apoptotic 
marker bcl-2 in previously treated CLL patients (Byrd JC et a! 2000). The main 
disadvantage of this drug is its myelotoxicity and immunosuppression, which can lead to 
an increase in the risk of infection, especially with opportunistic organisms (Margolis J and 
Grever MR 2000). Treatment with pentostatin can lead to a significant decrease of total 
lymphocytes, particularly in the CD4 T cell compartment (Kraut EH et al 1990). Levels of 
both immunosuppression and myelotoxicity however, are lower than with the other purine 
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analogues (Weiss MA et al 2000). Cladribine, another adenosine deaminase, is believed to 
work by inducing apoptosis through mitochondrial transmembrane loss and other similar 
mechanisms (Marzo I et a! 2001). It has been used in combination with mitoxantrone and 
cyclophosphamide in the treatment of previously untreated B-CLL patients (Robak T et al 
2001). Studies have shown that cladribine gives similar complete response (CR) rate and 
overall response (OR) rate as fludarabine in the treatment ofCLL (Robak T 2001). 
Cyclophosphamide 
This is another alkylating drug that causes apoptosis of the cell (Haskell CM 1995). 
Cyclophosphamide may be used as single agent therapy, but it also plays an important role 
in combination treatments such as COP (Cyclophosphamide, Vincristine, Prednisolone) 
and CHOP (Cyclophosphamide, Doxorubicin, Vincristine, Prednisolone). However, studies 
have shown no differences in survival in patients with stage B disease treated with CHOP 
compared to those treated with chlorambucil plus prednisolone (French Cooperative Group 
1994). 
Pred11isolo11e 
This synthetic corticosteroid is used for short periods during treatment to reduce the size of 
the spleen and lymph nodes and also to alleviate anaemia and thrombocytopaenia and other 
conditions which have an autoimmune basis. Recently, high dose methyl prednisolone has 
been shown to be an effective treatment regime either alone or in combination with other 
regimes in salvage treatment for CLL patients with p53 abnormalities and those refractory 
to previous treatment regimes (Thornton PD et al 2000). They are not used to obtain lasting 
remission, although they are directly lymphocytotoxic. 
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Vi11cristi11e 
This drug is used in combination therapy alongside such other agents as prednisolone and 
cyclophosphamide and may be effective in patients refractory to alkylating agents. 
Vincristine is a vinca alkaloid that exerts its effect on malignant cells as a spindle poison 
by inhibiting the mechanisms essential in cell replication. The drug interacts with tubulin 
subunits within the cell and prevents microtubule assembly, inducing abnonnal 
chromosome segregation in dividing cells (Gonzalez M et a! 1999). However, side effects 
of vincristine treatment can include peripheral neuropathy, as the vinca alkaloids may 
interfere with nonnal axon microtubule assembly (Sahenk Z et a! 1987). 
Radiotllerapy 
The use of radiotherapy for patients has been shown to be beneficial when there are 
localised bulky lymphoid masses or for an enlarged spleen. Patients often respond well to 
only small doses of radiation although it is important to monitor blood counts closely as 
this fonn of treatment can lead to bone marrow suppression (Whittaker JA 1990; Digheiro 
G et a! 1991). Splenic irradiation will also induce the "abscopal" response, in which 
malignant cells beyond the filed of irradiation undergo apoptosis. This response has never 
been fully explained (van Mook WN et a! 2001), but mechanisms may include direct cell 
kill, immune modulation via changes in lymphocyte subsets or the induction of a cytokine 
response (Weinmann M et al2001). 
Sple11ectomy 
Patients with very large spleens or those who are diagnosed with hypersplenism or with 
problematic auto immune thrombocytopaenia or anaemia may benefit from a splenectomy if 
localised splenic irradiation is not effective or if the patient is refractory to treatment with 
steroids. (Digheiro G et a! 1991; Whittaker JA 1992). This fonn of treatment can help to 
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control the disease for some time but can cause serious morbidity and carries a 7% 
mortality rate from overwhelming post splenectomy infection (OPSI) (Montserrat E 1999; 
Mauro FR et al 2000), often form pneumocystis carinii pneumonia. 
Blood Transfusions 
Patients who are anaemic as a result of extensive replacement of bone marrow by 
leukaemic cells, because of myelosuppression by cytotoxic chemotherapy or because of 
hypersplenism may benefit from regular or "top-up" blood transfusions. They usually 
improve general well being and alleviate symptoms such as tiredness and lethargy due to 
the anaemia, so they are useful in maintaining quality of life. However, repeated 
transfusions over extended periods of time can lead to difficulties with future transfusions 
through the development of allo-antibodies, which make cross matching more complicated, 
and iron overload (Williams W J 1996). 
DiSC Assay 
The differential staining cytotoxicity (DiSC) assay involves ex vivo drug panel testing 
against patient tumour cells to identify optimal therapy (Mason JM et al 1999). To date, 
there have been numerous studies using this method to identify effective, patient-based 
treatment regimes in B-CLL. This ex vivo method of drug testing has proved useful in the 
treatment ofB-CLL, particularly in relapsed patients where several therapeutic options may 
exist (Bosanquet AG and Bell BP 1996). 
1.2.5 Recent advances in the treatment ofB-CLL 
1.2.5.1 Autologous a11d alloge11eic stem cell tra11splants 
The use of stem cell transplants to treat CLL has been increasing over the last few years 
(Montserrat E 2001). This modality is only applicable to younger patients because of the 
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toxicity associated with the treatment. The use of allogeneic transplants, when the patient 
receives stem cells from an HLA- matched (related or unrelated) or mis-matched donor, is 
also limited by the age of the patient. Although allogeneic transplants, when successful, can 
carry good durable responses with 40% of patients remaining disease free at 4 years, they 
also carry a high transplant-related morbidity (TRM) of between 25-50% (Montserrat E 
2001). The conditioning therapies carried out before transplant lead to profound 
pancytopenia, and consequently infections are common. In addition there are therapy 
related organ-toxicities, especially to the liver and kidneys (Negrin R et al 1998). 
Autologous transplants, which involve the patient receiving a re-infusion of their own stem 
cells, has a lower TRM (<2%), but the absence of a plateau in survival curves for these 
patients suggests that this form of treatment is not a "cure" for CLL. Survival time, 
however, may be prolonged (Montserrat E 2001 ). A recent report (Khouri I et al 1998) has 
shown that patients who become refractory to treatment with fludarabine show good 
responses to stem cell transplantation, with those receiving allogeneic transplants having 
the most favourable survival times. 87.5% were in complete remtsswn following 
transplantation and 57% had survival rates of 3 years. Survival times are becoming 
increasingly more promising, particular in early stage patients (Dreger P et al 2000). 
1.2.5.2 Graft-versus-lrost (GVH) and graft-versus-leukaemia (GVL) 
Two immunological barriers need to be crossed for a successful stem cell allograft to take, 
the host-versus-graft (HVG) and graft-versus-host (GVH). In order to minimise HVG, the 
immune system of the patient must be eradicated before transplantation occurs to prevent 
the host system attacking the new graft (Negrin R et al 1998). Conversely, GVH must be 
minimised after transplantation to prevent the newly infused donor stem cells from 
recognising the host immune system as foreign. Both of these responses are mediated by 
alloreactive T cells from either the hosts' immune system or from the donor stem cells 
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(Hoffbrand A et al 1999; Burakoff SJ et al 2001). The incidence of GVH is influenced by 
the number of alloreactive T cells infused, but there is no direct correlation between the 
total amount ofT cell numbers infused and the severity of the GVH reaction. 
Evidence from research carried out on murine models and on selective depletion ofT-cell 
subsets in human transplants suggests that the CD4 and CD8 T cell subsets are responsible 
for the GVH, and that the subset responsible would depend on the class of mismatch that 
occurred between host and donor (Ferrara JL and Deeg HJ 1991). For instance, if the class 
I MHC antigens were mis-matched, CD8 T cells would dominate the response and 
conversely, if the disparity between host and donor was in the class II MHC antigens, CD4 
subsets would be the main initiators of GVH (Ferrara JL and Deeg HJ 1991). Both CD4 
and CD8 are important when the difference between host and donor is in the minor 
histocompatability complex. Cytokine release is also an important factor in GVH. IL-l, IL-
2 and Tumour Necrosis Factor (TNF) have all been identified during a GVH response 
(Hoffbrand A V et al 1999). 
However, while the GVH reaction can be fatal if not properly controlled, it has been shown 
that a type of GVH is responsible for many of the observed cures seen after stem cell 
transplantation (Weiden PL et al 1979). This response, termed graft-versus-leukaemia 
(GVL) occurs when donor T cells from the newly infused stem cells recognise and respond 
to the malignant leukaemic clone. Whether GVL and GVH are either similar phenomena or 
two distinct and different responses remains to be discovered. The GVL effects indicates 
that donor T cells can respond to the leukaemic clone whilst the patients own T cells 
cannot, implying that the malignant clone may be preventing the host T cells from 
mounting the response observed in the newly infused donor lymphocytes. In comparison, 
the fact that patients are able to mount a host-versus-graft response suggests that the host T 
cells can recognise foreign antigen from the donor, but not the malignant clone. This 
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apparent "anergy" is relevant for this study and for the implications of potential for 
adoptive immunotherapy using host T cells. 
1.2.5.3 Donor lymplrocyte i11jusio11s 
Until recently, the only chance of a cure after a relapsed bone marrow or stem cell 
transplant was a second transplant (Porter DL and Antin JH 1999). However, it has since 
been discovered that an infusion oflymphocytes collected from the original stem cell donor 
back to the patient can induce a direct graft-versus-leukaemia reaction. Using donor 
lymphocyte infusions (DLl), complete remission can be re-established in many patients 
whose haematological diseases have relapsed post-allograft, but the exact mechanisms of 
this effect are not well understood. The effector cells and target antigens that control GVL 
are poorly defined, but once identified, they may lead to the possibility of harnessing the 
immune system for a clinical response. The success of DLl again suggests that there is a 
failure of the patients T cell compartment in responding to the leukaemic clone, whilst the 
donor lymphocytes are somehow able to identify and respond to the malignant cells and, in 
some cases, induce a complete remission 
1.2.5.4 Monoc/01ra/ antibodies 
Campath 1-H and Rituximab (also known as Mabthera) are monoclonal antibodies (mAb) 
which have been used extensively in the treatment of CLL. Campath 1-H is a genetically 
engineered antibody directed against the CD52 antigen (Rai KR et al 1998) and has 
recently been licensed in the UK for use in CLL. CD52 is found on the surface of most 
lymphocytes including normal B and T cells and CLL B cells. It is not expressed on 
granulocytes, platelets or haemopoietic progenitor cells (Osterborg A 1999). 
Rituximab is also a mAb directed against the CD20 antigen found on all B cells and CLL B 
cells (Montserrat E 2001). It is licensed for the treatment of follicular lymphoma. The 
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levels of expression of CD20 are much lower on the surface of CLL cells and therefore the 
clinical effects seen with rituximab in CLL are not as impressive (Dyer MUS 1999). 
Both monoclonal antibodies mediate anti tumour activity using immunological effects such 
as complement-mediated lysis, antibody dependent cellular cytotoxicity (ADCC) and 
signalling pathways that lead to induction of cell death (Stanglmaier M et al 2000; 
Pedersen IM et al 2000). Both agents can be used to treat minimal residual disease and can 
be applied in stem cell transplantation to "purge" any residual malignant cells (Rai KR et al 
1998; Binet JL 1999; Rai KR et al 2000). Currently these antibodies are being used in 
combination with chemotherapeutic agents such as fludarabine in order to improve 
complete response (CR) rates from 25-30% as seen with fludarabine alone (Rai KR 1999). 
Recent studies comparing apoptotic rates offludarabine with Campath 1-H and Rituximab 
have shown that both are less toxic than fludarabine and that both monoclonal antibodies 
were efficient at inducing good rates of apoptosis when used in conjunction with 
fludarabine in vitro (Grdisa M et al 2000). 
Both antibodies however, can have serious side effects (Rai KR 1998; Montserrat E 2001). 
Campath 1-H can cause fever, chills and rash as "first-dose" reactions and an increased 
susceptibility to opportunistic infections, in particular, reactivation of cytomegalovirus 
(CMV). Campath 1-H can also deplete T cells, as CD52 is expressed on the T cell surface, 
which increases the risk of infection to the patient. In particular, patients with 
prolymphocytic fonns of CLL have been shown to express higher levels of CD 52 on the T 
cell surface compared to T cells from nonnals (Binet JL, 1999). Patients with high white 
cell counts who are treated with rituximab may develop "cytokine-release syndrome", 
characterized by fever, rigors, skin rash, nausea, vomiting and hypotension (Montserrat E 
2001 ). 
There are a number of newer monoclonal antibodies, which utilise radioactive moieties 
attached to anti-CD20 to deliver localised targeted radiotherapy to disease sites. These may 
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improve response rates and play a role in transplant conditioning. A new contender 
currently undergoing phase I and II trials is the radiolabeled Lym-1, an lgG2a mouse 
monoclonal antibody conjugated with 1131 , which is directed against one of the HLA-D 
antigens on human B cells. Results for this drug are still in the early stages (Waldmann TA 
et al2000; Montserrat E 2001). 
Whilst immunotherapy using monoclonal antibodies appears to be promising, it is clear 
that the effect of these antibodies is seen not only on the malignant B cells, but also on the 
non-malignant T cells. This response is undesired as the exact role played by T cells in 
CLL is still unclear. There is clear evidence, however, that the peripheral malignant B cells 
are able to express surface antigens such as CD5 which are normally only expressed on 
peripheral blood T cells and that the expression of other critical activation and interaction T 
cell antigens is dysregulated (Scrivener S et al 2001). Until more is known about the 
dialogue that takes place between B and T cells during this response, the use of monoclonal 
antibodies to control the disease could have unwanted side effects. Although monoclonals 
such as Campath 1-H have shown good partial responses in patients refractory to treatment, 
the duration of response is relatively short (Rai KR et al 1998). Monoclonal antibodies 
have not provided a "cure" for CLL. 
1.2.5.5 Adoptive immunotherapy 
Recently, there have been a number of advances made in adoptive immunotherapy, ranging 
from the transfection of DNA into tumour cells to the generation of cytotoxic T cells raised 
against specific antigens expressed on the cell surface of the malignant cells. In 
haematological malignancies much of the work has centred on lymphoma, chronic myeloid 
leukaemia and multiple myeloma, but the field is rapidly expanding and an increasing 
number of studies have been using these methods in CLL. 
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DNA vacci11es 
Three conditions are required for successful antitumoral vaccination: the existence of a 
tumour antigen, an efficient vaccine delivery system and a relatively intact immune system 
(Binet JL 1999). Recent work has focused on inducing anti-idiotypic antibodies in mice 
which recognise mutated and un-mutated immunoglobulin V gene sequences (Stevenson 
FK et al 1999) using a fusion gene design. Using this method, antigens fused to an "alert" 
signal such as Fragment C of Tetanus Toxin are delivered via DNA and these fusion gene 
designs can induce antibodies against the malignant clone. The same design has also been 
able to induce antibodies against alternative tumour antigens such as adhesion molecules. 
The prospect of such treatment suggests that a vaccine against specific proteins found in 
leukaemic clones could be used to treat CLL patients, either alone or in combination with 
conventional drug therapy or to clear residual disease (Binet JL 1999). However, CLL is a 
heterogeneous disease, with patients displaying a wide range of different cellular and 
molecular markers, many of which are also found in normal Band T cells. To identify one 
particular marker which is specific to CLL may be problematic and cause destruction of 
normal, healthy cells in addition to the malignant cells. 
Pre-exisiting but incomplete evidence and the work that forms the basis of this PhD 
research suggest that T cells may be dysfunctional in CLL. Such a finding implies an 
immune system that is not "intact" and until such findings are considered, DNA vaccines 
are unlikely to provide significant forms of treatment or a cure for CLL. 
Ge11e Therapy 
Gene therapy is another rapidly expanding field in which cellular antigens are transferred 
into leukaemic B cells in an attempt to stimulate a host anti-leukaemia immune response 
(Kipps TJ 1999). The theory behind this suggests that despite expressing MHC molecules, 
CLL B cells are ineffective antigen presenting cells (APCs) and are therefore unable to 
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stimulate T cells. If this could be reversed and B cells could present antigen, the T cells 
would become activated and recognise the malignant cells. Using high-titre, replication-
deficient adenovirus vectors housing a recombinant CD154 transgene (Ad-CD154) for 
transfection, CLL B cells were made to express CD 154, an activation and adhesion marker 
normally only found transiently expressed on the surface ofT cells. 
In a normal immune response, CD 154 on the T cells binds to CD40, which is expressed on 
B cells and dendritic cells. By transfecting CD154 into the leukaemic B cells, it was 
envisaged that the CLL cells would be able to up-regulate critical eo-stimulatory molecules 
on the infected leukaemia cell surface by interacting with other leukaemia cells and 
inducing these changes in bystander leukaemic cells as well. In vitro experiments have 
shown that these transfected leukaemia cells can generate cytotoxic T cells specific for the 
non-infected leukaemia cells (Kato K et al 1998). 
In a phase I trial, patients with intermediate or high-risk disease received infusions of 
autologous, Ad-CD 154-infected leukaemia cells (Kipps TJ et al 1999). The patients did not 
experience any significant toxicity, apart from the minor side effects of fever, fatigue and 
nausea, which resolved spontaneously after a few days. Observed changes in the leukaemic 
and T cells included expression of eo-stimulatory molecules on bystander CLL B cells, 
significant plasma levels ofiFN-y and IL-12, a 2-3 fold increase in absolute T cell numbers 
associated with a 21-72% reduction in absolute lymphocyte counts and a 33-90% reduction 
in lymph node size within 1-4 weeks of treatment. However, there was no report of 
clearance of the disease from the patient or of the duration of the observed responses. 
Transfecting leukaemic B cells with CD 154 may enable them to communicate with each 
other exclusively and the long-term effect of this on the patients' immune system is 
unknown, but it could further enhance T cell defects that may prevent B and T cells from 
communicating with each other. While this research suggests a reduction in lymphocyte 
count and a possible form of increasing biological activity in CLL, longer term 
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observations will be needed both in vitro and in vivo for evidence of durable and cytotoxic 
T cell responses to the leukaemic clone. Again, the possibility of existing T cell 
dysfunction in this disease is not taken into account and without the "intact" immune 
system, results are unlikely to be satisfactory in the treatment of CLL. 
Dendritic cell immunotlrerapy 
Dendritic cells (DCs) were discovered in mice 28 years ago (Steinman RM and Cohn ZA 
1973) and since that time, they have become recognised as the most potent cell type for 
initiating cellular immune responses (Brenner M et al 2000). They are specialized antigen 
presenting cells which express all the relevant accessory cell surface antigens such as MHC 
I and ll and the adhesive and eo-stimulatory markers necessary to stimulate an immune 
response. After capturing foreign antigen, DCs migrate to the secondary lymphoid organs 
to complete their activation process while stimulating T cells, a process they can carry out 
without any additional cytokine release, hence they have been termed "professional antigen 
presenting cells" (Ridge JP et al 1998). There has been a surge of interest in DCs and their 
potential for creating a vaccine which harnesses the patients' own immune response to 
malignant cells. This form of immunotherapy has already shown encouraging results in 
both haematological and non-haematological malignancies. 
In CLL patients, autologous CLL T cells have been cultured alone or with B-CLL lysate-
pulsed and unpulsed autologous dendritic cells. Those T cells cultured with the autologous 
CLL lysate-pulsed dendritic cells showed a significant increase in the secretion of IFN-y 
and also a specific cytotoxicity to autologous B-cell targets (Goddard RV et al 2001). 
Those T cells cultured with non-CLL B cell lysate showed no response. The majority of the 
responding T cell population were CD4+ve. Such results suggest that there is potential for 
an in vitro system that can prime the in vivo immune response to recognise and respond to 
the malignant cells. However, while some patients show a good cytotoxicity response 
36 
following culture with the pulsed DCs, this was not observed in every patient, suggesting 
that this procedure is not suitable for all CLL cases. For those patients that did show a 
response, it was necessary to present the CLL 8 cell lysate in a different way to normal 8 
cell antigen before the T cells were able to recognise it as foreign and elicit a cytotoxic 
response. A proportion of the patients were unable to respond at all, suggesting that the T 
cells may not be capable of either recognizing the malignant lysate as foreign or that they 
were unable to react due to a dysfunctional immune response. The maximum CTL 
response observed was only 30%, even at a very high effector:target ratio ( 40: I), which 
again suggests that there may be an underlying T cell dysfunction preventing a full 
response. 
The theory of requmng an "intact" Immune system for effective adoptive 
immunotherapeutic techniques is demonstrated in each of these new approaches to treating 
CLL. In each case, while initial results have been promising, the techniques have so far 
failed to prove clinically successful and are not equally tolerated by each patient. Until T 
cell function in CLL is more thoroughly investigated and any dysfunction addressed and 
corrected, it is unlikely that adoptive immunotherapy will be successful in treating or 
curing CLL. 
1.2.6 Disease Transformation 
A small group of patients have been shown to respond poorly to treatment and can go on to 
develop transformation of 8-CLL (Enno A et al 1979). Disease progression correlates with 
refractiveness to treatment. The blood of these patients contains more immature-appearing 
cells with the morphological characteristics of a prolymphocyte. In a patient with stable, 
early 8-CLL, approximately 15% of cells are of this sort (Oscier D 1999), but in disease 
progression, between 20 and 50% of all cells appear as prolymphocytes. Progression to this 
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stage signals more aggressive disease, responding poorly to chemotherapy with a very poor 
prognosis (Kipps TJ 2000). 
Disease transformation in B-CLL is not necessarily linked to exposure to treatment 
regimes. Between 3 and 10% of patients will develop Richter's syndrome (Montserrat E 
2001) and a third of these patients will not have received any treatment. This syndrome was 
described (Richter MH 1928) as an aggressive, high-grade, Jarge-B-cell lymphoma, 
occurring in patients around 2 years after the initial diagnosis of CLL. Symptoms of 
Richter's syndrome include rapid lymph node enlargement, fever and weight loss 
accompanied by the laboratory findings of a monoclonal gammopathy and an increase in 
p53 genetic mutations (Giles FJ et al 1998). Median survival time is 5 months after 
transformation and chemotherapy treatment produces only (Kipps TJ 2000). 
A very rare transformation occasionally observed in patients is from CLL to ALL (acute 
lymphoblastic leukaemia), where the B cells originate from the same CLL B cell clone. 
This is associated with high levels of expression of c-myc, a proto-oncogene which 
positively regulates cell proliferation (Ceballos E 2000). Malignant transformation 
frequently occurs in cells which over-express c-myc and its expression results in 
continuous proliferation (Larsson LG et al1991). 
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1.3 Biology of B-CLL 
The CLL B cell clone is an accumulation of mature long-lived B cells, which express many 
surface markers distinguishing them from normal B cells (Caligaris-Cappio F 1996; 
Dierlarnm J et a1 1997; Jurlander J 1998; Soderberg 0 1998; Caligaris-Cappio F and 
Hamblin TJ 1999). It is likely that these cells have arisen from one progenitor cell as 
indicated by the presence of identical light chains and other key markers, but uncertainty 
remains as to the genetic origin of the clone. While many clonal cells express genetic 
abnormalities, phenotypically identicalleukaemic cells are found with different genotypes 
in the same patient (Jurlander J 1998). These genetic abnormalities may be pathogenetic or 
secondary phenomena. Of equal importance to the development of this disease is the 
potential loss of homeostasis in B cell ontogeny which may not be related to specific 
genetic abnormalities. It is necessary, therefore, to understand how normal B cell 
development progresses in order to understand the possible ways in which the malignancy 
may arise (Fig. 3). 
1.3.1 B cell development 
B cell development begins when lymphoid stem cells in the bone marrow differentiate into 
the earliest distinctive B-cell lineage, the QIQgenitor B cell (pro B cell). Each stage in the 
development pathway of B cells is accompanied, and often defined by, re-arrangements of 
the B cell immunoglobulin (Ig) genes and is often under the tight control of cytokines and 
the microenvironment (LeBien TW et al 2000). 
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Fig. 3 Normal 8 cell development 
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1.3.1.1 Pro B cells 
Pro B cells are the most primitive recognizable cells in the B cell lineage (Stiles DP et al 
1997). They express the surface proteins CD 1 0, CD 19 and the nuclear proteins terminal 
deoxynucleotidyl transferase (TdT) and recombinant activating genes l and 2 (RAG-I and 
RAG-2) (Schatz DG et all989; Oettinger MA et all990). RAG-I and RAG-2 both play an 
important role in immunoglobulin gene re-arrangement as they have the ability to 
recognize and cleave DNA at specific re-combination sequences. Antibody diversity is 
increased by the insertion of N regions at the points of joining between variable (V), 
diversity (D) and joining (J) segments (Oettinger MA et al 1992; Spanopoulou E et al 
1995). TdT is responsible for these insertions. The first immunoglobulin re-arrangements 
to take place in the B cell are heavy chain genes (Tonegawa S 1983). Once this has 
occurred, the cell can be classified as a pre-B cell. Pro-B cells which fail to make a 
functional VDJH rearrangement undergo apoptosis. 
The bone marrow stromal environment plays a critical role in the development of pro-B 
cells to pre-B cells (Hahn BK et al 2000; Ansel KM and Cyster JG 2001). Pro-B cells are 
able to bind to the stromal cells through very late antigen-4 (VLA-4), which binds with 
vascular cell adhesion molecule (VCAM-1) on the stromal cell. This interaction promotes 
the binding of another receptor pair, c-Kit on the pro-B cell with stem cell factor, which in 
turn triggers the expression of interleukin-7 (IL-7) receptors on the pro-B cell surface. IL-7 
released by the stromal cells binds to the IL-7 receptors (IL-7R), inducing the pro-B cell to 
mature into a pre-B cell. Studies have shown that mice bred with disruptions in the genes 
for IL-7 and the IL-7 receptor a chain all lead to severe impairment in B cell development 
(von Freeden-Jeffry U et al 1995). Other important chemokines in B cell development 
include CXCLI2, produced by bone marrow stromal cells that provide a stimulatory factor 
for pre-B cells (Ansel KM and Cyster JG 2001). 
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1.3.1.2 Pre-B cell 
Pre-B cells are found almost exclusively in the bone marrow and are representative of a 
transient phase in B cell development that lasts approximately 2 days (Stiles DP et al 
1997). IL-7 continues to be secreted by the stromal cells which drive the maturation 
process by inducing down-regulation of the adhesion marker VLA-4 on the pre-B cell 
surface. The pre-B cell can now detach from the stromal cell, as direct contact is no longer 
required for growth. However, IL-7 released from the stromal cells is still required for 
growth and maturation. Re-arrangement of the light chain genes begins in the pre-B cell 
once heavy chain gene re-arrangements have stopped (Levine M et al 2000). TdT is no 
longer expressed and as a result, there is no insertion of N-regions into light chain genes 
(LeBien TW 2000). Re-arrangement continues until a functional (kappa) K or (lambda) A. 
light chain is produced. Once either light chain protein is produced, it associates with the 
existing heavy chain unit and together they are transported to the cell surface as membrane 
immunoglobulin M (mlgM). Expression of RAG-I and RAG-2 is downregulated and the 
cell therefore loses the ability to further re-arrange its light chain genes. This successful 
assembly of one heavy chain and one light chain gene prevents any further gene re-
arrangements. Clonal restriction arises from this process, known as allelic exclusion. 
Should a specific lymphocyte divide after this stage, all daughter cells will express the 
same heavy and light chains, as there can be no further immunoglobulin re-arrangements. 
One B cell can therefore give rise to a whole population of clonal cells in response to 
antigenic stimulation. 
1.3.1.3 Immature B lymplwcyte 
Once the B cell begins to express surface IgM it becomes an immature B lymphocyte. At 
this stage, it will remain in the bone marrow for approximately l-3 days. Bone marrow B 
cells with functional heavy and light chains express B cell receptors (BCRs). At this point, 
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immature B-lymphocytes will undergo negative selection. Any B cell that can cross-link its 
IgM receptors or bind to self-antigen on the cell surface will undergo apoptosis. Large 
numbers of B cells are "lost" within the bone marrow, either as a consequence of self-
reactive lgM or through non-functional immunoglobulin production (Duchosal MA 1997; 
Rudin CM and Thompson CB 1998). Of the 2 x 107 lgM+ B cells that develop each day 
within the bone marrow, 10% will reach the spleen and only 1-3% will enter the mature B 
cell pool (Loder F et al 1999). Without this fail-safe mechanism, the immune system 
would be constantly under threat from B cells recognising their own proteins as foreign. 
Alternative splicing of RNA transcripts from the already re-arranged heavy chain leads to 
the production of immunoglobulin D (IgD), which occurs before the cell becomes mature 
and leaves the periphery (Levine MH et al 2000). Once a cell has successfully completed 
this process, it can exit the bone marrow and enter the peripheral organs as a mature B 
lymphocyte. 
1.3.1.4 Mature B cell 
Mature B cells, now expressmg the surface receptors CD23, lymphocyte function 
associated antigen-1 (LFA-1 ), intercellular adhesion molecule-1 (ICAM-1 ), major 
histocompatability complex 11 (MHC 11) and CD40 among others, will now enter the 
peripheral blood and organs. Expression of these key surface antigens allows for the 
interaction with APCs such as T cells. The in vivo activation and differentiation of B cells 
occurs within designated lymphoid follicles found within the lymph nodes (Thorbecke GJ 
et al 1994; Kuby J 1997). Antigen is filtered through the lymphatic system and is delivered 
to the lymph node via afferent lymphatic vessels. The antigen is taken up by macrophages 
and DCs within the paracortex of the lymph node, where it is presented to na"ive T cells. 
This results in T helper (Tu) cell activation and proliferation. B cells which have 
successfully bound antigen on their smlg will process and present it in association with 
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MHC II, enter the paracortex and interact with an activated T H cell specific for the antigen. 
A T cell-B cell conjugate is formed and T cell dependent-B cell activation takes place. The 
activated, proliferating B cells now start to form small complexes at the edge of the 
paracortex where they begin to differentiate and grow, a process that takes 3-4 days. At this 
point, some of the B cells will continue to develop into plasma cells, which will start to 
secrete antibody which, until now, has only been expressed as cell surface protein 
(Duchosal MA 1997; Rudin CM and Thompson CB 1998). 
The majority of plasma cells will home to the bone marrow, where they will mature. These 
cells express little or no CD40, CDI9, CD20, CD22, MHC II or surface lg (slg) and no 
longer require T cell help (Burrows PD and Cooper MD 1993). The remaining B cells, 
which do not differentiate into plasma cells, migrate with T H cells to primary follicles, 
which will develop to become secondary follicles. These secondary follicles are specialised 
microenvironments where interactions can take place between B cells, T cells and follicular 
DCs (FDCs). 
As cell proliferation continues, activated B and T cells move towards the centre of the 
follicle to form the germinal centre (GC). GC formation relies heavily on B and T cell 
interactions through CD40 and CDI54. Blockade of this receptor pair prevents GC 
formation, B cell activation and memory B cell development. (Gray D et al 1994; Grewal 
IS and Flavell RA 1997). 
As the GC forms, the activated B cells undergo intense proliferation and are termed 
centroblasts. These centroblasts will now move to one side of the follicle, where they form 
the dark zone (Thorbecke GJ et al 1994) and continue to divide, giving rise to small cells 
expressing membrane lg, known as centrocytes. As these centrocytes proliferate in the dark 
zone, they will undergo somatic mutation of the heavy and light chain variable regions. The 
molecular mechanisms which underlie somatic mutation are poorly understood, but require 
the presence of both T H cells and GCs, suggesting that interaction with T cells in this 
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specialised environment is critical for B cell development to continue. The process of 
somatic mutation will produce a small number of cells which have a high affinity for 
antigen and these cells will undergo positive selection by binding to the antigen presented 
by the FDCs, delivering a signal that protects them from apoptosis. 
Centrocytes that successfully bind to antigen on the FDCs will undergo differentiation to 
become either small memory B cells or larger plasma cells (Agematsu K 2000). 
Plasmablasts are induced by interleukin-1 (IL-l) and CD23 produced by the FDCs. The 
CD23 is expressed in a membrane form and secreted as a soluble form. The plasmablasts 
will develop into plasma cells within the medulla of the lymph node, where they will begin 
to secrete antibody. 
Memory B cells are formed when the centrocytes bind antigen which is released from the 
FDCs (MacLennan IC et a! 1997). After this antigen has been processed, it is presented in 
association with MHC II to activated T H cells. The up-regulation of the surface marker 
CD 154 on the T cell surface binds to CD40 on the centrocyte, the signal necessary for the 
formation of a memory B cell. 
Follicular centres are therefore critical for the selection of B cells with the best fit for 
antigen after somatic mutation and for the differentiation of B cells into plasma cells or 
memory cells. Each process requires the presence ofT cells to provide stimulatory signals 
such as CD154 for signalling within a microenvironment. Plasma cells can also develop 
outside of follicular centres, in either lymph nodes or spleen. Activated B cells proliferate 
within these areas and can differentiate into plasma cells, which release antibody, a 
secreted form of membrane-bound immunoglobulin. Plasma cells do not divide, have a life 
span of approximately 4 weeks and do not express cell surface immunoglobulin (Parham P, 
2000). 
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1.3.2 Normal cellular replication and cell cycle control 
The cell cycle can be divided into four distinct stages, growth 1 (G1), synthesis (S), growth 
2 (G2) and mitosis (M) (Alberts B et al 1994) (fig 4). At the end of each of these stages, 
certain cell cycle requirements must have been fulfilled before progression to the next stage 
(Stiles DP et al 1997). The M phase, which incorporates the whole process of mitosis, 
involves the division of nuclear material. The time between one M phase and the next is 
known as interphase, during which G., S and G2 occur. 
After a phase of mitosis has taken place, the cell will enter G., when it will undergo 
synthesis and accumulation of structures and molecules necessary for cellular and DNA 
replication. During G1, the cell monitors its environment and size for favourable replication 
conditions. As it progresses through G1, proteins including Fos, Jun and c-myc accumulate 
as transcription factors and act on other genes required for DNA synthesis. Cells which 
have p53 mutations are much more susceptible to genetic instability and the potential to 
become malignant. Cells in G1 that have not committed themselves to DNA replication can 
temporarily or permanently cease dividing, a stage termed G0• These cells are capable of 
remaining in this state for days, weeks or even years before proliferation resumes. 
If feedback signals from the environment and the cell are favourable, the cell enters S 
phase, during which all nuclear DNA is replicated. G2 represents a phase where the cell 
produces sufficient material for the mitotic division (Wolfe SL et al 1993) and ensures that 
DNA replication IS complete before entering the M phase. 
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Fig 4: Normal cellular replication and cell cycle control 
M= Mitosis 
G1 =Gap 1 prior to DNA synthesis 
S = DNA synthesis 
G2 = Gap 2, between DNA synthesis and mitosis 
The length of each segment depends on the cell 
type and conditions of growth. 
Illustration showing the various stages of the cell cycle 
47 
1.3.3 Apoptosis 
Under certain environmental or cellular signals, cells will undergo a programmed cell death 
known as apoptosis, from the Greek word apo meaning "off' and ptosis, meaning "falling". 
Apoptosis is a common occurrence in many cell types, including those of the haemopoietic 
system and it is essential for maintaining a stable population of cells by ensuring that the 
rate of new cell production is balanced by an equal rate of cell death (Stites DP et al 1997). 
Any disruption to this equilibrium may cause either an accumulation of cells resistant to 
apoptosis or a loss of cells that are more susceptible to it. 
One of the most critical factors controlling apoptosis is the oncoprotein family Bcl-2 (Stiles 
DP et al 1997; Osorio LM and Aguilar-Santelises 1998). Most members of the Bcl-2 
family, which includes Bax, Bcl-x, Bak and Mcl-1, are integral membrane proteins that are 
found associated with organelles that include the endoplasmic reticulum (ER), 
mitochondria and the plasma membrane (Kuby J 1997). Each member of this family will 
fall into one of two groups; those that actively induce apoptosis and those that inhibit it. 
Whether or not a cell will undergo apoptosis appears to be related to the levels of 
expression of these proteins. Cells expressing high levels ofBcl-2 will be more resistant to 
apoptosis, whilst those with a greater expression ofBax will be more susceptible to it. 
Other membrane proteins involved in the regulation of apoptosis in lymphocytes include 
the tumour necrosis factor receptor (TNFR) family, which incorporates TNFR1 and 
TNFR2, Fas and CD40 (Rudin CM et at 1996). Binding of Fas with Fas ligand or cross-
linking Fas with anti-Fas antibodies and receptor ligand binding of TNFR1 induce 
apoptosis in lymphocytes, including autoreactive and cytotoxic T cells via the "death 
domain", a cytoplasmic tail region through which programmed cell death signals can be 
initiated (Rudin CM et at 1996; Osorio LM and Aguilar-Santelises M 1998). CD40, 
expressed on activated B cells, prevents B cell apoptosis after binding with its ligand, 
CD154 on activated T cells (Rudin CM et al1996). 
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Caspases play a vital role in apoptosis. They are a family of cysteine proteases produced in 
cells as catalytically inactive zymogens (Chai J et al 2000). Effector caspases, such as 
caspase-3, are activated by initiator caspases, such as caspase-9, through proteolytic 
cleavage at specific internal residues. Once these become activated, the effector caspases 
are responsible for proteolytic cleavage of many different cellular targets, which ultimately 
leads to death of the cell. 
A family of cysteine proteins, the caspases, also play a critical role in apoptosis. When 
activated, caspases act in a cascade and cleave specific substrates, mediating many of the 
biochemical and morphological changes that take place in a cell undergoing apoptosis, 
such as cell shrinkage, chromatin condensation, DNA fragmentation and and plasma 
membrane blebbing (Kohler C et al 2002). 
Once a cell has received the appropriate signal that triggers apoptosis, it will undergo a 
series of morphological changes. Over the course of several hours, the cell will shrink as its 
nucleus, nuclear chromatin and cytoplasm become condensed (Osorio LM and Agular-
Santelises M 1997). The chromosomal DNA is cleaved and fragments of the cytoplasm are 
pinched off as the cytoskeleton starts to degrade, a process known as "blebbing". After 
these processed have occurred, the cell will shed tiny membrane-bound bodies that contain 
intact-organelles. These organelles are quickly phagacytosed by surrounding macrophages, 
preventing the release of any intracellular cell contents into the surrounding tissue, thus 
preventing an inflammatory response. 
In contrast to this process, cells can also die by necrosis, from the Greek word meaning 
death. Necrosis is not programmed or triggered and is usually the result of accidental injury 
(Kuby J 1997). It results in the cell swelling and bursting, releasing intracellular contents 
into the surrounding tissues. These intracellular contents are cytotoxic to bystander cells 
and as a result, an inflammatory response is usually triggered. 
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1.3.4 Origins of the CLL cell 
In an attempt to identify the possible origins of the CLL B cell, it is necessary to first 
examine the cellular and genetic features that are both unique to the malignant cell and 
those that it has in common with normal B cells in the developmental pathway. 
CLL B cells have a low to undetectable expression of surface immunoglobulins and, if 
detected, they are usually IgM or IgM and IgD. Only rarely are they IgG or IgA (Caligaris-
Cappio F 1996; Soderberg 0 1998; Caligaris-Cappio F and Hamblin TJ 1999). The 
immunoglobulins detected on the cell surface often have a polyreactive, autoantibody 
activity and can behave as rheumatoid factor (RF), specifically identifying the Fe region of 
human IgG (Parham P 2000). IgM autoantibodies against RF are frequently found on both 
the cell surface and in the serum of patients with CLL (Borche L et al 1990). Autoantibody 
activity can also be directed against haemopoietic antigens expressed on the surface of red 
blood cells and, occasionally, platelets, which can lead to autoimmune haemolytic anaemia 
(AlliA) and autoimmune thrombocytopenic purpura (AITP) respectively (Caligaris-Cappio 
F 1996). 
The CLL B cells accumulate in the peripheral blood and bone marrow in the Go phase of 
the cell cycle, yet these apparently resting cells also express membrane markers of cellular 
activation such as CD80 and CD86, which are normally restricted to activated normal B 
cells (Caligaris-Cappio F et al 2001). Under normal conditions, the CLL B cells appear 
anergic. They have a reduced capacity to act as efficient antigen presenting cells (APCs), 
whilst normal B cells are highly effective APC (Caligaris-Cappio F 1996). However, if the 
CLL B cells are stimulated through CD40, either using monoclonal antibodies or activated 
T cells expressing the CD40 ligand CD 154, they can become highly efficient APCs, 
suggesting a restricted dialogue between CLL B and T cells during a normal immune 
response. 
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CD5 expression is found on all malignant CLL B cells, but is also expressed on T cells and 
a subset of normal B cells (Lydyard PM et al 1999). Nonnal B cells expressing CD5 are 
also known as B 1 cells, and they represent the most prominent B cells in early foetal life, 
decreasing with age. Circulating B 1 cells in the adult are normally found in the follicular 
mantle zone (FMZ) of lymph nodes, but a limited number of normal B I cells can also be 
found in the bone marrow. Normal B 1 cells produce polyreactive autoantibodies, including 
those directed against blood group antigens (Lydyard PM et al 1999). B l cells are also the 
main source of TgM derived autoantibodies. Patients with rheumatoid arthritis have 
increased levels of B I cells (Piater-Zyberk C et al 1985). It is unclear what controls the 
levels of nonnal Bl cells in the bloodstream, but children with DiGeorge syndrome 
(lacking a thymus) have decreased levels of B I cells, suggesting a role for the thymus in 
maintaining B l cell numbers in the periphery (Kourtis AP et al 1997). Normal B I cells 
express low to undetectable amounts of Bcl-2 (Caligaris-Cappio F 1996). 
Early studies on the V11 genes in CLL suggested that most malignant 8 cells had unmutated 
Vu genes (Kipps T et al 1989). As larger studies were carried out however, up to 50% of 
CLL patients V11 genes were shown to be mutated, indicating that they would have passed 
through the gem1inal centre (Caligaris-Cappio F et al 2001; Hamblin T J et al 1999). 
As the nature of the CLL B cell has become clearer, attempts to identify its origin have 
combined the evidence above (Figure 5, pg 53). Initially, much work focused on the 
similarities between the CLL CD5+ B cell and the normal CD5 B cell, B1 (table 7). 
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Table 7: Similarities and differences between CLL CD5 8 cells and normal CD5 81 
cells 
Feature CD5+ CLL 8 cell CD5+ normal 81 cell 
polyreactive autoantibodies yes yes 
somatic hypermutation yes/no (50% of patients) no 
formation of mouse yes yes 
erythrocyte rosettes 
Bcl-2 expression yes no 
low surface Ig expression yes no 
Table showing the similarities and differences between CD5+ve CLL B cells and the normal subset of B cells 
that naturally express COS. 
A number of cellular and molecular similarities between the two cells have emerged. CLL 
patients, CD5+ 8 cells and normal Bl cells produce polyreactive IgM autoantibodies 
directed against RF and haemopoietic cell antigens (Caligaris-Cappio F 1996). Both are 
also able to produce these antibodies in the absence of somatic mutation, suggesting that 
neither subset has passed through the germinal centre. In addition, both CLL 8 cells and Bl 
cells express CD20 and both are able to form rosettes with mouse erythrocytes (Caligaris-
Cappio F 1996). The CD5 normal 8 cell is considered to be one of the possible candidates 
for the origin of the CLL clone. Normal CD5 8 I cells are located in the mantle zone of 
secondary lymphoid follicles and it is from here that it is suggested CLL B cells may arise 
(Caligaris-Cappio F 1996; Soderberg 0 1998; Caligaris-Cappio F and Hamblin TJ 1999; 
Caligaris-Cappio Fetal 2001 ). One possible theory suggests that CLL is a malignancy of a 
mantle-zone-based subpopulation of anergic self-reactive CD5+ B cells devoted to the 
production ofpolyreactive natural autoantibody (Caligaris-Cappio F et al2001) 
However, there are also striking differences between CLL 8 cells and normal 8 I cells. 
While CLL B cells express low to undetectable levels of surface Ig, normal 8 I cells 
express normal levels of surface lg. CLL B lymphocytes are stuck in G0, yet are able to 
express cell surface markers and cytokines that are inoicative of an activated 8 cell 
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(Caligaris-Cappio F et at 2001). B1 cells do not follow this pattern. The B1 cell cycle 
correlates with expression of cell surface markers and there is no discrepancy between their 
activated and resting state. They also express low levels of Bcl-2, whilst CLL B cell Bcl-2 
expression is high. Normal B 1 cells do not demonstrate somatic hypermutation, yet 50% of 
CLL B cells do (Hamblin TJ et al 1999; Caligaris-Cappio F et al 2001). In addition, the 
production of the autoantibodies in CLL is believed to be from the residual"normal" B cell 
population (Hamblin TJ and Oscier DG 1997). 
Whilst it is appealing to try to identify a normal cellular counterpart for the CLL B cell, 
attempts have so far failed. Such a hypothesis would need to encompass all aspects of the 
disease, such as the autoimmunity, hypogarnmaglobulinaemia, low surface lg, CD5 
expression, accumulation in Go but expression of activation markers and cytokines, the 
discrepancy between somatic mutation in only half the patients and an inconsistent genetic 
repertoire, and the identified dysregulation in T cell function observed in CLL patients. 
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Figure 5: Possible cellular origins of CLL B cell 
BONE MARROW 
LYMPH NODE 
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MOVE TO DARK ZONE 
UNDERGO SOMATIC MUTATION AND 
AFFINITY MATURATION 
4, 4, 
PLASMA CELLS 
REMAIN IN LYMPH NODE 
* Indicates possible place of origin of CLL B cell 
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Illustration showing possible cellular origins of the leukaemic clone. As the B cell develops, positions marked 
with an asterix indicate where it is possible for the clone to develop 
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1.3.5 Morphology 
CLL B cells appear as small, mature, unstimulated peripheral blood B cells which are 
easily damaged on preparation of a blood film, giving a characteristic smear cell 
(Calligaris-Cappio F and Hamblin TJ 1999). Within the peripheral blood, the malignant 
cells can be distinguished by heavily clumped basophilic chromatin within the nucleus and 
a small, agranular, pale blue cytoplasm (Dadmarz Rand Cawley JC 1987; Dierlamm J et a! 
1997). Approximately 15% of patients have larger B cells with a more prominent nucleolus 
(prolymphocytes) (Oscier D 1999) and others may display a cleaved nucleus or 
lymphoplasmacytoid features. The bone marrow and lymph nodes are infiltrated by 
identical lymphocytes. 
1.3.6 Immunophenotype 
One of the key distinguishing features of the CLL cell is its low to undetectable levels of 
surface immunoglobulins (slgs) (Dohner H and Stilgenbauer S 2001) (table 8). The 
majority ofCLL cases express surface immunoglobulin M {slgM) alone or with slgD. The 
presence of slgA or slgG is rare. The presence of either slgM and/or slgD is detected only 
very faintly by immunoflourescent methods. However, experiments involving detection of 
total cellular immunoglobulin content (i.e. both internal and external) have shown that 
levels of total IgM are comparable with those of normal B cells, whilst IgD varies greatly, 
with patients varying in expression from very low to near normal. The low level of 
expression of slgM has only been seen in normal B cells which have been anergized via 
interaction with self-antigen (Goodnow CC et al 1989). 
The malignant cells will all express either kappa or lambda as a light chain, this being 
indicative of a clonal population of cells (Jurlander J 1998). In CLL there is usually a clear 
imbalance in the kappallambda ratio, which in a normal patient should be 2:1. 
55 
CLL B cells have been shown to express the interaction and activation markers CD80 and 
CD86 (Caligaris-Cappio F et al2001) (table 8). 
Expression of the B cell receptor (BCR) is altered in CLL patients. The BCR consists of 
surface Ig non-covalently linked with Iga!Igp (CD79a/CD79b) and CDS. In most CLL 
patients, the extracellular domain CD79b is absent (Alfarano A et a! 1999; Hamblin TJ et 
a! 1999; Oscier DG et a! 1999; Garcia-Vela Jet a! 1999; Caligaris-Cappio F et a! 2001). 
However, CD79b has been shown to be functionally normal in all CLL patients, regardless 
of whether it is expressed at the cell surface (Rassenti LZ and Kipps TJ 2000). Normal B 
cells use CD79b after activation to downregulate BCR expression, suggesting that the CLL 
B cells may be activated. The use of CD79b as a marker for accurate diagnosis of CLL is 
now becoming more common. 
CDS, CD19, CD20, CD21, CD22 and CD23 are expressed in a characteristic manner by 
the malignant B cells and are now described. 
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Table 8: Antigen cell surface expression in CLL 
Marker Molecular Normally found Role: ± on CLL B cells 
weight on: 
part of the BCR, 
cos 67kDa T cells, B-1 B cells activation and + 
differentiation 
T-B cell interactions, 
CD19 95kDa B cells activation, + 
differentiation 
B cell activation and 
CD20 33-37kDa B cells signal transduction + 
mature B cells, complement, antigen 
CD21 145kDa mature T cells (low), presentation to T + 
immature T cells cells, CD23R 
(high) 
accessory signalling 
CD22 135kDa B cells through the BCR 
-
B cells, monocytes, 
CD23 45kDa macrophages marker of B cell + 
activation 
part of the BCR, 
CD79b 33-40kDa B cells spliced after --
activation to 
downregulate BCR 
8 cell activation, T-B 
CD80/CD86 60kDa/80kDa B cells, dendritic cell interaction + 
cells, some T cells 
slg 
-- B cells antigen binding ± 
cells protected from protects against 
Bcl-2 25kDa apoptosis apoptosis + 
Table showing molecular weight, normal cell expression and function of key B cell antigens. The table 
indicates those antigens which are found on the CLL B cell and those that are absent 
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CD19 
CD 19 is a 95 kDa pan B cell antigen and a member of the immunoglobulin supergene 
family that plays a critical role as a response regulator, influencing activation, 
differentiation and survival of the B cells (Gardby E and Lycke NY 2000). Mice deficient 
in CD19 lack 8-l cells and B-2 cells respond poorly to thymus dependent antigens. As a 
result of this poor interaction with T cells, generation ofTh2 T cells is impaired because of 
reduced signalling through CD40 on CDl9 deficient B cells, identifying a key role of 
CDl9 in T and B cell interactions (Gardby E et al 2001). 
After B-cell antigen receptor (BCR) cross linking with antigen, CD 19 becomes rapidly 
phosphorylated, triggering critical activation pathways that lead to B cell receptor-mediated 
survival in vivo (Otero DC et al 2001). CD19 also plays an important role in the balance 
between humoral immunity and autoimmunity by regulating signalling thresholds from 
antigen stimulation of the BCR. Transgenic mice, which overexpressed the CD 19 antigen 
by 3-fold, generated spontaneous autoantibodies in an environment that otherwise did not 
predispose them to autoimmunity (Sato Set a12000; Tedder TF et a12000). CDl9 signals 
as a complex with CD21 in the recognition of microbial antigens through the complement 
system (Fearon DT and Carroll MC 2000) and also a complex with CD22 in governing 
mature B cell activation (Tedder T et al 2000). 
CD 19 is expressed on CLL 8 cells, but expression is significantly lower on the CLL 8 cell 
surface, compared to expression on normal 8 cells (Ginaldi L et al 1998; Cabezudo E et al 
1999). 
CD20 
CD20 is a 33-37 kDa non-glycosylated pan B cell integral membrane protein which plays a 
critical role in B cell activation, modulation of growth signals and signal transduction 
(Deans JP et al 1998; Shan D et al 1998; Riley JK and Sliwkowski M~ 2000). CD20 has 
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been shown to be both physically and functionally coupled to MHC II and CD40 and may 
have an important role in modulating effects on their functions (Leveille C et al 1999). 
CD20 is expressed on all CLL B cells but expression is significantly lower on the B cell 
surface compared to normals (Almasri NM et at 1994; Ginaldi L et at 1998). A small 
subset of patients has been identified with high CD20 expression, but it has been 
speculated that they may represent a biologically different disease (Aimasri NM et at 
1997). 
CD21 
CD21 is a 145kDa antigen, which interacts with CD23 and IFN-a, is the receptor for the 
Epstein Barr Virus (EBV) and binds the complement fragments iC3b, C3dg and C3d (the 
low affinity receptor for IgE) (Braun M et al 1998). CD21 is tightly regulated during B 
lymphocyte differentiation and is only expressed on mature B cells, not pro-, pre-, or 
plasma B cells (Schwab J and Illges H 2001). CD21 is also expressed at low density on 
mature T cells and at high density on immature thymocytes (Braun M et at 1998; Fischer 
EM et al 1999). Although mature T cells only express low levels of CD21, both B and T 
cells express equal amounts of CD21 mRNA (Braun M et al 1998). CD21 is critical for 
antigen presentation to T cells and other APC. CD21 captures immune complexes on the 
surface of follicular dendritic cells and presents them to activated B cells in germinal 
centres (Zabel MD and Weis JH 2001). CD21 expression is up-regulated on CLL B cells, 
but expression on the B cell surface varies between patients, with one study citing a link 
between high CD21 cell surface expression and soluble CD23 levels which correlated with 
a good prognosis (Gagro A et al1997). 
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CD22 
CD22, a member of the Ig superfamily, is a 135 kDa B-cell transmembrane glycoprotein 
which acts as an accessory antigen in signalling through the BCR (Hatta Y et al 1999). It 
plays a critical role by down modulating signals through the BCR and preventing 
autoimmune responses, as demonstrated by CD22 knockout mice (O'Keefe TL et al 1999). 
After eight months, CD22 deficient mice develop high levels of multiclonal, somatically 
mutated, high affinity serum IgG antibodies directed against double stranded DNA, 
cardiolipin and myeloperoxidase, suggesting that a single gene defect is sufficient to trigger 
autoantibody production in aged populations. CD 19 and CD22 influence each other's 
functions; CD22 negatively regulates CD 19 tyrosine phosphorylation and CD22 function is 
dependent on CD19 expression (Fujimoto M et al 1999). CD22 expression is down 
regulated in CLL and is often not expressed on the cell surface at all (Matutes E and 
Polliack A 2000). However, cytoplasmic CD22 has been identified in small numbers of 
patients who have no CD22 surface expression (Kanikova E et al1994). 
CD23 
CD23 is a 45 kDa transmembrane protein expressed on the surface of B cells, monocytes 
and macrophages. It binds IgE, CD21, CD11b and CD1lc and is classed as a lectin (Gu B 
et al 1998; Rogola B and Rymarczyk B 1999; Payet ME et al 1999; Lampert lA et al 1999). 
CD23 is a marker ofB cell activation, normally induced after activation by other cell types 
such as T cells (Karagiannis SN et al 2001). CLL patients have an increased expression of 
surface CD23 (Lampert lA et al 1999; Kneitz C et al 2000) and soluble CD23 (sCD23) in 
their serum, with 3 to 500 times greater expression than normals (Molica S et al 1999; 
Chen JR et al 1999). The level of sCD23 in patients' serum may be a prognostic marker, 
which is more accurate than clinical staging (Sarfati M et al 1996). Those patients who 
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express higher amounts of sCD23 have a poorer prognosis and earlier disease progression. 
CD23 expression is upregulated variably on CLL 8 cells. 
CDS 
CD5 is a 67kDa transmembrane glycoprotein (Freedman AS et al 1987) normally 
expressed on the surface of T cells, but has been shown to be present on a sub-set of 
normal 8 cells (Lozano F et al 2000; 8ondada S et al 2000). 8 cells expressing CD5 are 
classified as 8 I, whilst normal CD5 negative cells are identified as 82 cells (Lydyard PM 
et al 1999). CLL is classed as a CD5 malignancy (Caligaris-Cappio F 1996; Soderberg 0 
1998; Geiger KD et al 2000) with mantle cell lymphoma (MCL). Almost all CLL 8 cells 
express CD5, although it remains unknown whether CD5 expression on malignant cells 
represents transformation from a normal 81 cell or whether CD5 is an acquisition of a 
previously transformed 8 cell (Hamblin TJ and Oscier DG 1997; Lydyard PM et al 1999). 
The expression of CD5 on malignant 8 cells is one of the main diagnostic features of CLL 
and its presence is important with relation to the aetiology of the disease (Lydyard PM et al 
1999). 
CD5 is part of the 8CR (Lankester ACetal 1994) and an important co-receptor in antigen-
specific receptor-mediated activation and differentiation (Lozano F et al 2000). It has been 
suggested that CD5 plays an important role in keeping normal 8 I cells in a partial state of 
activation. The high prevalence of autoimmunity in CLL has led to different speculations 
as to the role of CD5. One such hypothesis supports the idea that CLL is a tumour of a 
separate lineage of CD5+ve 8 cells mainly involved in the production of polyclonal 
autoantibodies (Bondada S et al 2000), supported by the fact that some CLL cells have 
been stimulated in vitro to produce these polyclonal autoantibodies (Caligaris-Cappio F 
1996). However, it has also been shown that cos-v• 8 cells can be induced to express 
autoantibodi~;.s in response to stimul!ltion. Finally, the autoantibodies produced in CLL 
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have been shown to be from the "normal" B cells as opposed to the leukaemic clone. COS 
is expressed on CLL B cells and intensity is significantly higher compared to other B cell 
malignancies and normal B cells (Cabezudo E et al 1999). 
1.3.7 Development and progression of the leukaemic clone 
The CLL B cell originates in the bone marrow, where it is believed to arise from a single 
progenitor cell which becomes malignant when its replication and survival escape from 
normal regulation. One of the key factors thought to be involved in the accumulation of the 
malignant cells is a resistance to the normal processes of cell death and apoptosis. The anti-
apoptotic protein Bcl-2 is overexpressed in 90% of CLL patients B cells (Kipps TJ 1997). 
The mechanisms behind this are poorly understood, but it is not a result of Bcl-2 gene re-
arrangement, gene amplification or a prolonged half-life of Bcl-2 mRNA (Gottardi D et al 
1995). Expression of Bcl-2 protein in CLL does not correlate with stage of disease or prior 
treatment (Binet JL et al 1996), but it has been suggested that it may not only inhibit 
apoptosis and prolong survival, but may also lead to the accumulation of the malignant 
cells stuck in Go (Gottardi D et al 1995). CLL B cells, while resistant to apoptosis in vivo, 
spontaneously apoptose and down-regulate Bcl-2 expression when cultured in vitro, 
suggesting a critical role of the micro-environment in the prolonged survival of these cells 
(Osorio LM et al 1998). 
In contrast to the up-regulation of Bcl-2 in CLL, levels of the pro-apoptotic protein Fas is 
low or undetectable (Panayiotidis Petal 1995). Even cells induced to express Fas are still 
resistant to apoptosis, suggesting a more complex process is at work. However, although 
cell surface expression ofF as is low, levels of soluble Fas are increased in CLL patients. 
The role of cytokines in apoptosis in CLL is unclear, with some groups reporting cytokine-
mediated prevention of B-CLL apoptosis, whilst others suggest Bcl-2 independent 
mechanisms (Osorio LM et al1998). Cytokines believed to be involved in suppression of 
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apoptosis in CLL include IFN-a, IFN-y, TNF-a, basic fibroblast growth factor (bFGF), 
granulocyte colony stimulating factor (G-CSF), IL-l, IL-2, IL-4, IL-6, IL-8 and IL-13. 
Recent reports have suggested that two cytokines may be capable of inducing B-CLL B cell 
apoptosis. IL-5 appears to increase spontaneous apoptosis (Mainou-Fowler T et a! 1994) 
and IL-10 may be involved in both the induction and prevention of B-CLL apoptosis, 
although reports are conflicting (Osorio LM et a! 1998) 
CLL cells may also avoid cell death by expression of CD6 on the cell surface, which 
protects against apoptosis after ligation and is expressed on a large proportion of B-CLL 
cells (Osorio LM et al 1998). 
As the Jeukaemic cell numbers, normal bone marrow function becomes compromised, 
although often the disease progresses very slowly. It is likely that this process within the 
marrow may begin many years before the patient becomes aware of any symptoms or the 
disease is diagnosed. Tumour load increases steadily and presentation is at least partly 
dependent on total body tumour load. It is impossible to say how long the tumour load has 
been present. CLL is a chronic disease, making it possible for the tumour dysfunction to 
begin at a very early age, although there is as yet no evidence to support this assumption. 
Once the clone begins to expand, normal B-cell haemopoiesis will become compromised. 
Red cell, granulocyte and platelet production are reduced as the B-cells take up more space 
within the marrow and the subsequent cytopaenias result in the key symptoms of CLL. 
Reduced red cell production and autoimmune haemolysis will eventually lead to anaemia 
and its associated tiredness and breathlessness (Caligaris-Cappio F and Hamblin TJ 1999). 
Reduced granulocyte production and low levels of normal gamma globulins lead to an 
increased risk of infection. Thrombocytopenia can lead to an increased risk of bruising and 
bleeding. 
A prominent finding in CLL presentation is large (sometimes tender or painful) lymph 
nodes and an enlarged spleen and liver. These symptoms and signs form the basis of 
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clinical staging. Total T cell numbers were initially thought to be reduced in CLL, but this 
has since been shown to be a result of the dilution effect from the large numbers of B cells 
(Catovsky D et al 1974; Totterman H et al 1989). Absolute T cell numbers actually 
increase as the disease progresses. In addition, an imbalance in the normal CD4/CD8 ratio 
can be seen, with an increase in total CD8 numbers (Kay NE et al 1979; Kay NE 1981; 
Semenzato Get al 1983; Totterman TH et al 1989; Burger T et al 1990). This increase may 
be linked to the stage of the disease, as the further the disease has progressed, the greater 
the number of CD8 cells. 
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1.4 B and T cell interaction and activation in the normal immune 
response 
The development, differentiation, growth and immune responses of B cells are intricately 
linked with T cells, for instance in the formation of germinal centres and the activation of 
naive B cells within secondary lymphoid follicles. Once the T cell dependent development 
of B cells is complete, B and T cells continue to play vital roles in the activation of each 
other. To study the immune response of a CLL patient, in particular the role of the T cell, it 
is necessary to understand how B and T cells are able to activate and interact with each 
other (fig 6). The activation of T cells is complex, incorporating many processes and 
interactions. Activation is regulated by other key immune responders, cytokines and the T 
cells themselves (Noelle JR and Snow EC 1990; Clark EA and Ledbetter JA 1994; Robey 
E and Allison JP 1995). T cells respond to antigen presented to them from antigen 
presenting cells (APC) such as B cells, dendritic cells, macrophages and monocytes. They 
are unable to respond to antigen that is not presented in association with the MHC (Owens 
T 1996). This chapter will detail the processes involved in activation ofT cells and their 
interaction with B cells during an immune response. Properties of the key cell surface 
markers are detailed in table 9. 
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TABLE 9: T cell surface antigens 
Antigen Class Molecular weight Role 
COlla transmembrane glycoprotein 
(LFA-1) intergrin 170kDa adhesion 
CD 54 transmembrane glycoprotein 
(!CAM-I) 90kDa adhesion 
TCR lg like glycoprotein a chain 43-53kDa antigen binding signal 
13 chain 43kDa transduction 
transmembrane adhesion and signal transduction 
CD4 protein 59kDa 
disulfide-linked dimer exists as adhesion and signal transduction 
COB a hornodimer or al3 34kDa 
heterodimer 
transmembrane signal transduction from 
CD5 glycoprotein 67kDa TCRICD3 
CD25 glycoprotein 55kDa 
(IL-2R) activation 
CD28 lnununoglobulin 44kDa adhesion and 
homodimer activation 
CD I 54 type 11 transmembrane protein 32kDa activation 
(CD40L) 
CD I 52 immunoglobulin 44kDa negative regulator of activation 
(CTLA-4) 
HLA-DR Ig like glycoprotein a chain 34kDa activation and 
(MHC 11) 13 chain 29kDa antigen presentation 
Table showing molecular weight, type and role of key T cell surface markers 
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1.4.1 Antigen presentation and recognition 
An immune response starts when an APC such as a B cell, dendritic cell (DC) or 
macrophage meets antigen. Macrophages derive from circulating monocytes. Circulating 
macrophages phagocytose and engulf dead cells and cell debris and are responsible for 
killing and breaking down microorganisms (Parham P 2000). They can recognize and react 
to pathogens and cooperate with lymphocytes during immune responses. Dendritic cells are 
the most efficient antigen presenters and their sole function is to present antigen to T cells, 
whereas macrophages and B cells have other additional effector functions. Within 
secondary lymphoid tissue, B cells can be found in the lymphoid follicles, macrophages are 
found throughout the lymph node whilst dendritic cells are only present in T cell areas. B 
cells in the lymph nodes will bind specific antigens via surface immunoglobulin (slg) and 
internalise them via receptor-mediated endocytosis. The antigen is transported away from 
the plasma membrane and as it travels into the cell, it becomes acidified, aiding the 
breakdown of the pathogen into residual peptides, proteins and glycoproteins. These 
smaller peptide units bind to MHC class II molecules and are carried back to the cell 
surface as a peptide:MHC II unit. The B cell is now able to present this peptide to aT cell 
which is specific for the particular antigen and is retained within the lymph node where it 
will come into contact with many passing T cells. The T cell specific for a given pathogen 
represents only one in I 04 to one in l 06 of the total number of circulating T cells (Parham P 
2000). 
At this stage, the role of interaction and adhesion molecules is critical. These cell surface 
molecules allow T cells to bind to the B cell and test for receptor specificity for the given 
pathogen (Clark EA and Ledbetter JA 1994). Adhesion molecules such as lymphocyte 
function-associated antigen-! (LFA-l) on T cells and intercellular adhesion molecule-! 
(ICAM-1) on APCs are critical for allowing contact to take place (Makgoba MW et al 
1989). These contact driven molecules are also vital in allowing the T cell to leave the 
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lymph node and re-enter the circulation. LF A-1 on the T cell surface binds strongly to 
ICAM-1 which is also expressed on the vascular endothelium, thus allowing the T cell to 
pass through. The T cell will move through the lymph node, coming into contact with 
many APC and testing each antigen:MHC ll complex for recognition. When the T cell 
binds successfully with a peptide:MHC ll complex, it will make contact with both the 
peptide and the surface of the MHC molecule and the activation process can begin (Fried) 
P and Gunzer M 2001). 
1.4.2 Signal transduction and activation - an overview 
Once a T cell recognises its specific antigen and binds with the MHC complex, a signal is 
sent through the T cell receptor (TCR) to change conformation of the adhesion molecules 
and increase cell to cell contact binding activity between LF A-1 and associated ICAM 
molecules, stabilising the interactions. A newly emerging theory suggests that within 0.5 -
3 minutes after T and 8 cell contact through the MHC/TCR, the T cell polarizes towards 
the 8 cell through cytoskeletal engagement and TCR, LFA-1, ICAM-1, CD28 and CD2 
among others are all recruited towards this crucial interaction (Fried) P and Gunzer M 
2001). After 3-10 minutes, an immunological synapse is fom1ed between the T and 8 cell 
(Holdorf AD et al 2000), incorporating more antigen ligand pairs. The central ligand 
consists of the TCR with CD4 or CD8 binding to the MHC. CD2 binds CD 58 and CD28 
binds the 87 components CD80 and CD86. CD28 is constitutively expressed on the T cell 
surface where it binds with either 87.1 (CD80) or 87.2 (CD86), both of which are up-
regulated at different time points following 8 cell activation. 
The ligation of CD28 signals to the nucleus of the T cell to up-regulate the production of 
the critical T cell cytokine IL-2 and its receptor (IL-2R), the cell surface marker CD25. IL-2 
provides signals for both the T cell producing it and recruits surrounding T cells to 
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continue activation, whilst CD25 provides the receptor for IL-2. Key cytoplasmic 
components, such as Lck, Fyn and ZAP-70, will also be triggered at this point. LFA-1 and 
ICAM-1 expression are increased on an outer plane, allowing for stronger binding of the T 
cell to the APC and also to form a protective zone to allow stabilising of TCR signalling 
(Dustin ML and Cooper JA 2000). 
The next stage in the activation process involves the expression on the T cell of CD154. 
This is another key cell marker which binds with CD40 on the 8-cell surface to further 
enhance the production of cytokines such as IL-2 and to prolong the expression of 
receptors such as IL-2R (Clark LB et al 1996). The final stage involves a definitive "off' 
signal, to ensure that the T cell response is controlled and does not involve any prolonged 
activation or non-specific responses. CD152 (CTLA-4) is expressed on the T cell and binds 
to the 87 proteins on the B cell which thus signals to the T cell once the activation process 
has been completed (Oosterwegel MA et al 1999) (Table 9). 
1.4.3 LFA-1 and ICAM-1 
LFA-1 plays a crucial role in cell-cell contact at the start of immune recognition, allowing 
T-cells to come into close proximity with APCs to test for antigen specificity (Rothlein R 
and Springer TA 1986; Rothlein R et al 1986). LFA-1 is a member of a large family of 
adhesion molecules known as the integrins (Makgoba MW et al 1989) and it binds to the 
80-114kDa integral membrane glycoprotein ICAM-1. LFA-1 shares a structure with its 
other family members and consists of two non-covalently linked polypeptides, the a and P 
subunits (Keizer GD et al 1985). Cloning of the genes for these two subunits has revealed 
three potential sites for binding that would facilitate cell-cell adhesion (Figdor CG et al 
1990). 
LFA-1 exists in both an active and inactive form. Resting lymphocytes express inactive 
LFA-1 and therefore do not adhere spontaneously. Stimulation with phorbol myristate 
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acetate (PMA), or monoclonal antibodies directed against CD2 and CD3, has been shown 
to strongly induce cell adhesion, suggesting that these surface molecules may activate 
LF A-1 via intracellular signalling pathways. Once a T cell encounters an APC, LFA-1 
binds to ICAM -1 for initial cell-cell contact. 
In the first instance, cell binding is non-specific and of low affinity. If cell recognition by 
the TCR occurs, a signal is delivered via CD3, activating LFA-1. The activated form can 
now facilitate high affinity binding between the two cells and antigen recognition can 
occur. Binding through LFA-1 is mediated through re-arrangements of the cytoskeleton 
that creates a specialised domain on the T cell surface and subsequently directs T cell 
effector functions towards the APC (Sedwick CE et al 1999). 
1.4.4 CD3 and the T -Cell Receptor (TCR) 
The TCR is structurally similar in many ways to immunoglobulin receptors found on B-
cells (Davis MM et al 1984; Samelson LE and Schwartz RH 1984; Clevers H et al 1988) 
(Fig 7). Each T cell expresses a unique receptor on its cell surface allowing it to bind a 
specific antigen. The TCR comprises of an acidic a chain of 43-53kDa and a basic ~ chain 
of 43kDa (Filch FW et al 1984; Clark SP et al 1984). The TCR is a disulfide-linked 
heterodimer, consisting of two forms, the a~ or the yo. An individual T cell will express 
one pair or the other, never both (Borst J et al 1990). The majority ofT -cells express the 
a~ chain. Each receptor complex will express one functional a chain (encoded on 
chromosome 14) and one functional p chain (chromosome 7). Amino acid analysis of these 
two chains shows them to have sequence homology with immunoglobulin and both consist 
of constant and variable regions, with antigen binding taking place at the variable regions 
(Kavaler J et al 1984). In comparison to its counterpart receptor CD3, the TCR only has a 
short cytoplasmic tail, as shown m figure 7 (Parham P 2000). 
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Fig 7. T cell Receptor 
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CD3 constant 
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TCR antigen 
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Figure showing the T cell receptor. The different regions are identified as the ap an tigen binding site with 
both constant and variable regions and the CD3 receptor, both on the surface of the cell, and the f,f, subunits 
located within the T cel l. 
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The CD3 molecule is a T cell specific marker, which is always found closely associated 
with the TCR and its related structures. CD3 is a complex consisting of three separate 
polypeptide chains, y (25kDa), o (20kDa) and E (20kDa) (Terhorst C and van den Elsen P 
1985), each of which is encoded on human chromosome 11 (Tunnacliffe A et al 1987). 
CD3 and the TCR are also associated with either a double 1; (zeta) chain (16kDa), or a 
single Tl (eta) chain that is linked to a single 1; chain (Letoumeur F and Klausner RD 1992). 
Together, these components make up the TCR complex. Neither TCR nor CD3 is found 
without expression of the other (figure 7). The CD3 polypeptides are found evenly 
distributed across the T cell membrane. Approximately 30,000-40,000 are found on the 
surface of each T cell (Reinherz EL et al 1986), with an intracellular immunoglobulin-like 
domain which is tightly linked to a kinase. CD3 and 1; are not responsible for binding 
antigen. 
As a part of the TCR complex, they transduce signals into the cell, which trigger 
transcriptional events within the nucleus once the TCR has formed a complex with the 
presented MHC: antigen (Letoumeur F and Klausner RD 1992). This binding of MHC: 
antigen to the TCR induces conformational changes and triggers signals through the CD3. 
The T cell activation process is complex, but key events conclude in the release of calcium 
from intracellular cytoplasmic stores, which, together with other signals, activates 
transcription of the interleukin-2 gene and the interleukin-2 receptor gene. This results in 
release of IL-2 from the cell and expression of the IL-2 receptor, both of which result in 
activation ofT cells. 
1.4.5 CD4 and CD8 
CD4 is a 56kDa protein, tightly but non-covalently linked to the TCR complex and its role 
in signal initiation and transduction (Janeway CA Jr et a! 1988). CD4, and its counterpart 
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CD8, a 34kDa glycoprotein, can be found on mature ap expressing T cells as well as on 
monocytes and macrophages. CD4 consists of four extracellular immunoglobulin-like 
domains, a hydrophobic transmembrane region and a long cytoplasmic tail and is encoded 
on human chromosome 2 (Barclay AN et al 1993). A T cell will express either CD4 or 
COS, dividing T cells into two distinct groups. CD4+ve T cells will only bind to and 
recognise antigen in association with MHC 11 on APC, whilst CDS+ve T cells will only 
interact with MHC I on APC (Fleury SG et al 1991; Janeway CA Jr 1991). CD4 will bind 
to the membrane-proximal p2 domain of MHC ll and its role is two-fold. During binding 
between the MHC II:antigen and the TCR, CD4 acts as an adhesion molecule by binding to 
the MHC Il, helping to tighten the bond between T cell and APC. CD4 also acts as a 
separate signal transducer, with the intracellular domain linked to kinases which become 
phosphorylated following TCR engagement due to the close proximity ofCD4 to the TCR 
These phosphorylated kinases can then activate the cytoplasmic protein tyrosine complex 
ZAP-70, which is critical for initiating subsequent intracellular T cell signalling. 
CD8 works in a similar way, strengthening the bond between the TCR complex and the 
MHC class I protein bound with antigen. It also binds intracellular kinases (Weiss A et al 
1994 ). Antibodies against CD4 or CD8 are capable of blocking the activation of T cells, 
demonstrating their importance in the activation pathway. 
1.4.6 CD5 
CD5 is a 67kDa glycoprotein, expressed on the cell surface of all T cells and a small subset 
of normal B cells (Verwilghen J et al 1990; Luo W et al 1992). CD5 is thought to play an 
important role in the regulation of signals transduced from the TCRJCD3 complex after 
activation (Carmo AM et al 1999) and to positively costimulate mature T cells activated 
through the TCR. It plays a pivotal role in inducing resting B-cells to proliferate after T and 
B-cell interaction (Bikah G et al 1998). CD5 is also associated with intracellular casein 
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kinase 2 (CK), which is a major regulator of cell growth and signalling (Raman C and 
Kimberley RP 1998). CD5 .can induce additional key cell factors for growth in mature T 
cells. Anti-CD5 stimulation in conjunction with anti-CD28/PHA ligation can enhance 
production ofiL-2 mRNA by L6 fold and secretion ofiL-2 protein by 2.2 fold (Gringhuis 
Sletal1997). 
1.4.7 CD28 
CD28 (also known previously as Tp44), characterised first as the human T lymphocyte 
surface·ahtigen reacting withmonoclonal antibody 9.3 (Hansen JA et al 1980), is a 44kDa 
transmembrane glycoprotein and a member of the immunoglobulin gene superfamily 
(Hatper K et all991; Freeman GJ et al1992; Yin D et al 1999). Many members of this 
family play important roles in adhesion and signal transduction. Other subfamily members 
include CD7 and CDl52 (Harper Ketal 1991), CD28 is expressed on the surface·of 80% 
of CD4 T cells and 50% of CD8 T cells (Lenschow DJ et al 1996) and it binds with two 
distinct receptors CD80 (B7.1) and CB86 (B7.2) expressed on B cells, dendritic cells and 
other APCs (Holdorf AD et al 2000). The eo-stimulatory signal provided through the 
ligation of these receptors is believed to be critical for providing activation signals to the T 
cell. 
Anergy, a term used to describe a state of T cell unresponsiveness, is prevented dt~ring T 
cell activation by the successful binding of CD28 to CD80 and CD86 after the initial 
antigen driven contact through the TCR (Lenschow DJ et al 1996; Chambers CA and 
Allison P 1999; Boulongouris G et al 1999). A concept termed the immunological synapse 
has been used to describe the specific reorganisation of proteins in the contact surface 
between the T cell and the. APC during antigen presentation to T cells and plays a crucial 
role in antigen receptor signalling (Holdorf AD et al 2000). In conjunction with other 
surface antigens, CD28 plays a critical role in adhesion between APC and T cells, as CD28 
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bound to 87 spans a distance identical to the TCR bound to MHC II/peptide. CD28 can 
also transduce signals to change cytoskeleton confonnation to further enhance T cell 
adhesion to APC. This is demonstrated clearly by T cells which lack CD28 and the 
adhesion molecule, CD2, as they are defective in their ability to interact with APCs (Green 
JM et al 2000). 
As the activation process of the T cell continues, CD28 is able to regulate sensitivity of 
signalling through the TCR. Once CD28 has bound its ligands, the number of engaged 
TCRs required for T cell activation decreases by approximately six-fold (Viola A and 
Lanzavecchia A 1996). CD28 is also involved in co-ordinating production of IL-2, via 
costimulatory signalling with CD3 to stabilise the IL-2 transcription mRNA and by 
activating nuclear factor-kappa B (NF-kappa B), a transcription factor involved in direct 
transcription ofinterleukin-2 (Jenkins MK et al 1991; Powell JD et al 1998; Boulougouris 
G et al 1999; Boonen GJJC et al 1999; Holdorf AD et al 2000). In addition to augmenting 
production of IL-2, ligation of CD28 also up-regulates CD25, the receptor for IL-2, 
enhancing T cell responses to IL-2 (Holdorf AD et al 2000). 
Other critical signals, which are up-regulated after CD28 ligation, include anti-apoptotic 
survival proteins such as bcl-xL (Boise LH et al 1995). Because CD28 ligation leads to 
increased T cell helper function, this also correlates with increases in CD154 (CD40L) cell 
surface expression, further enhancing the T cell immune response (Klaus SJ et al 1994). 
Mice deficient in CD28 are unable to form germinal centres, cannot sustain T cell 
proliferation, do not produce T cell growth factors and provide poor support for 8 cell 
activation, suggesting that CD28 plays a critical role in T and 8 cell interactions (Shahinian 
A et al 1993; Vallejo AN et al 1999; Sansom DM 2000). Expression of CD28 is reduced 
during the ageing process of lymphocytes, known as replicative senescence, which is 
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defined as a generalised, age-related decline in immune responses (Effros RB and Pawelec 
G 1997; Vallejo AN et al1999; Globerson A and Effros RB 2000). 
1.4.8 CD25 and Interleukin-2 OL-2) 
CD25, the IL-2 receptor, is made up of at least three distinct receptor chains; a 55kDa a 
chain (IL-2Ra, Tac, p55, CD25), a 70-75kDa ~ chain (IL-2R~, p70/p75, CD122) and a 
64kDa y chain (Il-2Ry, ye, p64) (Taniguchi T et al1986; Waldmann TA 1991; Taniguchi T 
and Minami Y 1993). The IL-2R, CD25, was first identified by a monoclonal antibody 
which did not bind to normal resting T cells but did react strongly with mitogen-activated 
T -cells and was initially named Tac as a result (I activated) (Uchiyama T et al 1981 ). 
Interleukin-2 is a 15.5kDa glycoprotein produced by activated T cells and in small amounts 
by B cells (Taniguchi T et al 1983; Gaff en SL et al 1996). 
Synthesis and secretion ofiL-2 and the expression ofCD25 occur as early consequences of 
activation of mature T cells. The expression of the IL-2 receptor CD25 is up-regulated 
following activation. The binding of IL-2 to its receptor causes rapid clonal expansion of 
the T cell population originally activated by antigen. It is also a growth factor that is 
required forT cells to progress from G1 into S phase (June CH et al 1989). Na'ive, resting T 
cells will only express the ~ and y chains of the IL-2 receptor. Activation through 
TCR:CD3 and eo-stimulatory molecules leads to the up-regulation of the a chain and 
together the three units comprise to create a high affinity receptor for IL-2 (Waldmann TA 
1986; Waldmann TA et al 1993). IL-2 then binds the IL-2 receptor, triggering the cell to 
undergo cell division. 
A T cell that is activated in this way can undergo two to three cell divisions a day, 
eventually producing thousands of daughter cells. T cells which are unable to produce IL-2 
or to express its receptor CD25 and cells which are unable to respond to IL-2 will not 
proliferate or respond and the immune response will fail. CD25 knockout mice have 
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provided evidence that IL-2 and its receptor CD25 are critical to prevent autoimmunity and 
maintain homeostasis of the immune system. Although IL-2 deficient mice demonstrate 
normal T cell development (Schorle H et al 1991), there are markedly reduced in vitro T 
cell responses and significantly increased levels of IgG I and lgE, suggesting an important 
role of IL-2 in B cell differentiation. However, many immune responses take place 
normally during early life, suggesting that other cytokines may be able to compensate for 
IL-2. In comparison, mice lacking CD25 develop autoimmune disorders such as haemolytic 
anaemia and massive enlargement of peripheral lymphoid organs (Willerford DM et al 
1995). 
Expression of IL-2 and its receptor CD25 are closely linked to ligation of CD28 and the 
TCR:CD3 complex, for without these signals, T cells fail to produce IL-2. Production of 
IL-2 begins when signals delivered through the TCR:CD3 receptors activate the 
transcription factor NF-kappa B which in turn activates transcription of the IL-2 gene. 
Regulation of IL-2 mRNA is under the tight control of both CD28 and the TCR which 
stabilises transcription and increases IL-2 production 20-30 fold (Umlauf SW 1995; 
Parham P 2000;). 
IL-2 shares many functional properties with IL-15 (Giri JG 1995; Bulfone-Paus S et al 
1997). Both cytokines are able to stimulate the proliferation of T cells, up-regulate 
expression of CD25 and CD95 (FasL) and downregulate CD27 and both can increase the 
mRNA transcription of IL-2 and CD25. IL-2 and IL-15 also share receptor components, 
with both cytokines utilising the p and y chains of the IL-2 receptor. 
Expression of CD25 is not restricted purely to T -cells. It has also been identified on normal 
B cells, CLL B cells, hairy cell leukaemia B cells, Burkitts lymphoma B cells and all B cell 
lines carrying the HTL V -1 genome. Other haematological cells expressing this receptor 
include cultured monocytes, Kupffer cells of the liver, cultured lung macrophages, 
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Langerhans cells of the skin and Reed-Stemberg cells in Hodgkin's Lymphoma (Waldmann 
TA 1986). 
1.4.9 CD154 
CD154 (CD40L, gp39), the ligand for CD40, is a type-IT transmembrane protein of 33-39 
kDa protein expressed on activated T cells, the majority of which are CD4+, in both the 
peripheral blood and lymph nodes (Ochs HD et al 1994; Clark L8 et al 1996). It shares 
significant sequence homology with TNF-a and has been classified as a member of the 
tumour necrosis factor cytokine family (Hollenbaugh D et al 1992). 8asophils, 8-cells, 
monocytes, NK cells, CD8+ T cells and mast cells also express low levels of surface 
CD154. The CD154 ligand, CD40, is expressed on the surface of APCs including 8-cells, 
dendritic cells, activated macrophages, fibroblasts, endothelial cells and follicular dendritic 
cells (Grewal IS et al 1997). Expression ofCD154 on T cells is detectable 1-2 hours after 
activation and reaches maximum expression between 4-8 hours, declining back to resting 
levels at 24 - 48 hours (Clark L8 et al 1996). 
CD154 is often classed as the second critical signal in T-cell activation after TCR ligation, 
the first involving the ligation of CD28 with CD80 (87.1) and CD86 (87.2). Activated T 
cells expressing CD 154 are able to induce resting 8 cells to express CD80 and CD86 
(Fanslow WC et a! 1994). This interaction between CD154 on the T cells and CD40 on 8 
cells provides critical signals to 8-cells for IL-4 production, lg class switching, 8 cell 
activation and progression through the G1-G2 stages of the cell cycle and upregulation of 
receptors for IL-2, IL-4 and IL-15 (8anchereau J et al 1994; Clark L8 et al 1996; Grewal IS 
and Flavell RA 1997). Monoclonal antibodies which block this CD 154-CD40 receptor pair 
prevent 8 cell activation, memory 8 cell development, entry of 8 cells into the cell cycle 
and germinal centre formation (Durie FH et al 1994; Gray D et a! 1994; Han S et al 1995; 
Grewal IS and Flavell RA 1997). 
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A classic example of the role ofCD154 is seen in patients who suffer from the rare genetic 
disorder hyper-IgM syndrome. An X-linked immunodeficiency, hyper-IgM syndrome is 
characterised by mutations in CD 154 expression. Patients display normal to high levels of 
the immunoglobulin IgM, but no IgG, lgA or lgE, demonstrating an inability of the B cells 
to switch immunoglobulin production away from lgM (Banchereau J et al 1994; Clark LB 
et al 1996; Grewal IS and Flavell RA 1997). When the B cells from such patients are 
cultured in the presence of normal T cells, immunoglobulin production returns to normal 
(Grewal IS and Flavell RA 1997). 
Important information about the role of this antigen can also be obtained by the study of 
CD154 knockout mice and blocking antibodies, which have demonstrated that CDI54 is 
also important in the regulation of costimulatory activity on APCs, T -cell activation and 
auto-immune responses. CD4 T cells from CD154 deficient mice show poor proliferation 
and express little or no IL-4 and IFN-y compared to normal mouse CD4 T cells (Grewal IS 
and Flavell RA 1997). Blocking antibodies against the CD40-CD 154 interaction produce 
symptoms in the mouse similar to hyper-IgM syndrome (Gray D et a! 1994) with increased 
IgM responses and production and decreased lgG production. Further, the blockade of this 
pathway demonstrated that this interaction is critical for B cell activation and proliferation, 
B cell differentiation into antibody-secreting plasma cells, isotype switching and the 
generation of memory B cells. 
1.4.10 CD152 (CTLA-4) 
Cytotoxic T-lymphocyte antigen 4 (CTLA-4) or CD152 is a 44-kDa member of the 
immunoglobulin supergene family and it is very similar to CD28 (Brunet J et al 1987). 
Genetically it maps close to CD28 on chromosome 2 (Freeman GJ et al 1992) and 
structurally, there are many similarities. Both glycoproteins show extensive amino acid and 
nucleotide homology and share a similar exon and intron structure (Harper KJ et al 1991; 
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Lindsten T et a! 1993). Functionally, both CD28 and CD152 bind to the receptors CD80 
and CD86. However, CD152 binds to CD80 and CD86 with 10-100 fold greater affmity 
than CD28 (Liu Y 1997; Oosterwegel MA et al1999). 
CD 152 is not expressed on the cell surface of naive, resting T cells, in comparison to CD28 
(Sansom DM 2000). Whilst CD28 mRNA can be found constitutively in all resting T cells, 
increasing only moderately after activation, CD152 mRNA can only be identified 
following T cell activation, and CD152 surface expression does not occur until 48 hours 
post activation (Walunas TL et a! 1994; Krummel MF and Allison JP 1995; 
Kosmaczewska A et al 2001). Surface expression, however, remains limited, even under 
optimal stimulating conditions, due to its unique storage conditions. CD 152 protein is 
produced in high quantities post activation, when it is transiently expressed on the cell 
surface before being rapidly endocytosed to be stored in intracellular vesicles (Alegre M et 
a! 1996; Sansom DM 2000; Kosmaczewska A et al2001). This storage ofCD152 suggests 
that it is present in significant levels and may play an important role in T cell regulation 
before being expressed on the cell surface. 
Whilst CD28 plays a critical role in the activation of T cells, CD152 provides the 
counterpart signal, inducing T cells to down-regulate their responses (da Rocha Dias S and 
Rudd CE 2001). Experiments crosslinking CD152 during activation have shown a 
reduction in IL-2 production and a decrease in up-regulation of the IL-2 receptor CD25 
(Brunner MC et a! 1999; Sansom DM 2000). This ultimately leads to G1 cell cycle arrest, 
through inhibition of the production of the cell cycle proteins cyclin D3 and cdk4 (Aiegre 
M et at 1998). Antibody cross! inking of CTLA-4 also prevents CD28 induced IL-2 mRNA 
production and CD69 expression, further inhibiting the T cell response (Brunner MC et a! 
1999). 
The role of CD I 52 can be observed clearly in CTLA-4 knock-out mice, which develop 
splenomegaly, lymphadenopathy, multi-organ lymphocytic infiltration and tissue 
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destruction, dying within 3-4 weeks (Tivol EA et a! 1995). These findings suggest that 
CTLA-4 plays a critical role in down-regulating T cell activation and preventing 
autoimmunity. Blocking antibodies to CD152 during activation produced a 4 to 5 fold 
reduction in the level of expression of CD95 (FasL), which induces antigen-induced cell 
death (AICD), a process that ensures the deletion of self-reactive T cells (da Rocha Dias 
and Rudd CE 2001). This suggests that under normal conditions of CD152 expression 
during T cell activation, ligation of CD152 with CD80/CD86 induces termination of the 
immune response by reducing IL-2 and IL-2 R production, arresting cell cycle progression 
and inducing AICD to prevent the initiation of autoimmunity. 
1.4.11 HLA-DR 
The major histocompatability complex (MHC), discovered in 1975 (Nabholz M et a! 1975) 
consists of two subtypes - MHC class I and MHC class 11. MHC molecules are coded by 
genes located on chromosome six (Sompayrac L, 1999). The three families of class II 
antigens, DR, DQ, and DP, are encoded within the HLA-D region of chromosome 6 as a 
series of discrete gene clusters. (Kappes DJ and Strominger 1986; Roucard C et a! 2001). 
All MHC II molecules are transmembrane with extracellular domains resembling 
immunoglobulin molecules, and cytoplasmic tails. All belong to the immunoglobulin gene 
superfamily. MHC II is expressed constitutively on B cells, dendritic cells, thymic 
epithelium cells, monocytes, macrophages and Langerhans cells but is also upregulated on 
T cells following activation by such factors as IFN-y (Amaldi I et a! 1989). HLA-DR, along 
with its fellow members DP and DQ, consist of an a chain (34kDa) and a ~ chain (29kDa), 
both of which are surface glycoproteins (Kappes DJ et a! 1984). The MHC II molecules are 
highly polymorphic and there are multiple alleles of each subtype. 
Normal immune surveillance depends on the ability of MHC class 11 molecules, expressed 
on cells such as B cells and dendritic cells, to bind antigens and carry them to the cell 
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surface for display to T cells (Nelson CA and Fremont DH 1999). MHC II molecules are 
able to bind peptides from a large array of antigens and then hold them at the cell surface 
long enough for T cell recognition to occur. This is done with the help of the MHC 
associated invariant chain and HLA-DM, which is a non-peptide binding class II molecule. 
In fulfilling their role in the presentation of processed antigen to T cells each class of the 
MHC is restricted. MHC I can only present antigen to CD8+ T cells and MHC II can only 
present to CD4+ T cells (Scholl PR and Geha RS 1994). CD4 T cells recognize peptides 
bound to MHC II, which are selectively expressed in specialized antigen presenting cells 
that take up extracellular microbial antigens (Jensen PE 1999). CD8 T cells recognize 
peptides bound to MHC class I, which are widely expressed and will bind peptides derived 
from intracellular sources ie viral peptides and tumour peptides, allowing cytotoxic T cells 
to monitor for foreign antigen. HLA-DR can be found expressed on the surface of the T 
cell following activation and, in conjunction with anti-CD3 stimulation, is responsible for 
inducing proliferation and expression of IL-2, IL-3, IFN-y and TNF- a (Spertini F et al 
1992). 
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1.5 The T cell in B-CLL 
1.5.1 Normal T cell haemopoiesis 
1.5.1.1 Thymic development 
T cells start their developmental life, like all other haemopoietic cells, in the bone marrow, 
or fetal liver, where they originate from a pluripotent stem cell (Spits H et al 1998; Robson 
MacDonald Het al 2001) (fig. 8). They undergo very little maturation within the marrow, 
travelling early in the growth stage to the thymus, the primary lymphoid organ, hence the 
term T lymphocyte, derived from !hymus-dependent (Green DR and Schuler M 2000; 
Moroy T and Karsunky H 2000). T cell development in the thymus can be broadly divided 
into two main areas. In the early developmental stage, common T -lineage-restricted 
precursors give rise to an ap or y8 T lineage cell. In the later stage, ap CD4+8+ double 
positive cells commit to become either CD4+ or CD8+ single positive T cells (Berg U and 
Kang J 2001). T cell precursors undergo an orderly series of movements between thymic 
subcompartments as they develop into mature T cells (Ansel KM and Cyster JG 2001). In 
the early stages of development, on entering the thymus, the immature T cell precursors, at 
this stage known as thymocytes, interact closely with thymic stromal cells and extracellular 
matrix components (ECM) which consist of fibronectin and soluble growth factors such as 
IL-7, as well as dendritic cells and macrophages. (Banwell CM et al 2000; Anderson Get 
al 2000). Stromal cells and ECM components play a critical role in the development ofT 
cell precursors, through soluble and cell surface molecules. Several different chemokines 
are produced by the thymus, such as macrophage inflammatory protein-2 (MIP-2), stromal 
cell-derived factor 1 (SDF-1) and thymus-expressed chemokine (TECK). Immature 
thymocytes have been shown to express receptors for many of these chemokines (Anderson 
G et at 2000). The colonization of the thymus and the continued development of the 
immature thymocytes are likely to rely heavily on chemokines produced by the thymus. 
Immature thymocytes will also express a range of cell surface receptors such as very late 
84 
antigen-4 (VLA-4), VLA-5 and CD44, which are capable of binding strongly to ECM 
components, supporting the hypothesis that ECM components play an important role in 
thymocyte maturation. Several studies have suggested that the ECM may act as a "scaffold" 
to concentrate and localize growth factors needed for thymocyte development (Anderson G 
et al 2000). At this point in thymocyte development, the production of IL-7, most notably 
from MHC class 11 thymic epithelial cells, plays an important role in the maturation of 
double negative T cells. Mice deficient in IL-7R function have severely reduced numbers 
of thymocytes (Berg JL and Kang J 200 I). 
Rearrangement of the T cell receptor (TCR) genes is a complex and highly regulated 
process (Davis MM et al I984; Sim GK et al I984; Born Wet al I985; Hedrick SM et a] 
I985). T-cells can express two different receptor types, classed as a:~ and y:o (Terhorst C 
and van den Elsen P I985; Robey E and Fowlkes BJ I998; Rothenberg EV 2000). There is 
no commitment to either lineage at this stage, as receptor expression simply depends on 
which re-arrangement is made first. Thymocytes will start to re-arrange their ~. y and o 
genes at approximately the same time. Although there is no pre-determined lineage, ~­
chain genes will more often than not become functionally re-arranged before those of a y:o 
receptor (Robey E and Fowlkes BJ I994). Once this has happened, a-gene re-arrangement 
begins, and once completed, leads to expression of an a:~ receptor on the cell surface (de 
Villartay JP et al I99I;Lacorazza HD et al 200I). It is now impossible for the cell to 
become y:o, as the o- chain gene locus is found in the middle of the a-chain locus and once 
this has re-arranged, the o-chain locus is deleted from the chromosome. Evidence suggests 
that lineage fate of the TCR may depend on a mutation of the Notch I gene (Washbum T et 
al 1997; Robey E and Fowlkes BJ 1998). T cells that have a heterozygous mutation of 
Notch I are more likely to develop as y:o T cells than a:~. If aT -cell fails to produce either 
an a:~ or y:o receptor it will die by apoptosis and in the same way as is observed in B 
cells, this will be the fate of most T cells (Wiest DL et al I999). 
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Fig. 8: T cell development 
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Figure showing a schematic representation ofT cell development from the pluripotent stem cell in the bone 
marrow through to functional T cells in the peripheral blood. Surface markers expressed at each stage are 
shown. 
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IL-7, as well as playing a critical role in early thymocyte development (DeLuca D and 
Clark DR 2002), also plays an important role in TCR gene re-arrangement (Soloff RS et al 
1997; Durum SK et al 1998; Berg U and Kang J 2001). This has been clearly 
demonstrated in IL-7 receptor negative murine thymocytes, which do not rearrange their 
TCR (Durum SK et al 1998). 
T cells bearing the a:Jl receptor are by far the most common T cell found within the 
immune system and make up 95% of all T cells. It is on these particular T cells that the 
remaining chapter will focus. Once dedicated to this lineage of receptor, the jl-chain locus 
will, like the genes for immunoglobulin heavy chains in B cells, begin re-arrangement first, 
with the a segment following second, comparable to the B-celllight chain. After successful 
rearrangement of the loci and assembly of both receptor protein products, the latter will 
become associated with CD3 proteins and a ~ chain to become a pre T-cell receptor that 
will be transported to the cell surface. The emergence of this receptor on the cell surface 
allows the T cell to communicate with surrounding ligands on dendritic cells and 
macrophages and provides the important signal for proliferation. T cell expression of the Jl 
chain within the pre T cell receptor will now induce expression of the two key markers in T 
cell development, CD4 and CD8. TECK in particular, has been shown to facilitate the 
migration of immature thymocytes, at this point CD4- CD8- and known as "double 
negative", from the outer cortex of the thymus to the inner cortex as they differentiate into 
CD4+8+ "double positive" cells (Crump AL et al1993; Norment AM et a12000) 
1.5.1.2 Positive and negative selection 
The next crucial stage in T cell development is the positive and negative selection ofT 
cells. This process involves only double positive a:Jl cells and is based on the ability of the 
T cells to recognise MHC class I or 11 on thymic epithelium (Benoist C and Mathis D 1989; 
Viret C and Janeway CA 1999). Positive selection is the process by which T cells are 
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selected from the repertoire of developing cells by their ability to recognise peptides 
presented by another cell bearing a self-MHC molecule (Wong Petal 2000). This process 
only occurs in about 1-2% of the total T cell population within the cortex of the thymus and 
the successful process leads to protection from apoptosis and continued maturation 
(Kisielow Petal 1988; Sha WC et al 1988; Nikolic Zugic J and Bevan MJ 1990; Viret C 
and Janeway CA 1999). Efficient positive selection of a broad repertoire ofT cells depends 
on the presentation of large numbers of diverse antigen peptides on MHC molecules within 
the thymus (Marusic-Galesic S et al 1989; Wong P et al 2000). Without a successful 
binding of the T -cell receptor to an endothelial bound MHC molecule, there will be no 
positive signal to the cell and it will be eliminated. 
Negative T-cell selection also takes place in the thymus and is similar to the process of 
negative B-cell selection described earlier. Any developing T cell that binds to self-antigen 
presented by dendritic cells or macrophages will be rendered anergic on arrival in the 
peripheral blood or undergo apoptosis (Buckland J 2002). It is estimated that half to two-
thirds of thymocytes able to undergo positive selection die before full maturation due to 
negative selection (van Meerwijk JP et al 1997). Whilst positive selection does not permit 
any unselected cells to leave the thymus, negative selection does. 
It is also at this point that the cells function as either a CD4 or a CD8 population is 
determined (Basson MA and Zamoyska R 2000). After positive selection, cells mature to 
express either CD4 or CD8. The subject of CD4 and CD8 lineage commitment is 
controversial. Work has shown that the MHC is critical in determining the T cell lineage as 
either CD4 or CD8 (van Meerwijk et al 1997; Germain RN 2002). Specific interactions of 
the T-cell receptor on immature thymocytes with thymic MHC antigens determines the 
differentiation of double positive CD4/CD8 T cells into either CD4 positive or CD8 
positive T cells (Teh HS et al 1988). Double positive T cells that interact with cells 
expressing MHC class I molecules in the thymus will differentiate to become CD8 T cells 
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(Kisielow P et al 1988; van Meerwijk JP and Germain RN 1993). Conversely, double 
positive T cell interaction with cells expressing MHC class II molecules will differentiate 
to become CD4 positive T cells (Kruisbeek AM et al 1985; BikoffEK et al 1993). Recent 
evidence (Berg U and Kang J 2001) also suggests that the quantity of signal through the 
TCR may determine both positive selection and the commitment ofT cells to either CD4 
or CD8. Mice with a reduced expression of TCR on their cell surface develop very few 
CD4 single positive T cells, suggesting that the decrease in TCR signalling results in a 
failure of positive selection. If the peptide antigen is administered to the mice, CD4 T cells 
develop normally. At lower levels of antigen, CD8 T cells develop, demonstrating the 
importance of the TCR in both positive and negative selection and CD4 or CD8 
development (Watanabe N et al 2000). Another key contender in lineage specification is 
Notch signalling, whose role as either committing the T cell to CD4 or CD8 development 
or in T cell survival is still debated (Berg U and Kang J 2001). Signalling through p56lck 
and Erk pathways may also play key roles in CD4 or CD8 commitment, as blockade ofErk 
pathways blocks CD4 maturation and promotes CD8 development. 
Controversial theories regarding the process of "instruction" versus "selection" for CD4 
and CD8 lineage differentiation still exist (Germain N 2002). However, there is, as yet, no 
clear evidence as to the pathway or pathways responsible for lineage commitment. 
1.5.1.3 A11tigen prese11tatio11 wit/rill tire seco11dary lymplroid tissues 
Once a T cell has successfully entered the peripheral blood, it will circulate into the 
secondary lymphoid tissues (the spleen, lymph nodes, and mucosal lymphoid tissues), the 
lymph system and back to the blood. It is within designated areas of the secondary 
lymphoid tissues that T cells encounter antigen presented by APCs such as dendritic cells 
in association with MHC class I and II (Pamer EG 1999; Thery C and Amigorena S 2001) 
and undergo the final stage of their development. T cells that interact successfully with 
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antigen will divide and become effector T cells. These cells will either stay within the 
lymph tissues until required, or migrate to sites of infection. Most of the effector T cells 
generated are relatively short lived and will die as a result of antigen overload or from lack 
of antigen or cytokines. A proportion of effector T cells will become long-lived memory T 
cells, able to respond to antigenic stimulation should it be presented to them again 
following a repeated infection. It is possible that these memory T cells may reqmre 
repeated antigenic stimulation to remain alive. 
1.5.1.4 Differentiation ofCD4 and CDB cells 
T-cells of each subset are able to differentiate further, depending on the type of antigen 
they encounter. The activation ofT cells results in the production of a number of soluble 
factors, known as cytokines. Many cytokines will have profound effects on the same T -cell 
that secretes it, on bystander T cells and on other key responders in the immune system 
(Table 10). 
TABLE 10: Key cytokines in T -cell activation 
CYTOKINE: PRODUCED BY: EFFECT ON T CELLS: 
IL-2 T cells Stimulates growth and 
activation 
IL-4 T cells Stimulates growth and 
survival 
IL-6 Activated macrophages and T Stimulates activation 
cells 
IL-10 T cells Inhibits production ofT H 1 
cells 
IL-12 Dendritic cells and Stimulates T HI 
macrophanges differentiation 
IL-15 Monocytes and epithelial cells Increases expression ofiL-2 
IFN-y T cells Inhibits T cell growth 
Table showing the key cytokines involved in T cell activation, from which cell they are normally produced 
and the effect of the cytokine on the T cell in terms of stimulation and growth 
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CD4 T cells can be further sub-divided into two main subsets, Th1 and Th2 (Liew FY 
1994; Romagnani S 2000; Raulet DH and Melchers F 2001). Th1 cells are involved with 
cell-mediated immunity and phagocyte-dependent inflammation and secrete IFN-y, IL-2 
and TNF-y. The differentiation ofT cells into Th1 cells is influenced strongly by signalling 
through IL-12 and recent evidence suggests that a sustained Th 1 immune response may 
require a continuous supply of 11-12 (Raulet DH and Melchers F 2001). Th2 cells evoke 
strong antibody responses, IgE production and eosinophil accumulation, but can inhibit 
phagocyte-independent inflammation. They produce Il-4, IL-5, IL-6, IL-9, IL-10 and IL-13. 
Differentiation into Th2 cells requires IL-4 signalling (Raulet DH and Melchers F 2001). 
The balance of these two subsets within the immune system can frequently determine the 
outcome of an immune response. 
1.5.2 The T cell in B-CLL 
B cell chronic lymphocytic leukaemia is a disease in which there is accumulation of large 
numbers of B cells within the peripheral blood and bone marrow. These cells are mostly 
arrested in Go stage of the cell cycle (fig IV) and are less susceptible to apoptosis (Bannerj it 
R and Byrd CJ 2000; Caligaris-Cappio F et al 2001 ). Whilst it is undisputed that this 
disease is a B cell malignancy, T cells may play an important role in its pathogenesis 
(Caligaris-Cappio F and Hamblin TJ 1999; Bannerjit R and Byrd CJ 2000; Caligaris-
Cappio F et al 2001). The immune system relies on a wide array of specific and critical 
interactions between many different cell types including B and T cells (Ciark EA and 
Ledbetter JA 1994; Robey E and Allison JP 1995). It is possible that a dysfunction in a cell 
type other than B cells may play an important contributory role in the development and 
progression of 8-CLL. The T cell undergoes many interactions with the B cell during the 
course of both Band T cell development and an immune response and it is feasible that aT 
cell dysfunction could affect normal B cell development and responses. 
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When compared to the current literature on the B cell, relatively little is known about the T 
cell in B-CLL. However, B cells are intricately linked to the presence and status ofT cells 
and invariably, one will be unable to respond effectively without the full co-operation of 
the other. A disease which consists of an uncontrolled B-cell proliferation implies some 
degree ofT cell dysfunction. T cell research within B-CLL has focused on the following 
five key areas as follows 
I. CD4 and CD8 subpopulations and total T cell numbers. 
2. T cell response to mitogen 
3. T cell colony formation. 
4. T cell cytokine expression. 
5. Altered T cell phenotype and functional abnormalities. 
1.5.2.1 CD4 and CDB subpopulatio11s a11d total T-ee// 11umbers 
A key finding in T cell studies has been that, whilst B cells numbers are invariably 
increased, so too are T cell numbers (Kimby E et al 1989; Janssen 0 et al 1989; Zaknoen 
SL and Kay NE 1990). Initially it was believed that T cell numbers were reduced, but early 
work showed that this was in fact a "dilution effect", whereby large numbers of B cells 
"dilute" the absolute number ofT cells, which is actually normal (Catovsky D et al 1974; 
Totterman H et al 1989; Briggs PG et al 1989). In addition, an imbalance in the normal 
CD4/CD8 ratio can be seen, with an increase in absolute CD8 numbers (Kay NE et al 
1979; Kay NE 1981; Semenzato Get al 1983; Totterman TH et al 1989; Kimby E et al 
1989; Janssen 0 et all989; Burger T et all990; Goolsby CL et al 2000; Porakishvili Net 
al 2001). This increase may be linked to the stage of the disease, as the further the disease 
has progressed, the greater the number of CD8 cells (Herrman F et al 1982). Levels of 
soluble CD8 have also been shown to be higher in CLL patients compared to normals, and 
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in those patients with progressive disease, levels were significantly higher than those with 
more indolent disease (Semenzato Get all9S9; Musolino C et all991). 
Studies have also shown that there may be differences in the expression of the C04 and 
COS antigens on the cell surface and that these differences may also be linked to the stage 
of disease (Dianzani U 1994 et al). CLL patients have been found to have an expansion of 
the absolute numbers of C04+ and COS+ cells but lower levels of C04 and COS 
expression on each individual T cell (Huang L and Crispe N 1992). These C0410 and COS10 
cells also both express lower levels of CD3 and TCRap antigens on each cell. A 
correlation could be found between expression of CD410 and COS10 with increased 
expression of HLA-DR and these subsets could be linked to intrinsic features of the 
tumour. CD410 HLA-DR+ cell numbers were increased in patients who were in stable 
remission. In particular, this cell group was expanded in patients with Stage A disease, but 
not in patients with Stage B or C. These C041° CDS10 cells are similar to the double 
negative T cells which have been identified as expanded populations in both human and 
murine autoimmune diseases (Huang L and Crispe N 1992). Other similar work has also 
suggested that these cells may also be specific for self-antigens and may either derive from 
a distinct pathway ofT cell development or belong to a unique T cell lineage that is not 
dependent on positive or negative selection (von Boehmer H 1992). 
1.5.2.2 T-ce/1 response to mitogen 
Studies investigating T cell responses to common mitogens such as phytohaemaggutinin 
(PHA) and pokeweed mitogen (PWM) have shown that there is a reduced proliferation and 
activation response by CLL T cells (Foa R et al 19SI; Foa R et al 19S2; Totterman TH et al 
19S9; Zaknoen SL and Kay NE 1990; Prieto A et al 1993). T cells in CLL also show a 
reduced ability to co-operate in the production of immunoglobulin (lg) when cultured with 
normal B cells, CLL B cells and a transformed B cell line (Callery RT et al 19SO). This 
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would suggest that there is an intrinsic T cell dysfunction which persists after the removal 
of the malignant B cells and which cannot be corrected by normal B cells. Such CLL T cell 
abnormalities have been linked to hypogammaglobulinaemia, as earlier studies have also 
shown that normal B cells are unable to produce immunoglobulin when cultured with CLL 
T cells (Hersey P et al 1979). Conversely, normal B cells cultured with normal T cells leads 
to normal immunoglobulin production. Lauria et al {1983) further confirmed these findings 
by showing that normal B cells were unable to differentiate when cultured with CLL T 
cells. 
In an attempt to distinguish a sub-group of CLL T cells that might be responsible for this 
reduced B cell support, Sieber et al (1983) showed that the "helper" T cells were 
functionally quite normal, whilst numbers of suppressor T cells were increased. This 
increase in suppressor cell numbers was suggested as the cause of the reduced T cell 
capacity, as opposed to an intrinsic T cell defect. This is supported by the finding that 
suppressor T cells from CLL patients were as effective as normal suppressor T cells at 
down-regulating differentiation of normal B cells (Lauria F et al 1983). However, these 
findings of reduced T cell help for B cells have been challenged, by a study showing that 
CLL T cells could provide adequate help for normal B cells in the generation of 
immunoglobulin secretion (Sieber G et al 1981 ). 
A possible cause of the reduced T cell response to mitogens may be a soluble factor present 
in CLL patient serum. When normallymphocytes were cultured in either normal AB serum 
or CLL AB serum and stimulated with PHA or PWM, the lymphocytes cultured in CLL 
AB serum showed a significantly marked decrease in stimulation as demonstrated by a 
reduced incorporation of tritiated thymidine (Utsinger PD et al1975). However, in contrast 
to this finding, research presented in this thesis has shown that when both normal and CLL 
purified T cells are cultured in CLL AB serum and stimulated with OKT3, more T cells 
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express the activation markers CD25 and CD152 compared to those cultured in normal AB 
serum. 
Antica et al (1993) suggest that CLL patients may have three different sub-groups ofT 
cells. The first has normal functional properties, the second has non-responsive properties 
and the third has greater reactivity than normal control T cell populations. 
Overall, the evidence for a dysregulated T cell response to mitogen in CLL is conflicting 
and there have been no clearly defined, recent studies that unequivocally demonstrate low, 
normal or increased responses to mitogens. 
1.5.2.3 T-cell colony formation 
T cells from CLL patients form colonies in vitro less efficiently than those from normal 
subjects (Jehn U et al 1990; Burger T et al 1990). CLL T cells grown in a double layer T 
colony-forming assay produced fewer colonies compared with T cells from normal 
subjects, even after enrichment of the T helper cells. This abnormality correlates with the 
stage of the disease since more patients in Stage 0 showed colony formation than those at 
Stages 1-N (Foa R et al 1982). T cell colony formation in one study of untreated B-CLL 
patients was as good as that obtained from T cells from normal subjects (Femandez LA et 
al 1983). 
Similarly, CLL T cells show a reduced response in a xenogenic graft-versus-host reaction 
(Stark Petal 1999). T cells were isolated from both normal controls and CLL patients and 
injected into the skin of rats which had been immunosuppressed with cyclophosphamide. 
After 4 days, the reaction was measured, calculated by the length, width and thickness of 
the lesion at the site of injection. T cells from normal controls caused a positive reaction in 
97-100% of the tests. In comparison, 37.1% of patients in the stable phase and 13.3% of 
patients in the progressive phase were able to cause a positive result, implying a 
dysfunctional T cell status in B-CLL which was worse in advanced disease. 
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There is clearly an unexplained degree of variability in the capacity to form colonies even 
at early stages ofthe disease. 
1.5.2.4 T-ce/1 cytokine secretion 
Research into the ability of CLL T cells to express appropriate cytokines has shown that 
this function is also deficient when compared to normals. Significant decreases in 
production ofiFN-y after PHA and PWM stimulation (Epstein LB and Cline MJ 1974) of 
IL-4 (Hill SJ et al 1999) and of IL-2 in a Mixed Lymphocyte Reaction (MLR) (Ayanlar-
8atuman 0 et al 1986) have all been shown . However, contrasting results have shown an 
increase in IL-4 production by CLL T cells (Mu X et al 1996; de-Totero D et al1999; Kay 
NE et al 2001) and CLL T cells have also been shown to produce similar quantities of IL-2 
when compared to normals (Foa R et al 1985; Janssen 0 et al 1989; Zaknoen SL and Kay 
NE 1990). This was reversed when large numbers of autologous leukemic B cells were 
added to the culture system, suggesting some form of immune control of the CLL T cells 
by the malignant B cells or of the CLL B cells themselves utilising the IL-2 produced by 
the T cells (Foa R et al 1985). 
CLL B cells have been shown to have high levels of the IL-2 receptor on their cell surface 
and also to secrete high levels of soluble IL-2 receptor into the serum (Zaknoen SL and 
Kay NE 1990). It has been shown that these malignant 8 cells are able to absorb the IL-2 
produced by the T cells by both the receptors on the 8 cell surface and also soluble 
receptors in the serum. Varying results in the amount of IL-2 are found measured in CLL 
patients, as the more B cells that are present, the more IL-2 will be absorbed. 
A more recent study has shown that CD4 and CD8 T cells from CLL patients produce 
increased levels of IFN-y and that this increase in production could contribute to the 
survival of the CLL B cells as well as to the other various immune abnormalities detected 
in these patients. CLL 8 cells have an increased expression of IFN-y receptors on the cell 
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surface compared to normals and the increased levels of IFN-y are believed to inhibit 
apoptosis and prolong survival of these cells (Zaki M et a12000). 
In a comparison of IL-6 and TNF-a production between patients of different disease stages, 
levels of both were very high after stimulation in patients with Stage A disease, but little to 
none in patients with advanced disease (Stage C). Those patients with Stage B disease 
expressed intermediate amounts (Hulkkonen J et al 1998). Comparable results were 
observed with TNF-a production, suggesting that as the disease progresses, production of 
these cytokines decreases, either as a result of diminishing T cell function or increased B 
cell numbers controlling the T cells or utilising the cytokines themselves. A recent study 
has also shown an increase in both secreted and intracellular TNF-a and IL-4 in CLL T 
cells, but a decrease in IL-10 (Mainou-Fowler T et al2001). 
In a study that compared soluble CD4 (sCD4) and soluble CD8 (sCD8) m stable or 
progressive B-CLL, sCD8 was increased in both groups and sCD4 in the progressive group 
only (Aguilar-Santelises M et al 1992), suggesting an increased T -suppressor activity in 
stable B-CLL and a selective increase of helper T cell activity in progressive B-CLL. This 
suggests that the T cells are affected as the disease progresses. The increase in helper T cell 
activity might imply that the T cells are trying to respond to the malignant cells or being 
stimulated to secrete T -helper cell factors by the CLL B cells. An increase in suppressor 
activity has been reported previously in T cell responses to mitogen and this finding of 
increased sCD8 would corroborate this finding. 
The ability of CLL T cells to respond to cytokines has also been studied (Briggs PG et al 
1991 ). Purified normal and CLL T cells were cultured in the presence of either IL-l or IL-2 
and stimulated with PHA. Normal T cell response was augmented by the addition of both 
IL-l and IL-2, whilst CLL T cells showed no response after the addition of IL-l and only a 
very small response with IL-2. Such data suggest that CLL T cells have an abnormal 
97 
response to cytokines compared to normals and this may contribute to the pathogenesis and 
to the clinical findings in the disease. 
1.5.2.5 T-cell surface antigen expression. 
Most studies on the T cell compartment of B-CLL patients have focused on the phenotypic 
expression of cell surface antigens, in particular those associated with activation and B cell 
interaction and there is much conflicting evidence. Early reports have shown that 
significantly more unstimulated CLL T cells express the activation markers CD25 and 
HLA-DR when resting, compared to normals (Zaknoen SL and Kay NE 1990; Jehn U et al 
1990; Garcia-Suarez J et al 1991 ). In contrast, other work has conversely shown that 
expression of CD25 and HLA-DR is normal on CLL T cells (Kay NE and Kaplan ME 
1986; Briggs PG et al 1989). This PhD thesis has shown that the number ofT cells 
expressing CD25 is significantly reduced and the number ofT cells expressing HLA-DR 
are significantly increased (Scrivener Set al2001). 
A recent report described an assumed acquired deficiency in B-CLL patients of the ability 
to express the activation marker CD40 ligand (CD154) on anti-CD3 activated T cells 
(Cantwell M et al 1999). This finding was said to be the result of the uncontrolled 
proliferation of B cells in B-CLL patients, since stimulated T cells, in the presence of 
increasing numbers of B cells show rapid down-modulation of the CD154 receptor 
(Cantwell M et al1999). Others studies have shown that expression ofCD154 on T cells is 
normal in CLL (Brugnoni D et al 1995 Scrivener S et al 2001). Similarly, levels of 
expression ofCD28 have been reported to be down-regulated (Scrivener Set al2001) and 
the zeta (l;) chain of the CD3 receptor have also been reported to be down regulated in B-
CLL patients (Frydecka I et al 1998), although a proportion of these patients had received 
treatment in the month prior to the study (Rossi E et al 1996). 
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Expression of the Fas receptor (FasR) was shown to be increased on CD4+ and CD8+ T 
cells in patients with B-CLL (Tinhofer I et al 1998). Although apoptosis was evident in 
both subsets, only the CD4 cells died in this manner in response to the Fas antibody CH1l. 
In addition, CD 19 cells from B-CLL patients constitutively express functionally active Fas 
ligand (FasL). This Fas sensitivity correlated with a lower CD4/CD8 ratio than normal and 
it has been hypothesised that an increase in Fas sensitivity on CD4 cells and the presence of 
functionally active FasL on B-CLL B cells may be responsible for the inverted CD4/CD8 
ratio observed in many patients, as discussed in 1.5.2.1 (Tinhofer I, et a! 1998). 
There is some controversy surrounding the T -cell phenotype in B-CLL. Early studies 
(Matutes E et a! 1981) described a reduction in patients' T cells which were able to bind to 
the CD4 monoclonal antibody OKT4 and normal or increased T cell number binding the 
CD8 monoclonal OKT8. A proportion of the patient T cells were umeactive to all the 
monoclonal antibodies tested. A later study suggested that there were normal numbers of 
both treated and un-treated patients' T-cells bound to OKT4 and a statistically significant 
increase in T-cells binding OKT8, compared to normals (Mills KHG et al 1982). This 
finding has been contradicted in a more recent study, which suggested that CD4 numbers 
were increased and these cells had TCRs with oligoclonal patterns (Serrano D et a! 1997). 
Higher numbers of these CD4 T cells with oligoclonal TCRs were observed in patients 
with more advanced disease, suggesting that there are profound alterations in the T cell 
compartment of patients with CLL and that there is also evidence of clonality among the 
CLL T cell population. Other work has also shown evidence of a clonal T cell population 
in small numbers of patients (Wen T et a! 1990). Such results suggest that there may be 
some degree of host response by the T cells against specific leukaemic antigens and that in 
early stage disease particularly, the T cells attempt to respond to the leukaemic clone. 
Supporting this theory, functional studies have shown that CLL patient CD4 and CD8 T 
cells express significantly greater levels of CD45RO and decreased absolute numbers of 
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CD45RA when compared to normals (Frolova EA et al 1995; Porakishvili Net al 2001). 
The increase in cells expressing the CD45RO suggests that there is a greater proportion of 
T cells in CLL with a "memory" capacity, having previously been exposed to antigenic 
challenge or arising as a clonal population from a previously challenged T cell. 
Most recently, CLL T cells have been shown to have significantly higher levels of type II 
TGF~ receptor when compared to normal T cells (Zaki MH et a! 2000). Evidence indicates 
that TGF~ can induce growth arrest in mid to late G 1 phase of the T cell cycle (Figure 4). 
CLL T cells, when stimulated with anti-CD3 and IL-2, show a reduced production of S-
phase fraction, suggesting that they are not completing the full cell cycle of replication. 
This could be caused by the increased expression of receptors to TGF~ on the cell surface 
preventing passage to further stages of the cell cycle. 
CLL T cells, when activated in the presence of CLL B cells, rapidly up-regulate the cell 
surface antigen CD30, an affect that is not observed in normal T cells (De Totero D et al 
1999; Cerutti A et al 2001). This expression of CD30 on the CLL T cells ultimately 
prevents the up-regulation of the CD40 ligand on non-malignant B cells. By preventing 
CD40 from binding with CD 154 on the T cells, IgA and IgG production by the B cells may 
be prevented, providing a possible hypothesis for the increased hypogammaglobulinaemia 
in CLL patients. Levels of soluble CD30 are also significantly increased in the supematant 
of activated CLL T cell cultures and in CLL serum samples (De Totero D et all999). 
CTLA-4 (CDI52), the ligand for CD80 and CD86 shows prolonged expression on the 
surface ofCLL T cells compared to normal T cells after activation (Frydecka IF et al200l). 
Maximum up-regulation of this cell surface antigen was at 72hrs for normals and 24hrs for 
CLL patients. After 72hrs, CD 152 was undetectable in norma Is, but expression persisted 
on CLL T cells until l20hrs, when expression became undetectable, suggesting a 
dysregulation in T cell kinetics and a possible prolonged T cell response. 
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A recent study of T cell surface markers in CLL has shown that there is a significant 
reduction in the expression of CD4, CD5 and LF A-1 on unstimulated T cells compared to 
normals and a significant reduction of CD25, CD28 and CDI52 on activated T cells 
compared to normals (Scrivener S et al 2001). Expression of HLA-DR on stimulated T 
cells was significantly higher on CLL T cells compared to normals. Removal of the 
malignant 8 cells did not correct the defect in surface expression of CD28 and CDI52, 
suggesting a possible intrinsic or long lasting defect in CLL T cells. Permeabilisation of the 
T cells after activation did not show a difference in intracellular CD25 or CDI52 in CLL T 
cells, but expression of intracellular CD28 was significantly lower in CLL patients. In 
contrast, resting CLL T cells have significantly higher levels of intracellular CD25 and 
CDI52 compared to normals. This suggests an intrinsic T cell defect that may be affected 
by external factors, preventing normal surface expression, and altering intracellular 
expression. 
1.6 Summary 
The evidence discussed here on the functional capacity of T cells in CLL suggests that 
there is undoubtedly some degree of T cell dysfunction in CLL. But many studies have 
produced conflicting evidence, in particular about T cell surface antigen expression and 
activation status, including the secretion of critical cytokines. 
Such variation in results could be a result of the different methods used to stimulate the T 
cells. Methods that act as general T cell mitogens, such as keyhole limpet haemocyanin 
(KLH) and OKT3 which acts directly through CD3 and was used in this study, both utilise 
different methods ofT cell activation and may give rise to some of the different responses 
observed. In addition, early methods of T cell activation involved purifying the T cell 
population using mouse erythrocyte rosetting, which relies on the CD2 antigen on T cells 
binding to the sheep red blood cells. By using this method, the T cells can also be 
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inadvertently activated and resting T cell status is not studied. Methods used today and in 
this PhD study both employ a procedure of negative selection, where the end T cell 
population has received no known prior activation signals. 
To date, there has been no conclusive study examining an array of key cell surface 
interaction and activation markers that would shed light on the capabilities of the CLL T 
cell to "talk" with the malignant B cells. 
The aim of this project was to determine the functional status of the T cell compartment in 
patients with B-CLL. Using cell culture, flow cytometry and ELISA techniques, studies 
were undertaken to elucidate expression of key activation and interaction markers on both 
the T cell surface and intracellularly, to measure secretion of key T cell cytokines in both 
resting and activated T cells and to identify a possible soluble serum factor in CLL patients 
which may account for the changes described here. 
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CHAPTER TWO: MATERIALS AND METHODS 
2.1 Patients 
2.1.1 Patie11ts and control groups 
This study was approved by the local research ethics committee. 
Between September 1997 and July 2001, blood samples were taken from 41 patients with 
B cell chronic lymphocytic leukaemia (30 males, 11 females median age 70 years, range 48 
- 87). Patients were selected from Haematology clinics after having established that they 
were either not treated or had not received any treatment in the preceding three months. 
Informed consent was obtained from each patient before samples were taken. Patient 
details are shown in table 11. 
53 Control blood samples were taken from a pool of 22 normal, healthy volunteers (6 
males, 16 females, median age 34 years, range 24- 63). 
2.1.2 CLL diagtwsis 
Patients are diagnosed routinely in the Derriford Laboratory with CLL by a series of 
haematological tests, as described below. 
A Full Blood Count (FBC) is carried out, either as part of a routine check or as part of a 
clinical investigation. If the FBC reveals an absolute lymphocyte count above 5.0 x 109/L, a 
blood film is prepared. The presence of smear cells and/or pleiomorphic lymphocytes 
indicates the need for an immunophenotyping panel which is done. This analyses 
expression of CD2, CD5, CD22, CD23, FMC7, kappa and lambda for a more accurate 
diagnosis. Some patients require no further investigations after this stage. Patients are 
classed as typical or atypical CLL. Typical CLL may require a bone marrow biopsy to 
evaluate the degree of cellular infiltration before treatment is decided. Cytogenetic testing 
is being used with increasing frequency as are molecular tests for gene rearrangement. 
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TABLE 11: B-CLL patient details 
PATIENT D.O.B AGE M/F wee STAGE PREV. TREATMENT DURATION NATURE 
AA 
05.07.22 71 M 30.7 AO NONE Sep-96 STABLE 
SL 
12.07.50 48 M 32.2 AO NONE Jan-97 STABLE 
DT 
19.07.19 79 F 11 1.6 A1 NONE Nov-89 STABLE 
VB 
27.05.17 81 F 115 AO 2X CHLOR SEP '96 Jan-92 STABLE 
BL 
08.05.44 54 M 270 B1 7X CHLOR + PRED JUN 97 Sep-92 STABLE 
JB 
16.10.43 55 F 60.8 A1 6X CHLOR + PRED DEC 96 Sep-96 STABLE 
6X CHLOR OCT 95, CYCLO MAR 
MW 05.12.22 76 F 32.7 AO 98 Jul-90 STABLE 
EM 1 OX CHLOR FEB 89 6X CHLOR 
05.07.22 76 M 46 AO JUNE 96 Oct-88 STABLE 
HS 
04.05.13 85 M 85 AO PRED JAN 94 Jul-93 STABLE 
NP 
29.06.29 69 M 170.9 AO NONE Jul-95 STABLE 
3X CHLOR OCT 93, 7X CHLOR + 
ss 21 .06.42 56 M 11.7 A1 PRED FEB 94 Mar-90 STABLE 
8.3 
DH 22.08.26 72 F *(4.7) AO PRED DEC 90 Jun-90 STABLE 
12X CHLOR APR 85 6X CHLOR 
CG 16.12.18 80 M 18.3 C4 FEB 93 4X CHLOR JAN 97 Apr-85 STABLE 
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PATIENT 0.0.8 AGE M/F wee STAGE PREV. TREATMENT DURATION NATURE 
2X CHLOR FEB 86 1 X CHLOR AUG 
86 1X CHLOR JUN 88 6X CHLOR + 
PRED NOV 89 4X CHLOR + PRED 
sv 31 .05.32 66 M 29.6 C3 AUG94 Oct-84 STABLE 
RM 
24.06.34 64 M 16.9 AO NONE Apr-97 STABLE 
GB 
07.09.28 71 M 30.3 AO NONE Oct-93 STABLE 
PS 
18.12.22 76 M 18.5 AO NONE Nov-98 STABLE 
RWi 
09.07.32 67 M 38.7 AO NONE Feb-91 STABLE 
RS 
14.01 .25 74 M 107 C4 NONE AuQ-98 STABLE 
WR 
25.10.19 80 M 20.2 AO NONE Apr-97 STABLE 
SX CHLOR APR 87 6X CHLOR OCT 
91 PRED JAN 92 6X IV FLUD JUN 
94 3X CHLOR + PRED JAN 97 SX 
NR 27.02.34 65 F 40.5 C4 CHLORAUG 98 Mar-87 STABLE 
JG 
12.05.23 76 M 11 .8 AO NONE Apr-98 STABLE 
PB 
06.03.42 57 F 73.9 AO NONE Mar-96 STABLE 
EP 
08.12.29 70 M 25.1 AO NONE Jul-98 STABLE 
VR 6.6 
28.03.35 64 M *(2.4) AO 6X CHLOR + PRED FEB 99 Jan-99 STABLE 
HC 
23.02.21 78 F 45.7 AO NONE Apr-96 STABLE 
JC 
12.11 .23 76 M 27.8 C4 CLAD JUL 98 Jun-98 STABLE 
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PATIENT D.O.B AGE M/F wee STAGE PREV. TREATMENT DURATION NATURE 
RB 
17.08.37 62 M 19.8 AO NONE Dec-99 STABLE 
WHS 
04.02.20 79 M 58.9 AO SPLENIC RA OCT 99 Oct-88 STABLE 
RB 
01 .07.45 54 M 8.9 AO NONE May-00 STABLE 
RJ 
09.06.33 66 M 46.3 AO NONE Sep-96 STABLE 
SLOWLY 
JC 18.12.26 73 F 29.9 B3 NONE Dec-00 PROGRESSIVE 
RB 
24.07.37 62 M 28.1 AO NONE Aug-99 STABLE 
FB 
24.07.22 78 F 33.5 AO NONE Oct-91 STABLE 
2X CHLOR MAR 90 9X CHLOR + 
PRED MAY 92 6X CHLOR JUL 94 
FM 15.05.39 61 M 17.5 AO 6X CDA + PRED MAY 95 Feb-89 STABLE 
JL 
01.02.23 78 M 12.3 AO NONE Sep-92 STABLE 
6X CHLOR SEP 91 5X CHLOR APR 
MRM 07.09.14 87 M 83.9 AO 99 Sep-91 STABLE 
KM 
19.04.31 70 M 60.8 AO NONE Oct-00 STABLE 
MS 
07.03.40 61 M 14.8 AO NONE Nov-00 STABLE 
RWr 
22.09.5 65 M 15.2 AO NONE Dec-99 STABLE 
HF 
17.1 0.38 63 F 6.2 CR NONE Sep-96 STABLE 
Table showing all patient details including age, date of birth, sex, white cell count at time of experiment, stage, treatment history, date of diagnosis and nature of disease * figures in brackets 
indicate the absolute lymphocyte count, as white cell count below normal range for CLL diagnosis. Increased absolute lymphocyte count indicates CLL. CR = clinical remission, CHLOR = 
Chlorambucil, PRED = Prednisolone, CDA = , CLAD = Cladribine, FLUD = Fludarabine, RA = radiotherapy, CYCLO = Cyclophosphamide 
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2.2 Reagents 
2.2.1 Cell culture reagents 
Reagent Supplier 
Roswell Park Memorial Institute - 1640 Gibco Life Technologies, Paisley, UK 
(RPMI-1640) 
Pencillin and Streptomycin antibiotics Sigma Aldrich, Poole, UK 
Normal human AB serum National Blood Transfusion Service, Bristol, 
UK 
Lymphoprep Nycomed Amersham, Amersham, UK 
Phytohaemagglutinin (PHA) Murex, Maidenhead, UK 
OKT3 Janssen-Cilag, High Wycombe, UK 
24-well, polystyrene, flat bottom, culture Nunclon, Fisher Scientific UK, 
plates Loughborough, Leics, UK 
5 ml, polystyrene, round bottom, Falcon Marathon Lab Supplies, London, UK 
tubes 
Bovine Serum Albumin (BSA) Lome Laboratories, Reading, UK 
Interleukin-15 (IL-15) Cambridge Bioscience, Cambridge, UK 
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2.2.2 Flow Cytometry reagents 
All samples were analysed on a Beckman-Coulter Epics Elite Flow Cytometer (Beckman 
Coulter, High Wycombe, UK) 
Reagent Supplier 
Flow check fluorospheres Beckman-Coulter, High Wycombe, UK 
CD 14/CD45 Leucogate Serotec, Kidlington, Oxford, UK 
CD2 FITC Serotec 
CD3 FITC Serotec 
CD4PE Serotec 
CD5PE Serotec 
CD8PE Serotec 
CDlla (LFA-1) PE Serotec 
CD25 (IL-2R) PE Serotec 
CD28PE Beckman Coulter 
CD54 (ICAM-1) PE Serotec 
CD152 (CTLA-4) PE Beckman Coulter 
CD154 (CD40L) PE Ancell Corporation, Nottingham, UK 
HLA-DRPE Serotec 
Mouse IgG 1 FITC Serotec 
Mouse IgG2b FITC Serotec 
Mouse IgG 1 PE Serotec 
Mouse IgG2a PE Beckman Coulter 
2.2.3 B cell depletion reagents 
Reagent/Equipment Supplier 
CD 19 magnetic beads Miltenyi-Biotech, Bergisch Gladbach, 
Germany 
EDTA Sigma Aldrich, Poole, UK 
LS+ separation columns Miltenyi-Biotech 
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2.2.4 Permeabilisation reagents 
Reagent Supplier 
DAKO intrastain kit DAKO, Ely, UK 
2.2.5 EL/SA reagents 
Reagent Supplier 
Quantikine human IL-2 ELISA R & D systems Europe Ltd., Abingdon, 
Oxon, UK 
Pelikine Compact Human IFN-y ELISA Eurogenetics (UK) Ltd., Hampton, UK 
Carbonate Sigma Aldrich, Poole, UK 
Bicarbonate Si gm a 
PBS: dibasic sodium phosphate, monobasic Si gm a 
sodium phosphate, sodium chloride 
Thiomersal Si gm a 
Tween 20 Si gm a 
Tetrarnethylbezidine (TMB) Si gm a 
Dimethylsulfoxide (DMSO) Si gm a 
Hydrogen peroxide (H202) Si gm a 
H2S04 Si gm a 
Sodium acetate Si gm a 
Glacial acetic acid Sigma 
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2.3 Preparation of solutions 
2.3.1 Cell culture 
Cell culture medium. Under sterile class 11 conditions (MDH lntermed class 11 cabinet) and 
at room temperature, I Omls of Penicillin and Streptomycin (Sigma Aldrich, Poole, UK) 
were added to 500mls RPMI-I640 (Gibco Life Technologies, Paisley, UK) at a final 
concentration of SOOU/ml and 500!lglml respectively. 5mls of L-glutamine (Sigma) was 
added to 500mls RPMI at a final concentration of2mM. Solution was stored at 4°C. 
RPM!+ 10% and 50% normal AB sen1m. Under sterile class 11 conditions, 10% or 50% 
normal AB serum (National Blood Transfusion Service, Bristol, UK) was added to pre-
warmed RPMI at 37°C as required. 
RPM!+ 50% CLL AB sernm. Blood was taken into sterile plain tubes from an AB Rh (Dt 
CLL patient and left to stand at room temperature for a minimum of 2 hrs. Once the 
contents had clotted, the sample was centrifuged and the serum removed under sterile 
conditions and aliquoted into sterile lml tubes (Greiner). Sample was heat inactivated at 
57°C for 30 minutes and then frozen for future use. 50% CLL AB serum (Smls) was added 
to pre-warmed RPMI at 37°C (Smls) when required. The CLL AB serum was analysed for 
total protein, immunoglobulins and lipids in both fresh and heat inactivated serum. 
Wash buffer. 400mls O.OIM PBS (Sigma) was supplemented with I% BSA (4mls) (Lorne 
Laboratories, Reading, UK). 
Ill 
2.3.2 B-ee// depletion so/utio11s 
Cell separation (Miltenyi Biotech MACS) buffer. Under sterile class ll conditions, 400mls 
PBS was supplemented with 2mM EDTA (Sigma) and stored at 4°C. Prior to use, 50mls of 
solution was sterile filtered under class ll conditions using a 0.2J.l filter (Nalgene, 
Rochester, New York, USA) and supplemented with 0.5% BSA (250J.ll) (Lorne 
Laboratories). 
2.3.3 EL/SA so/utio11s 
All reagents made up at room temperature. 
IFN-y EL/SA Coating buffer. Solution A: 0.124g carbonate (Sigma) was added to lOmls 
distilled water. Solution B: 0.168g bicarbonate (Sigma) was added to 20mls distilled water. 
Solution A was added to solution B until the pH was 9.6. Approximately 7mls of solution 
A and 17.5mls solution B were needed. 120J.ll of the supplied coating antibody (R & D 
systems Europe Ltd, Abingdon, Oxon, UK) was added to 12mls of this coating buffer. 
PBS stock solution. 16g dibasic sodium phosphate (Sigma), 3g monobasic sodium 
phosphate (Sigma) and 82g sodium chloride (Sigma) were added to 450mls distilled water, 
the pH adjusted to 6.8-6.9. lOmg thiomersal (Sigma) was added as a preservative. 
Working strength PBS. PBS stock solution was diluted 1:20 in distilled water 
Blocking buffer. 500J.ll of supplied blocking buffer (R&D systems) was added to 25mls of 
working strength PBS. 
Washing buffer. 50J.ll oftween 20 (Sigma) was added toIL of working strength PBS. 
Biotinylated IFN-y. l20J..Ll of supplied biotinylated IFN-y (R&D systems) was added to 
12mls of working strength dilution buffer 
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Substrate buffer. l.5g of sodium acetate (Sigma) was dissolved in 80mls distilled water. 
pH was adjusted to 5.5 with glacial acetic acid (Sigma) and distilled water was added to 
make up lL. 
TMB stock solution. 30mg tetramethylbezidine (TMB) (Sigma) was dissolved in 5mls 
dimethylsulfoxide (DMSO) (Sigma). 
Hydrogen peroxide solution. 3% (lml of a 30% stock solution) of hydrogen peroxide 
(H20 2) (Sigma) was added to 1 Omls of distilled water. 
Substrate solution. 12mls of substrate buffer was added to 200~1 of TMB stock solution 
and 12~1 of H20 2 stock solution. 
Stop solution. H2S04 (Sigma) was added to distilled water at a final concentration of 1.8M. 
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2.4METHODS 
2.4.1 Flow cytometry on the Beckmalf Coulter Epics Elite 
All cells were analysed on a Beckman Coulter Epics Elite. 
Before analysing patient and control samples, the flow cytometer was aligned usmg 
Beckman Coulter Flow Check beads. This was carried out at the start of every experiment 
to ensure that the laser was correctly aligned with the photomultiplier tubes (PMTs). This 
was established by ensuring both visually that the beads were aligned inside the central box 
in histogram 1 and that the peaks which fell within the set limits ofPMTl, PMT2, PMT3, 
PMT4 and PMT5 were narrow and high representing the particles passing the centre of the 
laser beam. Correct alignment was also verified numerically. The half coefficient variant 
(cv) value for each of the PMTs should be below 2.0. If either of these parameters fell out 
of their normal ranges, a full or partial re-alignment was carried out, as explained in the 
Beckman Coulter Epics Elite trouble shooting guide. 
After correct alignment was established, each set of samples was analysed in the same 
order, to ensure correct negative and positive gating and correct compensation. The 
negative control sample was always analysed first, to set the gates around the negative cells 
and to ensure that there were no cells that stained positive for the relevant mouse isotypic 
controls (fig 9). 
The cells stained with either CD2 FITC or CD3 FITC were analysed second to check that 
compensation between FITC and PE was correct. Different cell types and cells in different 
stages of activation could require compensation to prevent FITC fluorescence being picked 
up by PMT3 instead of PMT2. If this occurred, the voltage for PMT2 was increased and 
the cells re-aligned in the correct upper right quadrant of the dot plot. CD2 or CD3 were 
also analysed individually to obtain a total T cell number from which percentages could be 
calculated. 
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A sample containing· ~he' _rnonqclonals CD45 FIJ'€/CBf4 PE @!.eucogate) was always 
. 
analysed,. llhis:·allowed :the gated .cells• to lbe' identified .as Jymphocytes andl not monocytes' 
(fig 1.0)., 
The relevant ,sillilples were then analysed. Once the iymphocyte gate hao been ,set; .each' 
SaJ11plewllS coqnt~d.for:a total ()f:.5o'O(l!cells (lympho~yte~)l I' 
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Figure 2-: Flow cytometry dot plots showing cell populations after staining with 
negative isotypes 
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Figure 10: Flow cytometry dot plots showing cell populations after staining with 
Leucogate 
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2.4.2 PBMC isolation 
Blood was drawn into 1 Oml sodium heparin anticoagulated tubes and under sterile class II 
conditions, mixed in equal volumes with pre-warmed RPMI-1640 medium (Gibco Life 
Technologies, Paisley, UK) at 37°C containing penicillin, streptomycin and L-glutamine 
(Sigma Aldrich, Poole, UK) and layered in equal volumes on to the density gradient 
separation medium Lymphoprep (Nycomed Amersham, Amersham, UK). Cells were 
centrifuged for 20 minutes at 450g with the brake off (Labofuge 400R, Heraeus, Kendro 
Laboratory Products Ltd, Bishops Stortford, Hertfordshire, UK). PBMCs were removed 
from the interface, transferred to clean, sterile 12ml tubes (Greiner Bio-One, Stonehouse, 
Gloucester, UK) and washed twice in excess RPMI + 10% AB serum (National Blood 
Transfusion Service (NBTS), Bristol, UK) as described previously. Cells were resuspended 
in RPMI (Gibco) + 10% AB serum and counted by a haemocytometer (Sigma Aldrich, 
Poole, UK). 
2.4.3 Cell culture methods for cell surface expression of antigens CD25, CD28, CD152, 
CD154 and HLA-DR 
PBMCs were cultured under conditions described below to evaluate expression of the cell 
surface markers CD25, CD28, CD152, CD154 and HLA-DR on T cells after activation. 
For expression of CD28, CD154 and HLA-DR, the monoclonal antibody OKT3 (Janssen-
Cilag, High Wycombe, UK) was added to PBS at a final concentration of lmg/ml and 
SOOf.ll was plated on 6 wells of a 24 well, flat bottom, polystyrene, culture plate (Nunclon, 
Fisher Scientific UK, Leics, UK) for 2 hours at room temperature under class II sterile 
conditions. 6 wells on a separate 24 well plate were set up as controls containing SOOf.ll 
PBS alone in addition to the OKT3 wells. PBMCs were isolated as described in 2.4.2. 
The 24-well plate containing the OKT3 wells and the control 24 well plate containing the 
PBS wells were washed 3 times in 500f.1l of PBS. Cells for CD28, CD154 and HLA-DR 
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analysis were plated at a final concentration of I x I 06 in 1 ml RPMI (Gibco) + I 0% AB 
serum (NBTS) per well in each plate. 
Cells for CD25 and CDI52 analysis were plated on 4 wells in a 24-well plate at a final 
concentration of I x 106 /ml in RPMI + IO% AB serum per well. Cells for CD25 and 
CDI52 were not cultured with OKT3 in these initial experiments. Instead, 5f.!l of PHA 
(Murex, Maidenhead, UK.) was added to each well of PBMCs at a fmal concentration of 
5f.!g/ml. Corresponding controls were set up in a separate 24 well plate containing I x I 06 
PBMCs in Iml RPMI + IO% AB serum in each well with no PHA. 
After cells for CD28 and CD154 analysis had been plated on the 24-well plates containing 
both the OKT3 and the control PBS only, they were cultured for 4 hours in the incubator 
(Sanyo IR Sensor, Jencons Plc) at 37°C and in 5% C02• After culture, the cells from each 
well were transferred to separate 5ml, polystyrene, round bottom tubes (Falcon, Marathon 
Lab Supplies, London, UK.) centrifuged for 5 minutes at 1400rpm and washed twice in I ml 
wash buffer. 
After cells for CD25, CD152 and HLA-DR analysis had been plated on the 24-well plates 
containing both the PHA and the control wells, they were cultured in the incubator for 48 
hours at 37°C and in 5% C02• After culture, the cells from each well were transferred to 
separate 5ml tubes (Falcon), centrifuged for 5 minutes at 220g and washed twice in lml 
wash buffer. 
IOf.!l of antibody for negative controls (equivalent mouse isotypic controls), Leucogate 
(lymphocyte gating), CD2 (T cell confirmation), CD3 {T cell confirmation), CD3/CD25 
(test), CD2/CD28 (test), CD3/CD152 (test), CD2/CDI54 (test) and CD2/HLA-DR (test) 
(as described in 2.2.2 and 2.4.1) were added to each 5ml tube per I 06 cells and incubated 
for 15 minutes in the dark at room temperature in air. 
PBMCs were washed twice in wash buffer for 5 minutes at 220g, resuspended in I ml PBS 
and analysed using flow cytometry. 
119 
2.4.4 Cell preparation methods for surface expression ofCD4, CI!.5, CD8, CDlla, CD 54 
andTCRap 
PBMCs were isolated as described in 2.4.2. 1 OJ.1l of antibody for negative control 
(equivalent mouse isotypic controls), Leucogate (lymphocyte gating), CD3 (T cell 
confirmation}, CD3/CD4 (test), CD3/CD5 (test), CD3/CD8 (test), CD3/CDlla (test), 
CD3/CD54 (test) and CD3/TCRap (test) (as described in 2.2.2 and 2.4.1) were added to 
each tube per 1 x l 06 cells and incubated for 15 minutes in the dark at room temperature. 
PBMCs were washed twice in wash buffer for 5 minutes at 220g, resuspended in 1ml PBS 
and analysed using flow cytometry. 
2.4.5 T cell enrichment 
lOmls of magnesium and calcium free PBS, kept on ice to prevent antibody capping during 
staining, was added to each sample of lOmls of sodium heparin anticoagulated blood (no 
more than 8 hours old) and PBMCs were isolated as described in 2.4.2, with the exception 
that all wash stages in the centrifuge were carried out at l8°C. After final wash stage, l ml 
of cell separation buffer (described in 2.3.2) was added to the cells and they were 
immediately counted by a haemocytometer (Sigma Aldrich, Poole, UK). All buffers and 
reagents were kept on ice throughout. 
After the cells had been counted, they were diluted with 80J.1l of cell separation buffer and 
20J.1l ofCDl9 microbeads (Miltenyi-Biotech, Bergisch Gladbach, Germany) for every 107 
total cells, vortexed (Clifton Cyclone, Jencons Plc) and incubated at 4°C for IS minutes in 
the dark. Cells were then washed in excess cell separation buffer at 220g for l 0 minutes at 
l8°C. 
The cell separation MACS LS+ column (Miltenyi Biotech, Bergisch Gladbach, Germany) 
was washed 3 times with I ml of cell separation buffer, avoiding air bubbles. The cells to be 
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separated were resuspended in 500J.ll of cell separation buffer per 108 cells and run through 
the column in 500J.ll aliquots and the supematant collected. The column was washed 
through with 3mls of cell separation buffer and the supematant collected in 12ml tubes 
(Greiner Bio-One, Stonehouse, Gloucester, UK). Cells that were collected in the 
supematant were washed at 220g with excess cell separation buffer, resuspended in 1 ml of 
RPMI (Gibco Life Technologies) + 10% AB serum (NBTS) and counted by a 
haemocytometer (Sigma). 
White cell numbers were often high in CLL patients samples which can have much greater 
numbers of B cells than control samples, so it was necessary to titrate the amount of CD 19 
MACs (Miltenyi) beads required. In an attempt to achieve maximum purification of the 
isolated T cells, the above experiment was repeated, titrating the levels of CD 19 beads at 
concentrations ranging from 30J.ll to 70J.ll per I 07 total cells and staining with CD20 
(Sigma) to evaluate B cells remaining after depletion. Total CD20 numbers were analysed 
using flow cytometry. 
2.4.6 Permeabilisation met/rods 
To evaluate the expression of intracellular CD25, CD28 and CD 152, T cells were enriched 
as described in 2.4.5 and cultured as described in 2.4.3, with the addition that after time 
course and optimisation studies (described in 2.5.8), all cells were cultured for 48 hours 
and activated using OKT3. Intrastain reagents fix cell surface monoclonal antibodies and 
then penneabilise the cell membrane to allow for intracellular staining. After culture, cells 
were harvested from the 24-well, polystyrene, round bottom plates (Nunclon, Fisher 
Scientific) and 1 x 106 cells transferred to each of 6 clean, 5ml polystyrene tubes (Falcon) 
and washed twice in 1ml ofPBS at room temperature. Cells were then stained with lOJ.ll of 
antibody for negative control (equivalent mouse isotypic controls), Leucogate (lymphocyte 
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gating) and CD2 (T cell confinnation) as described in 2.2.2 and 2.4.1 for 15 minutes in the 
dark. 1 OOJ.!l of DAKO intrastain reagent A (DAKO, Ely, UK) was added to each tube and 
incubated for 15 minutes in the dark at room temperature. Cells were then washed twice in 
2mls ofPBS at 320g for 5 minutes. 
1 OOJ.!l of DAKO intrastain reagent B (DAKO) was added to each tube and vortexed 
(Clifton Cyclone, Jencons Plc). Monoclonal antibodies for intracellular staining were 
added to the cells (CD25, CD28 and CD152, as described in 2.2.2) and left for 15 minutes 
in the dark at room temperature. Cells were then washed twice in 1ml PBS at 320g for 5 
minutes, resuspended in 1ml PBS and analysed on the flow cytometer. 
2.4. 7 Expressiotr of CD25, CD28 atrd CD152 itr trormal controls atrd CLL patietrts after 
B-cell depletion and culture with OKT3 and 50% CLL AB serum 
T cells were enriched as described in 2.4.5 and prepared for culture with OKT3 (Janssen-
Cilag) as described in 2.4.3. Cells were resuspended in RPMI (Gibco) containing either 
50% CLL AB serum or 50% nonnal AB serum (NBTS) as described in 2.3.1 and cultured 
as described in 2.4.3 with the addition that after time course and optimisation studies 
(described in 2.5.8), all cells were cultured for 48 hours and activated using OKT3 
(Janssen-Cilag). Cells were harvested at 48 hours and transferred from the 24-well, 
polystyrene plates (Nunclon, Fisher Scientific) into each of 6 clean 5ml polystyrene tubes 
(Falcon, Marathon Lab Supplies). lOJ.!l of antibody for negative controls (equivalent mouse 
isotypic controls), Leucogate (lymphocyte gating), CD2 (T cell confinnation), CD2/CD25 
(test), CD2/CD28 (test) and CD2/CD152 (test) (as described in 2.2.2 and 2.4.1) were added 
per l x 106 cells in l ml and incubated for 15 minutes in the dark at room temperature. Cells 
were washed twice in 1ml of wash buffer for 5 minutes at 220g, resuspended in 1ml PBS 
and analysed in the flow cytometer. 
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A direct comparison was made between expression of CD25, CD28 and CDI52 after 
culture in CLL AB serum or in normal AB serum. 
2.4.8 Mixed lymphocyte reaction (MLR) 
For responder cells, PBMCs were isolated and B cells depleted as described previously in 
T cell enrichment (2.4.5). For stimulator cells, PBMCs were isolated as described 
previously (2.4.2). Stimulator PBMCs were irradiated at 25Gy (Gammacell 1000 Cs-137 
irradiator, Schering Health Care Ltd., Burgess Hill, West Sussex, UK) for IO.I minutes, 
counted in a haemocytometer (Sigma) and resuspended in RPMI (Gibco) + IO% normal 
AB serum (NBTS). Responder cells were counted in a haemocytometer and resuspended in 
RPMI + I 0% AB serum. I 06 stimulator cells in I ml were plated with I 06 responder cells in 
Iml in 24 well, polystyrene, flat bottom plates (Nunclon, Fisher Scientific) for the MLR. 
Control wells were set up containing responder cells only. Cells were cultured for 72 hours 
for IL-2 secretion and 96 hours for IFN-y secretion for optimum cytokine expression. At 
the appropriate time points, the medium was harvested under sterile class 11 conditions and 
centrifuged for 5 minutes at 400g. Leaving the cells in the tubes, the supematant was 
removed under sterile conditions and transferred to sterile I.5ml tubes (Nalgene Cryovials, 
Nalgene) and stored at -20°C until required. 
2.4.9 JL-2 EL/SA 
Supematants were thawed and all reagents brought to room temperature before use. 
The wash buffer (R&D systems) was reconstituted by adding 20ml of concentrate to 
480mls of deionised water. 5mls of the calibrator RD5 (R&D), for use with the cell 
supematant, was added to the supplied IL-2 standard stock solution (R&D) to make a final 
concentration of 2000pg/ml of IL-2. This was left for a minimum of I5 minutes at room 
temperature with gentle agitation. 500f.ll of calibrator RD5 was added to each of 6, 5ml, 
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polystyrene tubes (Falcon, Marathon Lab Suplplieaz) and to the first tube, 500J.1l of IL-2 
standard was added. A dilution series was carried out, with 500J.1l of the solution from the 
preceding tube being added to the next tube, to produce 6 tubes containing I 000, 500, 250, 
125, 62.5 and 31.2 pg/ml ofiL-2 standard. The 120-well microplate (R&D) was removed 
from its foil pouch and lOOfll of supplied assay diluent RDIA (R&D) was added to each 
well. I OOfll of each of the IL-2 dilution series of standards was added in duplicate with 2 
wells left for blanks. 
All patient and control samples were set up in duplicate at a I :2 and a 1:5 dilution. For the 
1:2 dilutions, each well contained lOOfll of supplied assay diluent (R&D) and l OOfll of 
patient or control supernatant from the MLR. For the l :5 dilutions, each well contained 
l60J.1l of assay diluent and 40J.ll of patient or control supernatant from the MLR. The whole 
plate was covered with an adhesive strip, incubated in air for 2 hours at room temperature 
and then washed 3 times in wash buffer in the autowasher (Kodak Amerlite, Kodak 
Clinical Diagnostics Ltd, Amersham, UK). The autowasher filled each well with 200fll of 
appropriate buffer and then subsequently removed it on each of the 3 cycles. The wells 
were left empty at the end of the three cycles. 
After washing, 200f.1l of the IL-2 conjugate (R&D) was added to each well. The whole 
microplate was covered with a new adhesive strip and incubated for a further 2 hours at 
room temperature and then washed 3 times in wash buffer in the autowasher (Kodak 
Amerlite), as described previously. The colour reagents A and B (R&D) were added in 
equal concentrations to make the substrate solution to be used within 15 minutes of 
mixing. After washing the microplate, 200111 of this substrate solution was added to each 
well of the microplate and incubated for 20 minutes at room temperature in air, protected 
from light. 50J.1l of stop solution (R&D) was then added to each well and a uniform colour 
change obtained by gently tapping the plate. The optical density of each well was measured 
using a microplate reader (DIAS, Dynatech Laboratories, West Sussex, UK). The test 
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wavelength was set to 450nm and the correction wavelength to 540nm. Using this dual 
wavelength reading mode to measure the absorbance of the sample, reading errors caused 
by dirt, scratches or moisture on the base of the plate were eliminated. 
Both normal and CLL supematants were analysed on the same ELISA plates 
simultaneously to avoid any intra assay variation. 
2.4.10 JFN-yELISA 
The 120-weiiiFN-y microplate (Eurogenetics UK Ltd) was removed from its foil pouch. 
l20f.ll of IFN-y coating antibody (Eurogenetics) was added to 12mls of IFN-y coating 
buffer (described in 2.3.3). 100f.ll of coating buffer plus coating antibody was then added 
to each well and incubated overnight at room temperature in air. The microplate was then 
washed 3 times in the autowasher (Kodak Amerlite), as described previously in 2.4.9, with 
wash buffer (described in 2.3.3). 500J.ll of blocking buffer (described in 2.3.3) was added 
to 25mls of working strength PBS and 200f.ll of the resulting solution was added to all 
wells, which were mixed by tapping the side of the microplate. The whole plate was then 
covered with an adhesive seal and incubated for 1 hour at room temperature in air. 
500J.ll of distilled water was added to 5300pg/m1 of IFN-y standard lyophilised powder 
(Eurogenetics) and incubated for 10 minutes at room temperature in air, with gentle 
mixing. Another diluting series of standards was set up with 7, 5ml polystyrene tubes 
{Falcon, Marathon Lab Supplies), labelled 500, 200, 80, 32, 12.8, 5.1 and 2.0 pg/ml. The 
concentrated dilution buffer (Eurogenetics) was diluted 5 times in distilled water to 
produce working strength dilution buffer. 480f.ll of this working strength dilution buffer 
was added to the first tube labelled 500pg/ml and 300J.ll to each of the other 6 tubes. 50J.tl 
of the IFN-y standard was added to the first tube labelled 500 pg/ml and 200J.tl of this 
solution was then transferred to the 200pg/ml (second) tube. The series was then completed 
by transferring 200J.tl from each preceding tube to the next. 
125 
The microplate was washed 3 times in wash buffer using the autowasher (Kodak Amerlite), 
as described previously. 1 00~1 of each standard from the 7 tubes was added to the 
microplate in duplicate, leaving the blank wells empty. Samples from the MLR supematant 
were added in duplicate at a I :2 dilution and at a 1 :5 dilution. For the I :2 dilution, 200~1 of 
the samples were pre-diluted with 200~1 of working strength dilution buffer and for the 1 :5 
dilution, 80~1 of the samples were pre-diluted in 320~1 of working strength dilution buffer. 
100~1 of sample was added to each well. The whole microplate was covered with a new 
adhesive strip and incubated for 1 hour at room temperature in air. After 1 hour, the 
microplate was washed 3 times in wash buffer using the autowasher, as described 
previously. 120~1 of biotinylated IFN-y (Eurogenetics) was added to I2mls of working 
strength dilution buffer just before use and 1 00~1 was added to each well, leaving the blank 
wells empty. The whole microplate was covered with a new adhesive strip and incubated 
for I hour at room temperature in air and then washed 3 times in the autowasher, as 
described previously. 
Just prior to use, the concentrated streptavidin-HRP conjugate (Eurogentics) was removed 
from the -20°C freezers and 3~1 was added to 30mls of working strength dilution buffer. 
I 00~1 of this solution was added to each well, leaving the blank wells empty. The whole 
microplate was covered with a new adhesive strip and incubated for 30 minutes at room 
temperature in air and then washed 3 times in the autowasher, as described previously. 
The substrate solution (described in 2.3.3) was prepared within I 0 minutes of use. 100~1 
was added to each well, including the blank wells. The plate was covered with a lid, gently 
tapped to mix and incubated for 30 minutes at room temperature in the dark. 
I 00~1 of stop solution was added to all wells and the plate read in the plate reader (DIAS, 
Dynatech Laboratories, West Sussex, UK). The test wavelength was set to 450nm and the 
correction wavelength to 540nm. Using this dual wavelength reading mode to measure the 
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absorbance of the sample, reading errors caused by dirt, scratches or moisture on the base 
of the plate were eliminated 
Both normal and CLL supernatants were analysed on the same ELISA plates 
simultaneously to avoid any intra assay variation. 
2.4.11 MLR with /L-15 
For responder cells, PBMCs were isolated and B cells depleted as described previously in 
2.4.5. For stimulator cells, PBMCs were isolated as described in 2.4.2. Stimulator PBMCs 
were re-suspended in PBS, counted using a haemocytometer (Sigma) and irradiated at 
25Gy (Gammacell 1000 Cs-137, CIS Radiopharmaceuticals, Schering Health Care Ltd, 
West Sussex, UK). After irradiation the stimulator cells were spun for 5 minutes at 320g 
and resuspended in RPMI (Gibco) plus 10% normal AB serum (NBTS). After T cell 
enrichment, responder cells were re-suspended in RPMI plus 10% AB serum and counted 
using a haemocytometer. 106 stimulator cells in lml RPMI plus 10% AB serum were plated 
with 106 responder cells in 1ml RPMI plus 10% AB serum in 3 wells of a 24 well 
polystyrene plate (Nunclon, Fisher Scientific UK) for the MLR. Corresponding controls 
were set up in 3 wells of a separate 24-well plate containing 106 responder cells in 1 ml 
RPMI plus 10% AB serum only. Interleukin-15 (IL-15) (Cambridge Bioscience, 
Cambridge, UK) was added to the first MLR and control wells at concentration of 1 Ong/ml, 
to the second MLR and control well at lng/ml and the final MLR and control wells were 
left with no addition of IL-15. For IL-2 secretion, cells were cultured for 72 hours in an 
incubator at 37°C and 5% C02• After 72h, the medium was harvested, transferred to 6 
separate 5ml, polystyrene tubes (Falcon) and centrifuged for 5 minutes at 400g. Leaving 
the cells in the tubes, the supernatant was removed and transferred to l.5ml tubes (Greiner 
Bio-One, Stonehouse, Gloucester, UK) and stored at -20°C until required. 
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Supernatants were thawed when required and evaluated for IL-2 secretion, as described 
previously in 2.4.9. Supernatants were only frozen and thawed once. 
2.4.12 Expression of CD25, CD28 and CD/52 after OKT3 stimulatio11, /L-15 and 
permeabilisation. 
T cells were enriched as described in 2.4.5 and cell cultures with OKT3 (Janssen-Cilag) 
prepared as described in 2.4.3. 6 wells of a 24 well, polystyrene plate (Nunclon, Fisher 
Scientific UK) were set up with OKT3. 6 wells were set up as controls with no OKT3. 
After T cell enrichment, cells were re-suspended in RPMI (Gibco) plus 10% normal AB 
serum (NBTS) and plated on 12 wells of a 24 well plate at 106 per well in lml. IL-15 
(Cambridge Bioscience) was added to the first four wells of the 24 well plate at a 
concentration of lOng/m!, to the second four wells at a concentration of 1ng/ml and the last 
four wells were left without IL-15. Cells were cultured as described in 2.4.3 with the 
addition that, after time course and optimisation studies (described in 2.5.8), all cells were 
cultured for 48 hours and activated using OKT3. To half the cells were added IOJ.ll of 
antibody for negative control (equivalent mouse isotypic controls), Leucogate (lymphocyte 
gating), CD2 (T cell confirmation), CD2/CD25 (test), CD2/CD28 (test) and CD2/CD152 
(test) (as described in 2.2.2 and 2.4.1) per 106 cells, incubated for 15 minutes in the dark in 
air and at room temperature, washed twice in 1 m! of wash buffer for 5 minutes at 220g, 
resuspended in 1 m! PBS and analysed in the flow cytometer. 
The remaining cells were permeabilised and stained for intracellular antigens as described 
previously in 2.4.6. 
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2.5 OPTIMISATION METHODS 
A series of experiments were carried out to establish optimum time points for each of the 
cell surface markers studies and for culture with OKT3. Although the majority of these 
data have been previously demonstrated, as indicated by references in each subsection, it 
was important to verify them to ensure accurate comparisons between normal and CLL 
samples. Direct comparisons were also made between the different methods for cell 
separation and cell permeabilisation. CLL cells are known to be more fragile and it was 
therefore important to establish a suitable protocol for both normal and CLL cells. 
Where appropriate, data was analysed using means plus coefficient of variation (cv). Cv is 
expressed as a percentage and has been used to assess sampling methods and the spread of 
data within each test. 
2.5.1 Time course for OKT3 adherence to culture plates 
Under sterile class IT conditions, OKT3 (Janssen-Cillag) was added to PBS to a final 
concentration of lmg/ml. 500f.1l was plated on I well in each of 6 separate 24 well, 
polystyrene culture plates (Nunclon, Fisher Scientific UK). Half of these were left at room 
temperature and half at 4°C, so that each time point was studied at two different 
temperatures. 500fll of PBS only was also plated into a separate well of each of these six 
24 well plates as controls. OKT3 was left to adhere for either 2, 16 or 24 hours. After each 
relevant time point, the appropriate well was washed 3 times in lml ofPBS. PBMCs were 
isolated as described previously in 2.4.2 and were added to both the OKT3 and control 
wells in each of the 24 well plates at a concentration of 106 in RPMI (Gibco) plus 10% AB 
serum (NBTS) and cultured for 4 hours in an incubator at 3 7°C in 5% C02 in air. After 
culture, medium and cells were harvested, transferred to clean 5ml, polystyrene tubes 
(Falcon, Marathon Lab Supplies) then centrifuged at 220g for 5 minutes and the 
supematant removed. I ml wash buffer was added to each tube and cells were washed for 5 
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minutes at 220g. 1 O!J.I of antibody for negative controls (equivalent mouse isotypic 
controls), Leucogate (lymphocyte gating), CD2 (T cell confirmation) and CD2/CD154 
(test) (as described in 2.2.2 and 2.4.1) was added to 106 cells and incubated for 15 minutes 
in the dark at room temperature in air. Only normals' cells were used. Cells were then 
washed twice in 1ml wash buffer at 220g for 5 minutes, resuspended in 1ml PBS and 
analysed using flow cytometry. Results for CD2/CD 154 only are shown in the results 
section (table 12). Other control data not shown in the results sections are available outside 
the thesis. 
The optimum time scale for leaving OKT3 binding to culture plates could be determined 
by the expression of the activation marker, CD 154, after culture with each OKT3 plate, as 
described in section 3.1. CD154 was selected as the activation marker as it is up-regulated 
in a relatively short period of time and also because it was a marker to be studied. 
2.5.2 Tile use of CD2 or CD3 for T cell isolation following OKT3 activation 
As previous studies show that OKT3 binds to the CD3 receptor (Bonnefoy-Berard N and 
Revillard JP 1996; Broders N et al 1998; Brusa P et al 1998), it was important to determine 
whether CD2 might detect a significantly different number of T cells compared to CD3 
after OKT3 activation. 
For this optimisation study, 4 normal subjects were used. Under sterile class II conditions, 
OKT3 (Janssen-Cilag) was added to PBS at a final concentration of 1mg/ml. 5001J.I was 
plated into four wells of a 24 well, polystyrene plate (Nunclon, Fisher Scientific UK) for 
each normal subject analysed. In addition, another four wells containing 5001J.I ofPBS only 
were set up as controls on the same plate for each individual analysed. Each time a subject 
or subjects were studied, a single plate was left for 2 hours in air at room temperature for 
the OKT3 to adhere to the wells. PBMCs were isolated from normals only as described 
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previously in 2.4.2, re-suspended in RPMI (Gibco) plus 10% AB serum (NBTS) and plated 
into both the OKT3 and the control wells at a final concentration of 106 cells in Iml. The 
plate was then cultured in the incubator for 4 hours at 37°C in 5% C02 in air. After culture, 
cells and medium were harvested and transferred to clean 5ml, polystyrene tubes (Falcon, 
Marathon Lab Supplies), centrifuged at 220g for 5 minutes and the supernatant removed. 
I ml wash buffer was added to each tube and cells were washed for 5 minutes at 220g. 
A direct comparison was made between the binding of CD2 and CD3 after culture with 
OKT3. I OJ.1l of appropriate monoclonal antibodies, consisting of negative controls 
(equivalent mouse isotypic antibodies), Leucogate (lymphocyte gating) and CD2 (T cell 
numbers) (as described in 2.2.2 and 2.4.1) were added to 106 cells in the first experiment. 
IOJ.1l of appropriate monoclonal antibodies, consisting of negative control, Leucogate and 
CD3, were added to I 06 cells in the second experiment. All cells were incubated for 15 
minutes in the dark at room temperature in air. Cells were then washed twice in I ml wash 
buffer at 220g for 5 minutes, resuspended in lml PBS and analysed using flow cytometry. 
Results for CD2 and CD3 only are shown in the results section (table 13). Other control 
data not shown in the results section are available outside the thesis. 
A comparison could be made between monoclonal antibody binding of CD2 to the CD2 
receptor and monoclonal antibody binding of CD3 to the CD3 receptor after 4h incubation 
with OKT3 (anti-CD3), as described in more detail in section 3.2. 
2. 5.3 Time course for expression of CD 154 
These experiments were performed to confirm previous findings (Foy TM et al 1994; Clark 
LB et al1996; Cantwell M et al 1997) for expression ofCDI54 under these experimental 
conditions. 
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Two normal controls were analysed for this optimisation study. Under sterile class IT 
conditions, OKT3 (Janssen-Cilag) was added to PBS at a final concentration of 1mg/ml. 
For each normal control studied, 500j.ll of OKT3 was plated into six wells of a 24 well, 
polystyrene plate (Nunc Ion, Fisher Scientific UK). Six wells containing 500j.ll of PBS only 
were set up as controls on the same plate. The plate was left for 2 hours for the OKT3 to 
adhere to the wells. From each normal, PBMCs were isolated as described previously in 
2.4.2, re-suspended in RPMI (Gibco) plus 10% AB serum {NBTS) and then plated into six 
of both the OKT3 and the control wells at a final concentration of 106 cells in 1ml. The 
plate was cultured in the incubator for 2, 4 and 6 hours at 37°C in 5% C02 in air. Two 
wells of OKT3 (activated) and 2 wells of control (PBS) cells were harvested at each time 
point, transferred to clean 5ml, polystyrene tubes (Falcon) and washed twice in 1ml wash 
buffer for 5 minutes at 220g. Cells from both OKT3 and control tubes were then divided 
into four tubes and monoclonal antibodies to stain for negative controls (equivalent mouse 
isotypic antibodies), Leucogate (lymphocyte gating), CD2 (T cell confirmation) and 
CD2/CD154 (test) (as described in 2.2.2 and 2.4.1) were added at 10jll per 106 cells and 
incubated for 15 minutes in the dark at room temperature in air. PBMCs were then washed 
twice in wash buffer for 5 minutes at 220g, resuspended in 1 m! PBS and analysed using 
flow cytometry. Only the CD2/CD154 data are shown in the results (table 14). Control data 
not shown in the results section are available outside the thesis. 
The optimum time point for expression of CD 154 was determined, as described in section 
3.3. 
2.5.4 Time course for expressi01r ofCD25, CD28 a11d CD152 
These experiments were performed to confirm previous findings (Waldmann TA 1986; 
Waldmann TA 1991; Lindsten T et al 1993; Walunas TL et a1 1994; Krummel MF and 
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Allison P 1995; Alegre ML et al 1996) for expression ofCD25, CD28 and CD154 under 
these experimental conditions. 
Two normal controls were analysed. Under sterile class IT conditions, OKT3 (Janssen-
Cilag) was added to PBS at a final concentration of lmg/ml. 500J.1l was plated into 6 wells 
of 3 separate 24 well, polystyrene plates (Nunclon, Fisher Scientific UK). 6 wells 
containing 500J.1l of PBS only were set up as controls on each of the three 24 well plates. 
All 3 plates were left for 2 hours at room temperature in air for the OKT3 to adhere to the 
wells. PBMCs were isolated as described previously in 2.4.2, re-suspended in RPMI 
(Gibco) plus 10% AB serum (NBTS) and plated into both the OKT3 plates and the control 
plates at a final concentration of I 06 cells in I ml in each well. One 24 well plate was 
cultured in the incubator for each of the time intervals, 24, 48 and 72 hours, at 37°C in 5% 
C02 in air. Cells were harvested from the 24 well plates at each time point, transferred to 
clean 5ml, polystyrene tubes (Falcon, Marathon Lab Supplies) and washed twice in lml 
wash buffer for 5 minutes at 220g. Monoclonal antibodies for negative controls (equivalent 
mouse isotypic controls), Leucogate (lymphocyte gating) CD2 (T cell confirmation), 
CD2/CD25 (test), CD2/CD28 (test) and CD2/CD152 (test) (as described in 2.2.2 and 2.4.1) 
were added at 1 OJ.ll per 106 cells and incubated for 15 minutes in the dark at room 
temperature in air. PBMCs were then washed twice in wash buffer for 5 minutes at 220g, 
resuspended in 1ml PBS and analysed using flow cytometry. Results for CD2/CD25, 
CD2/CD28 and CD2/CDI52 only are shown in the results section (table 15). Other control 
data not shown in the results section are available outside the thesis. 
The time points for optimum expression of surface CD25, CD28 and CD152 were 
determined, as described in section 3.4. 
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2.5.5 Time course for expression of HLA-DR 
These experiments were performed to confirm expression of HLA-DR under these 
experimental conditions. 
One normal control was analysed. Under sterile class II conditions, OKT3 (Janssen-Cilag) 
was added to PBS at a final concentration of lmg/ml. 500~-Ll was plated on 6 wells of a 24 
well, polystyrene plate (Nunclon, Fisher Scientific UK). Six wells containing 5001!1 of PBS 
only were set up as controls. The plate was left for 2 hours for the OKT3 to adhere to the 
wells. PBMCs were isolated as described previously in 2.4.2, re-suspended in RPMI 
(Gibco) plus I 0% AB serum (NBTS) and plated into both the OKT3 and the control wells 
at a final concentration of 106 cells in lml. The plate was cultured in the incubator at 37°C 
in 5% C02 in air. Under sterile conditions, cells from two wells of the OKT3 and control 
samples were harvested from the 24 well plate at each time point (24, 48 and 72 hours) 
transferred to clean 5ml, polystyrene tubes (Falcon, Marathon Lab Supplies) and washed 
twice in lml wash buffer for 5 minutes at 220g. Monoclonal antibodies for negative 
controls (equivalent mouse isotypic controls), Leucogate (lymphocyte gating), CD3 (T cell 
confirmation) and CD3/HLA-DR (test) (as described in 2.2.2 and 2.4.1) were added at 10111 
per 106 cells and incubated for 15 minutes in the dark at room temperature in air. PBMCs 
were then washed twice in wash buffer for 5 minutes at 220g, resuspended in I ml PBS and 
analysed using flow cytometry. Results for CD2/HLA-DR only are shown in the results 
section (table 16). Other control data not shown in the results section are available outside 
the thesis. 
The time point for optimum expression of HLA-DR was determined, as described in 
section 3.5. 
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2.5.6 Comparison of B-ce/1 depletion methods 
Two different methods ofB and T cell separation were evaluated. A comparison was made 
between these two different methods of T cell purification for the most effective way of 
removing the large numbers of B cells from CLL patients' blood samples and obtaining a 
pure T cell population. 
In addition to the MACs method ofT cell purification, described in 2.4.5, Dynabeads were 
also evaluated, as described below: 
Dynabeads 
The required amount of Dynabeads (Dynal Biotech Ltd, Bromborough, Wirral, UK.) for 
isolating I 06 cells was 
320jll I 4mls whole washed blood for CD4 cells and 
200111 I 4mls whole washed blood for CD8 cells 
Dynabead protocol 
Under sterile class 11 conditions, the required amounts of CD4 and CD8 beads were placed 
in l2ml tubes (Greiner Bio-One) and put into the magnetic particle concentrator (MPC) for 
60 seconds. The fluid was pi petted off and discarded. The 12ml tube was removed from the 
MPC and washed in excess PBS + 0.3% BSA (Lome Laboratories, Reading, UK.). 
The washing procedure was then repeated. The washed Dynabeads were resuspended in a 
volume ofPBS/BSA equal to that which was originally pipetted from the 12ml tube. Blood 
was drawn into sodium heparin tubes, transferred to 20ml sterile tubes (Greiner Bio-One) 
and washed in an equal volume ofPBS. The washed Dynabeads were added to 4 mls of the 
sodium-heparin anticoagulated blood pre-washed in PBS, ensuring that the ratio of beads 
to target cells was now at 10:1. All samples and buffers were kept cold during the entire 
procedure by keeping on ice. Blood was incubated for 60 minutes at 4°C, tilting and 
135 
rotating continuously. The tube containing the blood and Dynabeads together was placed in 
the MPC for 3 minutes, drawing the rosetted cells to the side of the tube. While the tube 
remained on the MPC, the supematant was pipetted off and discarded. The tube was 
removed from the MPC. The CD4 and CD8 cells rosetted around the Dynabeads were then 
resuspended in PBSIBSA. 
Detach ahead protocol 
20J.1l of Detachabeads (Dynal Biotech Ltd) were added to the rosetted cells/Dynabeads in 
the same l2ml tube (Greiner-Bio-One) and incubated for 45 minutes at room temperature 
in air, keeping the sample tilting and rotating. The 12ml tube was then placed in the MPC 
for 3 minutes, drawing the Dynabeads and Detachabeads only to the side of the 12ml tube 
and leaving the CD4 and CD8 cells in the suspension. The supematant containing these 
CD4 and CD8 cells was then pipetted out of the tube and placed in a fresh sterile 12ml 
container (Greiner Bio-One). The tube containing the Detachabeads and Dynabeads was 
then removed from the MPC and washed 2-3 times in PBS + 0.3% BSA (Lome 
Laboratories). This released any remaining CD4 and CD8 cells from the Dynabeads. The 
tube was placed back on the MPC and again, the suspension containing the CD4 and CD8 
cells was pipetted off and retained. The cell suspensions containing the CD4 and CD8 T 
cells were combined and washed 2-3 times to remove any remaining Detachabeads. The 
cells were resuspended in a volume ofRPMI (Gibco) plus 10% AB serum (NBTS) to equal 
I 06 cells/m!. 
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2. 5. 7 Comparison of cell permeabilisation metllods - paraformaldellyde and saponin vs 
DAKO intrastain kit 
In addition to the DAKO intrastain method of cell permeabilisation (as described in 2.4.6), 
a second method was also evaluated as described below. 
Paraformaldellyde and Saponin 
After culture as described in 2.4.3 for 48 hrs, cells were harvested from the 24 well, 
polystyrene plates (Nunclon, Fisher Scientific UK), transferred to clean 5ml, polystyrene 
tubes (Falcon, Marathon Lab Supplies) and resuspended in 1 00j.1l of 4% fixation buffer 
(PBS + 4% paraformaldehyde, (Sigma)) for 15 minutes at room temperature in air. Cells 
were stained with monoclonal antibodies for negative controls (equivalent mouse isotypic 
controls), Leucogate (lymphocyte gating) and CD2 (test) (as described in 2.2.2 and 2.4.1) 
and incubated for 15 minutes in the dark at room temperature. 
Cells were then washed twice in 1ml permeabilisation buffer (PBS + 10% AB serum + 
0.1% saponin (Sigma)) for 5 minutes at 320g. PBMCs were resuspended in 1 OOjll of 
permeabilisation buffer and incubated for 1 hour in the dark at room temperature in air. 
Appropriate antibodies for intracellular analysis (CD25) were added at l Ojll per 106 total 
cells and incubated for 15 minutes in the dark at room temperature in air. Cells were 
washed twice in l ml staining buffer for 5 minutes at l60g, resuspended in 1 ml PBS and 
analysed using flow cytometry. 
A comparison was made between the two methods of permeabilisation based upon cell 
structure, intact cell membranes and expression of intracellular and surface antigens using 
the flow cytometer, as described in section 3.7. 
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2.5.8 Time co11rse for expressio11 of CD25, CD28 a11d CD152 after B-ce/1 depletio11 a11d 
permeabilisation 
As no data were found in the literature on the time course of expression of these markers 
intracellularly, the following optimisation experiments were conducted. 
Under sterile class IT conditions, OKT3 (Janssen-Cilag) was added to PBS at a final 
concentration of I mg/ml. 500J1l was plated on 6 wells on three 24 well, polystyrene plates 
(Nunclon, Fisher Scientific UK). 6 wells containing 500J1l of PBS only were set up as 
controls on each of the 24 well plates. Each plate was left for 2 hours for the OKT3 to 
adhere to the wells. PBMCs were isolated as described previously in 2.4.2, re-suspended in 
RPMI (Gibco) plus 10% AB serum (NBTS) and plated on both the OKT3 plates and the 
control plates at a final concentration of 106 cells in 1 m!. 24 well plates were cultured in the 
incubator for 24, 48 and 72 hours at 37°C in 5% C02• Cells were harvested from the 24 
well plate at each time point, transferred to clean 5ml, polystyrene tubes (Falcon, Marathon 
Lab Supplies) and washed twice in lml wash buffer for 5 minutes at 220g. At each time 
point, cells were fixed, stained and permeabilised, resuspended in I ml PBS and analysed 
using flow cytometry as described in 2.4.1. Only results for CD2/CD25, CD2/CD28 and 
CD2/CD152 are shown in the results section (table 17). Other control data not shown in the 
results section are available outside the thesis. 
The optimum times for intracellular expression of CD25, CD28 and CD 152 were 
determined, as described in section 3.8. 
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CHAPTER THREE: RESULTS OPTIMISATION 
3.0 Results of optimisation studies 
3.1 Time co11rse for OKT3 adhere11ce to Clllt11re plates 
A time course study was carried out to establish the most effective time and temperature to 
achieve maximum adherence of OKT3 on 24 well culture plates, measured by expression 
ofCD154 on T cells after each time point. OKT3 was plated for 2 hours, 16 hours and 24 
hours, left at room temperature or at 4°C, washed and cells cultured for 4 hours for 
expression of CD154 as described in 2.5.1 (Table 12). As the time for OKT3 adherence 
increased from 2 hours through to 24 hours, total CD 154 expression decreased (2 hours = 
26.1 %, 16 hours = 20.3% and 24 hours = 15.9% ). Statistical analysis was not carried out on 
these figures as data were required from one individual experiment only to verify previous 
routine laboratory protocols. Plates left to adhere at 4 oc produced less CD 154 expression 
compared to plates left at room temperature. The optimum plating time for maximum 
OKT3 adherence was 2 hours at room temperature, as this produced the highest proportion 
ofCD154 expressing cells. This suggests that ifOKT3 is left on the plates for longer than 2 
hours, the antibody will start to disassociate from the plate and will therefore be unable to 
stimulate as many T cells. 
Table 12: Optimal coating conditions forT cell stimulation as determined by 
expression of CD154 over a time period and at different temperatures 
Time point for OKT3 room OKT34°C Control room Controi4°C 
platin2 OKT3 temperature temperature 
2 hours 26.1% 17.8% 0.9% 1.2% 
16 hours 20.3% 17.5% 2.6% 3.6% 
24 hours 15.9% 12.6% 0.8% 1.0% 
Table showing expression of CD 154 after adherence of OKT3 to 24-well plates over a 2 to 16 hour time 
period and at room temperature or 4°C. Corresponding controls of PBS only were set up on the same plates to 
ensure CD 154 expression was a result of OKT3 stimulation. 
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3.2 CD2/CD3 for ide11tijicatio~r ofT cell populatio11s after OKT3 stimulatio11 
The monoclonal antibodies directed against the T cell markers CD2 and CD3 were studied 
on the flow cytometer of PBMCs from 4 normal subjects to determine whether they 
detected similar numbers of T cells following activation with the anti-C03 monoclonal 
OKT3 as described in 2.5.2. As previous studies show that OKT3 binds to the C03 
receptor (Bonnefoy-Berard Nand Revillard JP 1996; Broders Net a! 1998; Brusa Pet a! 
1998), it was important to determine whether C02 might detect a significantly different 
number of T cells compared to CD3 after OKT3 activation. The total number of cells 
studied was the same for CD2 and CD3. CD3 counts were always lower than CD2 counts 
in each normal subject (table 13) and variation about the mean was low. Following this 
finding, CD2 was used in all subsequent experiments as the pan T cell marker where OKT3 
was used as the mitogen. 
However, it should be noted that another reason why C02 numbers may be consistently 
higher than CD3 numbers is the presence of Natural Killer (NK) cells. NK cells also 
express C02 and small numbers of them may have been included within the C02 counts. 
Although C03 binding appears to be affected by pre-incubation with OKT3, T cell 
numbers may not be accurate following CD3 binding as the inclusion of NK cells within 
the CD2 population cannot be excluded. This could potentially have been ruled out using 
two different methods. A comparison could have been made between CD3+ve T cells in 
OKT3 stimulated and control populations vs CD2+ve/CD56-ve in OKT3 and control 
populations, to exclude the presence ofNK cells. Additionally, measuring relative intensity 
of CD3 vs CD2 expression pre and post OKT3 stimulation would allow occupation of C03 
sites by OKT3 to be identified. However, at the time of testing, measurement of relative 
intensity was not a routine procedure and was not carried out. 
Although the possibility of NK cell inclusion is possible, the majority of key markers 
studied in this thesis are not known to be expressed on the surface ofNK cells. 
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Table 13: Surface staining of CD2 and CD3 after 4 hours activation with OKT3 
4hrs incubation 4hrs incubation 
T cell with OKT3 CV with PBS control CV 
marker (mean) (mean) 
(n=4) (n=4) 
CD2 83.1% 6% 85.8% 10% 
CD3 71.3% 10% 77.5% 20% 
Table showing the difference in expression of the monoclonal antibodies CD2 and CD3 after 4 hours 
incubation with OKT3 or 4 hours incubation with PBS alone as control (described in 2.5.1 ). 
cv = coefficient of variation 
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3.3 Time course for optimal expressio11 of CD 154 
A time course was study was done to detennine the time of maximum expression of 
CD154 over a six hour period as described in 2.5.3. CD154 expression was detennined at 
shown intervals by flow cytometry of OKT3 stimulated PBMCs from two nonnal subjects. 
In both, maximum expression (mean= 19.3%) was obtained between 4 and 6 hours (table 
14). In unstimulated PBMCs, there was consistently very low CD154 expression at all 
times. Statistical analysis (cv) shows method perfonnance to be good for the stimulated T 
cell populations, as variation around the mean is low. Previous findings also showed 
maximum expression of CDI54 after 4-6 hours of activation (Foy TM et al 1994; Clark LB 
et al 1996; Cantwell M et al 1997). 
Table 14: Time course for optimal expression ofCD154 
OKT3 activation Control 
Time point (mean) CV (mean) CV 
(n=2) (n=2) 
2hrs 9.4% 10% 0.25% 20% 
4hrs 19.3% 10% 0.25% 20% 
6hrs 18.5% 10% 0.1% 100% 
Table showing expression of CD 154 over a 6 hour time period with OKT3 activation. Corresponding controls 
of PBS only were set up on the same plates to ensure CD 154 expression was a result of OKT3 stimulation. 
cv = coefficient of variation 
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3.4 Time course for optimal expressio11 of surface CD25, CD28 a11d CD152 
A time course study was set up to determine the maximum expression of surface CD25, 
CD28 and CD152 over a 72 hour period at intervals of24 hours as described in 2.5.4 (table 
15). In 2 normal controls, maximum expression of CD25 occurred at 48 hours, CD28 was 
equally highly expressed at each time point and CD152 was expressed maximally at 48 
hours, but CD152 expression was consistently much lower then either CD25 or CD28. 
Statistical analysis (mean + cv) shows a variable cv, suggesting a variation of expression 
within normal controls, although number of controls used is low. Previous findings have 
shown surface expression ofCD25, CD28 and CD152 at the same time points (Waldmann 
TA 1986; Waldmann TA 1991; Lindsten T et al 1993; Walunas TL et al 1994; Krummel 
MF and Allison P 1995; Alegre ML et al 1996). 
Table IS: Time course for optimal expression of surface CD2S, CD28 and CD1S2 
Time CD2S CD28 CD152 
point (mean) CV (mean_ CV (mean) CV 
(n=2) (n=2) (n=2) 
24hrs 48.9% 40% 88.8% 8% 7.3% 30% 
48hrs 80.5% 10% 90.2% 30% 16.7% 10% 
72hrs 61.6% 30% 93.5% 6% 6.5% 30% 
Table showing surface eKpression ofCD25, CD28 and CD I 52 after OKT3 activation for 24,48 and 72 hours 
in two nonnal controls. 
cv = coefficient of variation 
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3.5 Time course for optimal expression of HLA-DR 
A time course study was carried out to identify the time point for optimal expression of 
HLA-DR as described in 2.5.5. Results showed that over a 72 hour period of activation 
with OKT3, maximum HLA-DR expression occurred at 48 hours, but did not exceed 20% 
(table 16). Statistical analysis was not carried out, as this data was verification of previous 
findings that have shown surface expression ofHLA-DR at the same time point (Griffin JD 
et all985; Griffiths CE et all989; Fratazzi C and Carini C 1997). 
Table 16:Time course for optimal expression of HLA-DR 
Time point HLA-DR expression 
24 hrs 10.0% 
48 hrs 18.9% 
72 hrs 4.5% 
Table showing surface expression of HLA-DR after OKT3 activation for 24, 48 and 72 hours in one nonnal 
control. 
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3.6 Compariso11 of B-cell depletio11 metllods 
A study was carried out to detennine the most efficient method of depleting the large 
number of B cells from CLL patients as described in 2.5.6. Dynabeads and MACS beads 
were both initially evaluated for T cell enrichment using flow cytometry to analyse the cell 
population remaining after B cell depletion. Studies with Dynabeads gave an unsatisfactory 
result, with the presence of a large number of debris cells. Results with MACS beads gave 
a cleaner population of cells in the flow cytometer (Figure 12) compared to Dynabeads 
(Figure 13). Mean CD20 count after B cell depletion with MACS was 3.2% for CLL 
patients (n=4) and 2.4% for nonnal controls (n=4) after titration experiments for the 
optimum amount of beads required to deplete the B cells. CD20 was used to evaluate 
remaining B cells as CD 19 always gave a negative result. This was due to the CD 19 beads 
used for depletion occupying the CD 19 receptor site on the B cell surface preventing CD 19 
monoclonal antibody binding. The MACS method was used for all subsequent T cell 
enrichment experiments. 
However, it must be pointed out that the two methods of cell separation, whilst both 
removing B cells and leaving an untouched T cell population, have important differences in 
their methods that may explain why the flow cytometry results are different. Dynabead cell 
separation starts with whole blood, whilst MACs cell separation begins with a sample that 
has already had red blood cells and other possible contaminating cells removed during the 
lymphoprepping procedure. As a result of this difference, there will be a proportionately 
greater number of contaminating cells and debris (ie red blood cells and neutrophils) within 
the Dynabead separated cell populations compared to the MACs separated cell populations 
and this fact must not be ignored when selecting a suitable method for B cell removal and 
T cell enrichment. 
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Figure 11: Flow cytometrv dot plot showing cell population after B cell depletion 
using CD19 MACS beads 
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Figure ~hawing a forward scatter/side scatter dot plot of PBMCs after depletion of CD19+ve cells with 
MACS beads. Note the clean and evenly distributed cell populations wi th very little debris. 
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Figure 12: Flow cytometry dot plot showing cell population after B cell depletion 
using CD19 Dynabeads 
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Figure showing a forward scatter/side scatter dot plot of PBMCs after depletion of CD 19+ve cells with 
Dynabeads. Note the large amount of cell debris in the bottom left hand corner 
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3. 7iComparison: of cetlpermeabilisation •met/rods 
A study .was carried out to det~I)riindhe most ,effective way.of;fixirrg,cell surface· markers 
. . 
and .penneabilising ,the, cell 1to' analyse intracellulariCD25; .€D28 :and €D152 expression as 
·described in 2~5:7, . .The first method using 
1
parafonnaldehyde andi saponin' as described :in 
3;() did not gtve:a satisfactory result wltentanalysed .onrthe tflow cytometer,.for ceil structure 
and the :expression ,ofboth :ilittacellidat ,arid' •stirface -antigens: In comparison; 1the ~nAK0 
intraStliin:iriethodidest:ribedi in 2A,6 :gaV.e;lr good ;tesult,ori the ,flow cytometetWith1 an·. intact 
t:«<ll ~~truC.tllr!! and •expression of both •intracellular andl surface antigens'[ 'fhe. 'DAK0 
[infrast!!in method W!IS ,usedi for !ill Sli!Jseg_llen! ctilllpenneal:>ilisati()h ,experlments: 
3.8 Time course for optimal expression ofCD25, CD28 and CD152 on stimulated Tcells 
after B cell depleti011 and permeabilisation 
A time course study was carried out on one normal control to identifY the time point for 
maximum expression ofCD25, CD28 and CDI52 after B cell depletion, OKT3 stimulation 
and permeabilisation over a 48 hour time period at 24 hour intervals as described in 2.5.8 
(table 17). Expression of intracellular CD25 and CD! 52 was highest at 48 hours (CD25 = 
64.2%, CD152 = 71.3%). Levels of intracellular CD! 52 were much higher than expression 
on the cell surface at 48 hours and rose steadily over the time course (CD152 surface 
expression= 8.6%, CD I 52 intracellular expression= 71.3%). Levels of intracellular CD28 
did not change significantly over the 48 hour time period (Ohrs = 41.3%, 24hrs = 31.9%, 
48hrs = 54.1 %). All subsequent cell permeabilisation experiments for analysis of CD25, 
CD28 and for CD I 52 were cultured for 48 hours in OKT3 before permeabilisation. 
Table 17: Time course for expression of CD25, CD28 and CD152 on stimulated T 
cells permeabilised and non-permeabilised. 
Time point CD25 CD28 CD152 
0 hrs 4.9% 41.3% 7.0% 
_Qermeabilised 
Ohrs 4.5% 52.9% 0.9% 
non-permeabilised 
24 hrs 25.4% 31.9% 27.9% 
permeabilised 
24 hrs 47.8% 62.1% 3.3% 
non-permeabilised 
48 hrs 64.2% 54.1% 71.3% 
permeabilised 
48 hrs 73.5% 58.5% 8.6% 
non-permeabilised 
Table showing surface and intracellular expression of CD25, CD28 and CD 152 after OKT3 activation for 0, 
24 and 48 hours in one nonnal control. A comparison is made at each time point between the permeabilised 
(intracellular) and non-permeabilised (surface) expression of each antigen. 
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Optimisation - summary of results 
The results from these experiments enabled parameters to be set for the culture and 
activation ofT cells and the subsequent B cell depletion and T cell permeabilisation for 
intracellular studies. The results showed that the optimum time point for plating OKT3 
prior to PBMC or T cell culture was two hours and that after OKT3 culture, CD2 was the 
most efficient monoclonal for correctly identifying total T cell numbers. Time course 
studies showed that CD154 was optimally expressed at 4 hours, whilst CD25, CD152 and 
HLA-DR had optimum expression at 48 hours. CD28 was generally expressed at similar 
levels at all time points and could therefore be investigated at any time point. 
B cell depletion experiments showed that for this study involving the depletion of large 
numbers of B cells, leaving the T cells untouched, the MACS system was most effective 
compared to Dynabeads. This does not imply that the Dynabead system is ineffective, 
simply that for the purpose of this research, MACS was more appropriate and gave a 
cleaner and better defined untouched T cell population. In comparison, the DAKO system 
for cellular permeabilisation also gave a better result when compared to using saponin and 
paraformaldehyde. Cell integrity was retained with the DAKO method, as shown by direct 
comparisons between permeabilised and non-permeabilised cells during forward scatter 
and side scatter analysis on the flow cytometer. 
Time course experiments for intracellular expression of CD25, CD28 and CD 152 showed 
that, in keeping with earlier experiments, CD25 and CD152 were optimally expressed at 48 
hours and CD28 was continually expressed at all time points. 
From the results obtained in these studies, it was then possible to begin experiments 
studying expression of cell surface and intracellular markers in CLL and normal T cells. 
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CHAPTER FOUR: RESULTS- SURFACE MARKERS 
All statistical analysis was carried out using the Mann-Whitney (Wilcoxon) comparison of 
medians. The number of patients used in each group was too small to assess normality and 
as a result, the non-parametric Mann-Whitney test has been used throughout. 
4.0 Expression of activation and interaction markers in CLL patients and norma Is 
4.1 Expression of CD25, CD28, CD152, TCRaP, CD4, CD5, CDB and HLA-DR 011 T 
cells from B-CLL patients and normals 
Significantly fewer T cells from B-CLL patients (n=10) compared to normals (n=7) 
expressed the markers CD25 (IT...-2R) (23.1% v 80.8%: p= 0.007), CD28 (52.8% v 84.5%: 
p= 0.01) and CD152 (CTLA-4) (0.0% v 16.5%: p=O.OOI) after stimulation described in 
2.4.3. Fifty percent of B-CLL patients failed to express any surface CD152 following 
OKT3 activation (range 0%- 7.5%), whilst the percentages of CD2+ve T-cells expressing 
CD25 after activation varied greatly between patients (range 1.8% - 91.2%) (Table 18) 
(Figure 13). 
In unstimulated T cells from patients with B-CLL (n=7) compared to normals (n=5) 
described in 2.4.4, there was a significant reduction of the percentages expressing the cell 
surface markers CD4 (54.8% v 70.2%: p=0.03) and CD5 (83.3% v 98.5%: p=0.05), with a 
wide range of expression between patients (Table 18). 
Percentages of unstimulated CD2+ve cells expressing CD8 and TCRap, as described in 
2.4.4, were reduced, but not significantly (Table 19). 
Greater numbers of stimulated CD2+ve cells from CLL patients (n=4), as described in 
2.4.3, expressed HLA-DR compared to normals. Although this was not significant, the 
range of expression between patients and normals was striking (n=4) (100% v 63.9%: 
p=0.05) (Table 19). 
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Table 18: Expression of cell surface markers that were significantly different between 
CLL patients and normal controls 
Cell type Cell marker B-CLL Normal p-value 
(median) (median) 
CD3 CD4 54.8% 70.2% 0.03 
(16.6- lOO%)' (58.7- 71.3%)* 
(n=7) (n=5) 
CD3 CD5 83.3% 98.5% 0.05 
(74.5- lOO%)" (99.6- lOO%)" 
(n=5) (n=4) 
CD3 CD25 23.1% 80.8% 0.007 
(1.8- 91.2%). (43.0- 95.1%>* 
(n=lO) (n=7) 
CD2 CD28 52.8% 84.5% 0.01 
(19.5 -lOO%)' (56.4- 92.4%)* 
(n=lO) (n=7) 
CD2 CD152 0.0% 16.5% 0.001 
(0.0- 7.5%). (6.4- 24.4%). 
(n=lO) (n=7) 
CD2 CDlla 89.4% lOO% 0.01 
(43.6- 100%). (99.8 -lOO%)' 
(n=6) (n=6) 
• = range 
Table showing expression ofT cell surface markers on both CLL patients and nonnal controls. T cells were 
stimulated for expression ofC025, CD28 and COl 52. T cells were unstimulated for expression ofC04, COS 
and COlla. Expression of all surface antigens was significantly lower in CLL patients compared to norrnals 
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Table 19: Expression of cell surface markers that showed no significant difference 
between patients and normals 
Cell type Cell marker B-CLL Normal p-value 
(median) (median) 
CD3 TCRap 87.9% 95.2% ns 
(38.1- 100%)" (93.6- 98.6%)0 
(n=7) (n=5) 
CD3 CD8 37.3% 37.1% ns 
(20.3- 43.6%)0 (32.6 - 42.8%)" 
(n=5) (n=4) 
CD3 CD 54 40.4% 44.3% ns 
(23.4- 65.1%)0 (19.9- 54.6%)0 
(n=6) (n=6) 
CD2 CD154 10.5% 10.4% ns 
(3.6- 51.4%)" (5.5 - 18.5%)" 
(n=10) (n=7) 
CD3 HLA-DR 100% 63.9% ns 
(63.1- 100%)* (6.8- 89.2%)* 
(n=4) (n=4) 
• =range 
Table showing expression ofT cell surface markers on both CLL patients and normal controls. T cells were 
stimulated for expression ofCD154 and HLA-DR. T cells were not stimulated for expression ofCD8, CD54 
and TCR a~. Expression of CD 154 is higher in CLL patients but this difference is not significant. 
ns: not significant 
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4.2 Expression ofCD154 on Tcellsfrom B-CLL patie11ts a11d normals 
A greater number of CD2+ve T-cells from patients with B-CLL (n=10) expressed the 
CD40 ligand, CD154, described in 2.4.3, compared to normals (n=7) after stimulation 
(16.6% v 11.1%: p = 0.5) although this difference was not significant (Table 19). 
4.3 Expressio11 of tile adllesio11 molecules LFA-1 (CDlla) and /CAM-I (CD54) on tile T 
cells from B-CLL patients and normals 
Significantly fewer T cells of patients with B-CLL (n=6) expressed the adhesion molecule 
LFA-1 (CD11a) compared to normals (n=6), described in 2.4.4 (77.9% v 99.9%: p=0.01) 
(Table 18) (Figure 13) in unstimulated cells. Expression of ICAM-1 (CD54) was not 
significantly different between patients and normals (Table 19). 
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CeU surface markers - summary of results 
The results in this section show that significantly less T cells from CLL patients express the 
cell surface markers CD25, CD28 and CD152 when activated in a PBMC population. In an 
unactivated PBMC cell population significantly less T cells from CLL patients express the 
cell surface markers CD4, COS and COlla (LFA-1). HLA-DR was unchanged, although 
range of expression in norrnals was much larger compared to patients, and expression of 
CD 154, CD8 and CD 54 (I CAM-I) was unchanged between CLL and normal T cells. These 
results suggest a profound dysregulation in the up-regulation of key activation markers, in 
addition to a dysregulation in expression of markers normally present on resting T cells. 
Results obtained from this section were carried out by analysis ofT cells from a PBMC 
population with the malignant B cells present. In order to determine whether the B cells 
may be in some way responsible for this effect seen in the T cells, it was necessary to 
remove the B cells and repeat some ofthe above experiments on two key markers- CD I 52, 
expressed after activation with OKT3 and CD28, expressed continually. 
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4.4 Expression ofCD28 and CD152 on stimulated T cells after B cell depletion 
Fewer of the CLL patients' T cells (n=4) expressed the two surface antigens CD28 (49.9% 
v 92.2%: p = 0.01) and CD152 (4.9% v 17.3%: p = 0.05) compared to normals (n=3) after 
depletion of the malignant CD19+ve B cell population, as described in 2.4.5, and 
stimulation of the remaining cell population with OKT3 (Table 20). CD19 cells were 
depleted from PBMCs and any remaining B cells counted using CD20. Mean CD20 count 
after B cell depletion was 3.2% for CLL patients and 2.3% for normal controls. 
Table 20: Expression of CD28 and CD152 on stimulated T cells after B cell depletion 
CeDtype CeDmarker B-CLL(n=4) Nonnal (n=3) p value 
(median) (median) 
C02 CD28 49.'1'/o 92.2% 0.01 
(10.3 -61.5%)* (88.2- 96.3%)* 
C02 CD152 4.'1'/o 17.3% ns 
(3.1 - 14.3%)* (10.7- 26.3%)* 
• =range 
Table showing expression of CD28 and CD152 on the surface ofT cells from CLL patients and normal 
controls after magnetic cell depletion of the CD19+ve B cells and stimulation with OKT3. 
ns: not significant 
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B cell depletion -summary of results 
Using magnetic CDI9 B cell depletion methods, B cells were removed from both normal 
and CLL PBMC populations, with maximum B cells remaining after depletion no greater 
than 3.2% for CLL patients and 2.4% for normal controls as measured using CD20. After 
removal of the B cells, T cells were cultured for 48 hours to allow for any immediate effect 
the B cells may have had on T cell status. Despite this, significantly less T cells from CLL 
patients expressed the cell surface markers CD28 and COl 52 after culture with OKT3. 
As removal of the B cells could not be seen to have a noticeable effect on cell surface up-
regulation, expression of the two same antigens CD28 and CDI52 and also CD25, were 
investigated intracellularly to look for any possible dysfunction in production of these 
markers and their expression on the cell surface. 
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4.5 Expressio11 ofintracellular CD25, CD28 and CDJ52 011 stimulated a11d unstimulated 
T cells after B cell depletio11 
After penneabilisation of stimulated CD2+ve cells, as described in 2.4.6, intracellular 
CD28 was expressed in significantly fewer cells in B-CLL patients (n=7) compared to 
nonnals (n=7) (44.2% v 67.5%: p = 0.02) (Table 21) (figure 14). CD25 and CD152 
positivity were unchanged between patients and nonnals. In contrast, significantly more 
unstimulated CD2+ve cells from CLL patients expressed intracellular CD25 (5.8% v 2.5%: 
p = 0.01) and intracellular CD152 (8.7% v 4.5%: p = 0.03) compared to nonnals (table 22) 
(figure 15). Intracellular CD28 positivity was unchanged in CLL patients and nonnals. 
When levels of intracellular CD25, CD28 and CD152 were compared in activated and 
unactivated cells in normal and patients, there was a significant difference seen in 
expression of CD25 and CD 152 after activation. In contrast, levels of CD28 were not 
significantly different in either patients or controls after activation. 
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Table 21: Expression of intracellular CD25, CD28 and CDI52 on stimulated T cells 
following B cell depletion and permeabilisation 
Cell type Cell marker B-CLL (n=7) Normal (n=7) p value 
(median) . (median) 
CD2 CD25 44.2% 52.7% ns 
(32.1- 61.2%)* (28. 7- 86.5%)* 
CD2 CD28 44.2% 67.5% 0.02 
(21.5 -70%)* (54.1-74.7%)* 
CD2 CDI52 53.9% 69.4% 0.07 
(39.9- 80.3%)* (57.4- 75.3%)* 
*=range 
Table showing expression of intracellular CD25, CD28 and CD 152 in CLL and normal control T cells after 
magnetic depletion of CD 19+ve B cells and stimulation with OKT3 for 48 hours. There was a significantly 
lower expression of intracellular CD28 in CLL patients T cells compared to normals. There was no 
significant difference in expression ofCD25 or CD I 52. 
ns: not significant 
Table 22: Expression of intracellular CD25, CD28 and CD152 on unstimulated T cells 
following B cell depletion and permeabilisation 
Cell type Cell marker B-CLL (n=7) Normal (n=7) p value 
(median) (median) 
CD2 CD25 5.8% 2.5% 0.01 
(3.7- 11.8%)* (1.8- 8.0%)* 
CD2 CD28 40.9% 55.6% ns 
(18.1-64.0%)* (24.9- 80.9%)* 
CD2 CD152 8.7% 4.5% 0.03 
(2.7- 13.2%)* (2.5 - I 0.0%)* 
• =range 
Table showing expression of intracellular CD25, CD28 and CD I 52 in CLL and normal control T cells after 
magnetic depletion of CD 19+ve B cells. The T cells were not activated and were cultured for 48 hours with 
no mitogen. There was a significantly higher expression of intracellular CD25 and CD 152 in CLL patients T 
cells compared to normals. There was no significant difference in expression of CD28. 
ns: not significant 
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Permeabilisation - summary of results 
B cell depleted PBMCs were cultured for 48 hours using OKT3. A control population of 
unstimulated T cells was also studied. CLL T cells cultured with OKT3 and permeabilised 
expressed significantly less CD28 compared to normal T cells. There was no difference in 
intracellular expression of CD25 and CD 152 in activated CLL and normal T cells. 
However, in the resting (control) T cell populations, CLL T cells expressed significantly 
less intracellular CD25 and CD152 compared to normal T cells, whilst CD28 levels were 
unchanged between the two. 
Under normal conditions, CD28 is expressed continually on the T cell surface during T cell 
activation, whilst CD25 and CD 152 are up-regulated approximately 48 hours post 
activation. The fact that less CLL T cells express intracellular CD28 and less surface CD28 
after activation suggests a profound dysregulation in the ability of T cell to both up-
regulate and express this key second marker. CD28 interacts with CD80 and CD86 on B 
cells (and other APC) (Holdorf AD et al 2000) during activation to provide the critical 
second signal required for complete T cell activation. Without this second signal, the T cell 
would be unable to activate efficiently and would not up-regulate key markers such as 
CD25 (Jenkins MK et al1991; Powell ID et al1998; Boulougouris Get al1999; Boonen 
GJJC et al 1999; Holdorf AD et al 2000). IL-2 production would be compromised and 
some evidence suggests that anergy may result (Lenschow DJ et al 1996; Chambers CA 
and Allison P 1999; Boulongouris G et al 1999). The fact that CD28 levels are normal in 
resting CLL T cells implies there may be a problem with T cell activation and its response 
to the activation signals. 
In comparison, intracellular CD25 and CD 152 were unchanged between CLL and normal T 
cells after activation, but significantly less CLL T cells expressed intracellular CD25 and 
CD152 in resting (control) populations. The finding that levels of intracellular CD25 and 
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CD152 were unchanged between normal and CLL T cells after activation, whilst surface 
expresion was down-regulated, suggested that there may be a soluble factor produced by 
the CLL B cells that persists even after B cell removal and that may have an effect on T 
cell activation and up-regulation of these key markers. In order to study this further, 
normal and CLL T cells were both cultured in the presence of CLL AB serum, to determine 
if this would effect T cell surface marker expression. A patient who was AB Rh (D) + 
gave blood samples into plain sterile tubes, which were left to stand at room temperature 
for a minimum of 2 hrs. Once the contents had clotted, the sample was centrifuged and the 
serum removed under sterile conditions, heat inactivated for 30 minutes at 57°C and frozen 
for future use. The samples were analysed for total protein, immunoglobulins and lipids to 
ensure that there were no obvious factors that may cause T cell activation. Normal and 
CLL T cells were cultured with this serum. 
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4.6 Expression of CD25, CD28 and CD152 011 11ormal and CLL T cells after B cell 
depletion and OKT3 stimulatio11 in 50% CLL AB serum and 50% normal AB serum. 
When normal T cells are cultured in RPMI containing 50% CLL AB serum, as described in 
2.4.7, the proportion of cells expressing CD25 and CDI52 significantly increased (n=6) 
when compared to culture in 50% normal human AB serum (n=6) (CD25 73.5% v 19.8%: 
p = 0.002) (CDI52 13.6% v 4.6%: p = 0.01) (Table 23) (figure 16). Significantly more 
CLL T cells, when cultured in 50% CLL AB serum (n=4), expressed CD25 compared to 
culture in normal AB serum (n=4) (57.6% v 16.6%: p = 0.04) (Table 24) (fig 17). Levels of 
T cells expressing CD28 were unchanged in CLL AB when compared to normal AB serum 
in both CLL and normal controls. The proportion of CLL T cells expressing CD 152 was 
unchanged after culture in CLL AB serum (table 24) (figure 17). In one patient who failed 
to express any surface CD 152 after culture in normal AB serum, 1.2% ofT cells expressed 
CD 152 after culture in CLL AB serum (table 24). 
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Table 23: Expression of surface CD25, CD28 and CD152 on normal T cells after B 
cell depletion and OKT3 stimulation in 50% CLL AB serum and 50% normal AB 
serum 
Cell type Cell marker CLLAB Normal AB p value 
serum serum 
(median) (median) 
CD2 CD25 73.5% 19.8% 0.002 
(65.8 - 78.4%)" (12.1-43.8%)0 
CD2 CD28 87.0% 88.9% ns 
(66.0- 91.9%)" (70.0- 95.4%)" 
CD2 CDI52 13.6% 4.6% 0.01 
(7.1 - 32.5%)" (1.6- 10.7%)" 
• =range 
Table showing expression of surface CD25, CD28 and CD 152 in normal T cells (n=6) after magnetic 
depletion of CD19+ve B cells and stimulation with OKT3 for 48 hours in either 50% CLL or normal AB 
serum. There was a significantly higher expression of CD25 and CD152 on the T cells activated in the 
presence of CLL AB compared to activation in normal AB serum. No significant difference was observed in 
expression ofCD28. 
ns: not significant 
Table 24: Expression of CD25, CD28 and CDl52 on CLL T cells after B cell depletion 
and OKT3 stimulation in 50% CLL AB serum and 50% normal AB serum 
Cell type Cell marker CLLAB Normal AB p value 
serum serum 
(median) (median) 
CD2 CD25 58.5% 14.0% 0.04 
(40.5- 81.0%)0 (9.0- 22.2%)" 
CD2 CD28 58.9% 66.7% ns 
(56.5- 63.3%)0 (65.4- 68.8%)" 
CD2 CDI52 4.5% 1.2% ns 
(1.2- 7.5%)" (0.0 - 2.4%)" 
*-range 
Table showing expression of surface CD25, CD28 and CD 152 in CLL T cells (n=5) after magnetic depletion 
ofCD19+ve 8 cells and stimulation with OKT3 for 48 hours in either 50% CLL or normal AB serum. There 
was a significantly higher expression of CD25 on the T cells activated in the presence of CLL AB serum 
compared to activation in normal AB serum. No significant difference was observed in expression of CD28 
or CD152. 
ns: not significant 
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CLL AB serum results - summary 
When normal, B cell depleted PBMCs are cultured in OKT3 supplemented with 50% CLL 
AB serum, significantly more T cells express surface CD25 and CD152 when compared to 
culture in normal AB serum. In addition, when CLL B cell depleted PBMCs are cultured in 
OKT3 with 50% CLL AB serum, the number ofT cells expressing CD25 is significantly 
increased, compared to culture in normal AB serum. This suggests that there may be either 
a soluble factor present in the CLL AB serum that increases activation, or an absence of an 
inhibitory factor that prevents it. The total amount of both CLL AB serum and normal AB 
serum used was 50%. In previous experiments, only 10% normal AB serum was used. 
Increasing to 50% AB serum allowed any effects of the CLL serum to be amplified. This 
may help to explain why results for normal controls were lower than normally seen, 
particularly for CD152. Previous experiments with normal T cells have shown the median 
CD152 expression to be 17.3% in 10% normal AB serum (table 20), whilst results in this 
experiment show a median CD152 expression of 4.6% in 50% normal AB serum (table 
23). The difference in total amount of AB serum used is likely to be responsible for the 
changes in surface marker expression seen in normal T cells, although variation in patient 
samples is considered in more detail in the discussion. 
The increase in numbers of CD25 expressing T cells seen in the CLL patients was striking, 
although not as high as that seen in normal controls. It is possible that the B cells are 
producing a soluble factor that enhances their own survival, whilst providing T cells with a 
low grade, continuous activation signal that may ultimately effect the T cells ability to 
respond efficiently to a given mitogen. Alternatively, the T cells themselves may be 
producing a soluble factor in response to the malignant B cells that increases their 
activation. 
Although there was no evidence of a monoclonal antibody or any unusual chemistry in the 
CLL patients' AB serum that may have caused this response (all routine immunology and 
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chemistry results carried out on the sample were normal), it would have been useful to 
repeat these experiments with different CLL AB serum. However, this was not possible, as 
AB Rh (D)+ is a rare blood type (approximately 3% of the population) and none of the 
other patients suitable for this study were AB Rh (D)+. 
In an attempt to try and reproduce the results seen with CLL serum, recent work involving 
interleukin-15 (IL-15) was considered (Camp bell ID et al 200 I). This work has shown that 
in multiple myeloma patients, T cells cultured with IL-15 were able to proliferate and 
respond to IL-2 normally, even in the presence of tumour cells. IL-15 does not use the high 
affinity IL-2 receptor (CD25), and as the results presented earlier in this study have shown 
that T cells expressing CD25 are reduced, IL-15 may be able to restore some elements ofT 
cell function, such as up-regulating CD25 expression, as the results with the CLL AB serum 
had shown. 
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4. 7 Expression ofCD25, CD2B and CD152 on CLL Tcells after B cell depletion and 
OKT3 stimulation with interleukin-15 (/L-15). 
When CLL T cells (n=3) were depleted of B cells and cultured in OKT3 with l Ong/ml of 
IL-15, there was no significant change in the expression of CD25 (p = 0.2), CD28 (p = 0.5) 
and COl 52 (p = 0.3) when compared to culture without IL-15. Three CLL patient samples 
were analysed after culture with IL-15 and although there was a slight increase in the 
expression of each surface marker, the differences were not significant (table 25). 
Table 25: Expression of CD25, CD28 and COl 52 on CLL T cells after B cell depletion 
and OKT3 stimulation and culture with interleukin 15 (IL-15). 
CeU type CeUmarker OKT3+IL-15 
cm CD25 
C02 CD28 64.2% 
I 59.1 - 87.4% 0 ~---------+----------~r CD152 15.3% CD2 
(11.5- 15.3%. 
~--------~~----------~ 
*=range 
OKT3+0 
62.7% 
50.1- 89.3%. 
9.1)0/o 
(7.6- 17.1%. 
pvaloe 
ns 
ns 
os 
Table showing expression of surface CD25, CD28 and CD152 on CLL T cells (n=3) after magnetic 
depletion of CD 19+ve B cells and stimulation with OK T3 with and without IL-15 for 48 hours. There was 
no significant difference in the expression of any of the surface markers after culture with IL-15 
ns: not significant 
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Culture with interleukin-15 (IL-15)- summary 
When B cell depleted CLL PBMCs were cultured with OKT3 in the presence of lL-15, no 
difference was observed in the number of T cells expressing CD25, CD28 or CDI52 
compared to culture without IL-15. IL-15 was therefore unlikely to be responsible for the 
effects observed when T cells were cultured in CLL AB serum. If time had pennitted, it 
may have been useful to further investigate this soluble factor in the CLL AB serum. 
However, the possibilities were vast and it was decided that it would be more beneficial to 
continue to investigate ways in which the observed T cell defects could be reversed. 
Results presented here also show that there is a large range of expression of cell surfuce 
markers between patient samples. When results from table 25 for OKT3 stimulated T cells 
without IL-15 are compared to T cells cultured in an identical manner but on a different 
date, as shown in table 20, expression ofCD28 ranges from a median 49.9% (range 10.3-
61.5%) to a median 62.7% (range 50.7- 89.3%). Similarly, results in table 20 show that 
CD152 expression also differs from those given in table 25, with a median 4.9% (range 3.1 
- 14.3%) to a median 9.9% (range 7.6- 17.7%). This anomaly is discussed in greater depth 
in the discussion and reference is made to the effect that clinical disease parameters, patient 
age and previous treatment may have had on these results. 
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4.8 Expression of CD25, CD28 and CD152 on CD2+ CLL T cells from a patient in 
clinical remissio11 
T cells were enriched, as described in 2.4.5, from one patient who was previously diagnosed 
with CLL 6 years ago but who has now returned to normal blood counts and is in clinical 
remission. When stimulated for up-regulation of CD25, CD28 and CD 152, as described in 
2.4.3, levels of expression are lower than those seen in normal subjects, but, in keeping with 
those seen in other B-CLL patients, CD25 expression in was reduced at 61.7% compared to 
a median expression of76.5% by normal T cells. CD28 expression was 77.2% compared to 
a normal median of92.2% and CDI52 expression in the patient was 7.2%, with the normal 
median being 17.3% (median data taken from figures presented in this thesis for normal 
controls after B cell depletion and stimulation, table 20) 
Patient in remission -summary 
When T cells from a patient who had been in clinical and haernatological remission for 6 
years were cultured in OKT3, there were less T cells expressing CD25, CD28 and CD 152 
compared to the average numbers in normal controls. This suggests that even in a patient in 
clinical remission, with normal blood counts, the T cell dysregulation may persist, raising 
the question of whether this observed dysfunction is primary or secondary to the disease. 
However, it must be pointed out that only one patient was studied due to time restrictions. 
More remission patients would have given a more detailed picture. In addition, normal 
controls show a range of expression of CD25 (43.0- 95.1%), CD28 (56.4- 92.4%) and 
CDI52 (6.4- 24.4%) and whilst this patient was below the average for normals, they were 
at the lower end of the normal range and it is difficult to draw conclusions without 
additional data. 
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CHAPTER FIVE: RESULTS - CYTOKINE STUDIES 
All statistical analysis was carried out using the Mann-Whitney (Wilcoxon) comparison of 
medians. The number of patients used in each group was too small to assess normality and 
as a result, the non-parametric Mann-Whitney test has been used throughout 
5.0 Secretion of cytokines and serum factors 
5.1 Secretio11 of lllterleukill - 2 (IL-2) a11d lllterferoii-Y (IFN-y) by T cells ill a mixed 
lymplwcyte reactio11 (MLR). 
T cells were isolated from 5 CLL patients and 5 normal controls and cultured with normal 
allogeneic, irradiated PBMCs as described in 2.4.8. Cytokine secretion of IL-2 and IFN-y 
was measured using ELISA's as described in 2.4.9 and 2.4.1 0 respectively. Secretion of IL-
2 was significantly lower from the T cells of CLL patients compared to normal T cells 
(326.4pg/ml v 662.9pg/ml:p = 0.04). IFN-y secretion was unchanged between CLL patients 
and normal controls (1408.6pg/ml v 1176.5pg/ml: p = 0.3) (Table 26) (figure 18). 
All results were indicative of an MLR having taking place, as results for T cells alone 
without the allogeneic PBMCs were so low as to be umeadable by the plate-reader for each 
sample on the IL-2 ELISA. The range of IFN-y expression was 5. 7 - 11.1 pg/ml for normals 
and 8.6 - 40.1 pg/ml for CLL patients. The results for IFN-y expression in the control group 
ofT cells with no allogeneic PBMCs show that the level of background IFN-y in CLL 
patients was significantly higher than normal controls (p = 0.01) (table 27) (figure 19). 
169 
Table 26: Secretion of Interleukin-2 and Interferon-y from normal and CLL T cells in 
an MLR 
Cytokine 
Interleukin-2 
lnterferon-y 
• =range 
r for IL-2 ELISA = 0.993 
r for IFN-y ELISA = 0.976 
B-CLL (n=S) 
(median) 
326pglml 
(153.6- 602.5). 
1408.6pglml 
(239.8- 1696.2)* 
Normal (n=S) 
(median) 
662.9pglml 
(157.4- 1206.1). 
1176.5pglml 
(133.1 - 3131.1 )* 
All samples measured on the same ELISA plate to avoid interassay variation 
p value 
0.04 
ns 
Table showing results of IL-2 and IFN-y secretion from normal and CLL T cells in an MLR. There was a 
significant reduction in expression of IL-2 from CLL T cells compared to normals. There was no significant 
difference in IFN-y expression between CLL patients and normals. 
Table 27: Secretion of IFN-y from normal and CLL T cells; background readings 
Cytokine B-CLL (n=S) Normal (n=S) p value 
(median) (median) 
Interferon-y 20.1pg/ml 8.5pg/ml p = 0.01 
(8.6- 40.1). (5.7-11.1}* 
*=range 
r=o.976 
All samples measured on the same ELISA plate to avoid interassay variation 
Table showing secretion of IFN-y from CLL and normal T cells in the unstimulated wells of the MLR. In the 
absence of stimulator cells, CLL T cells produce significantly higher levels of IFN-y than normal controls. 
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Mixed Lymphocyte Reaction (MLR)- summary 
When CLL T cells are cultured with normal, irradiated B cells in an MLR, they secrete less 
IL-2 compared to normal T cells. Production of IFN-y is not reduced from CLL T cells 
compared to normal controls. The reduced IL-2 production observed by CLL T cells 
suggests that the dysfunction observed in the expression of cell surface and intracellular 
markers may persist through to the production of some cytokines. This observed reduction 
in IL-2 may be a cause of the decreased numbers ofT cells expressing activation markers 
that is preventing the T cells from entering a full state of activation and thereby IL-2 
production is reduced. Alternatively, if T cells are unable to produce sufficient IL-2, up-
regulation of the key activation and interaction markers may not occur efficiently. 
Although levels of secreted IFN-y are unchanged between CLL and normal T cells in an 
MLR, when control cell populations were measured {T cells cultured alone with no 
irradiated B cells), CLL T cells showed a significantly higher production of IFN-y 
compared to normal T cells. IFN-y is produced in response to tumour cells (Ferrantini M 
and Belardelli F 2000). It is possible that the continued exposure to malignant B cells over 
long periods of time could result in a low grade but continued secretion of IFN-y by the T 
cells as a response to the tumour cells. It has been suggested that 50% of CLL B cells 
express CD86, which is normally only up-regulated following activation and that 
expression of CD86 on these B cells can be further up-regulated by IFN-y (Zheng Z et al 
1998). This IFN-y secretion could be a response to the tumour or stimulated directly by the 
B cells. Conversely, the B cells may produce a serum factor, which causes the increased 
IFN-y response. CLL T cells appear to be able to increase IFN-y production and the B cells 
benefit from this by reducing their susceptibility to apoptosis (Zaki M et al 2000) implying 
B cells may somehow be inducing the T cells into secreting cytokines that can directly aid 
their survival. 
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5.2 Secretio11 of lllter/eukill-2 (IL-2) by T cells ill a mixed lympllocyte reaction 
suppleme11ted witll Interleukill-15 (IL-15) 
T cells isolated from 2 CLL patients and 1 normal control were cultured with normal 
allogeneic, irradiated PBMCs and supplemented with IL-15 at IOnglml, lnglml and Onglml 
as described in 2.4.11. Secretion ofiL-2 within the culture supematant was measured using 
an ELISA. The higher the concentration of IL-15 was in the culture, the lower the 
expression of IL-2 (Table 29). Statistical comparison between one normal and two CLL 
subjects was not done. 
Table 28: Secretion of Interleukin-2 
SUI!I!Iemented with lnterleukin-15 {! 
OL-2) from normal and CLL T cells in an MLR 
L-15) 
CLL 1 
CLL2 
Normal! 
~ = 0.999 
I Onglml IL-l 5 
112.4 
73.9 
Result out of r ange-
ad too low to re 
lnglml IL-15 
199.9 
107.6 
67.0 
All samples measured on the same ELISA plat e to avoid interassay variation 
Onglml IL-15 
558.6 
134.9 
213.3 
Table showing secretion oflL-2 from CLL T c ells after culture with IOng/ml, lng/ml or no IL-15 in an MLR. 
ecretion of IL-2 increased. As the levels of IL-15 in the MLR decreased, s 
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Mixed Lymphocyte Reaction (MLR) with IL-15- summary 
When the original MLR was repeated in the presence of varying amounts of IT.--15, the 
observed results appear to be "false". ll.--15 shares much homology with IL-2 (Giri JG et al 
1995; Bulfone-Paus S et al 1997). In an attempt to see if ll.--15 could increase IL-2 
production, it is possible that the ll.--15 from the culture medium bound to the monoclonal 
antibody for ll.--2 pre-coated onto the ELISA plate. The higher the initial concentration of 
ll.--15, the lower the ll.--2 result. This does not give a true representation of IL-2 secretion in 
the presence ofll.--15 in an MLR. 
Results presented here also show that there is a large range of ll.--2 secretion in CLL 
patients. Table 26 has a median of 326.4pg/ml (range 153.6 - 602.5pg/ml), yet cells 
cultured in an identical fashion in table 29 (no ll.--15 added) show an IL-2 secretion of 
558.6 and 134.9pg/ml. As discussed previously, these results are vastly different and will 
be considered in greater depth in relation to clinical disease parameters, patient age and 
previous treatment in the discussion. 
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CHAPTER SIX: DISCUSSION 
6.0 Results summary 
The results of this study suggest a profound dysregulation of the function of the CD2+ve T-
cells in patients with B-CLL. The significantly reduced expression of the key activation 
and interaction markers CD4, CD5, LFA-1, CD25, CD28 and CD152 and significantly 
increased expression of HLA-DR on these cells also suggests partial activation of these T 
cells and dysfunctional interaction with B cells. Removal of B cells before cell culture did 
not correct these abnormalities. In contrast, expression of intracellular CD25 and CD152 
was not reduced in activated T cells from 8-CLL patients compared to normal controls and 
their expression was significantly greater in resting CLL T cells. Intracellular CD28 
expression was reduced in activated, but not resting CLL T cells from B-CLL patients 
compared to normal controls. 
When T cells from normal controls were cultured in CLL AB serum, levels of expression 
of CD25 and CD 152 were significantly greater than with normal AB serum. T cells from 
B-CLL patients showed a similar response, but expression of CD25 and CD 152 did not 
increase as much as in normals, suggesting that B-CLL serum contains a factor which can 
increase activation. 
In a mixed lymphocyte reaction (MLR), T cells from B-CLL patients secreted significantly 
less IL-2 compared to normal controls. Levels of IFN-y were similar for CLL T cells from 
B-CLL patients and normal controls. However, secretion of IFN-y by resting, unstimulated 
T cells from B-CLL patients was significantly higher than secretion by those from controls. 
None of these defects could be corrected by the addition of exogenous IL-15. Finally, the 
abnormal expression of CD25 persisted at a level seen in untreated CLL in a patient who 
was in complete clinical and haematological remission, suggesting that these T cell 
changes may be persistent or even permanent. 
There are two hypotheses that may explain this apparent dysregulation ofT cell function in 
8-CLL. The first is immunosenescence and the second is anergy. Both immune 
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phenomena are well documented and will be discussed in relation to the findings in this 
study. 
6.1 Range of expression in samples 
6.1.1 Normal controls 
There is evidence within the results presented here that there is a degree of variability 
within normal controls. Data presented in different tables from cells cultured in a similar 
manner but from different controls and on different dates show wide variation. Table 20 
has a median CD152 expression of 17.3% (range 10.7- 26.3%), whilst table 23 has a 
median CD152 expression of 4.6% (range 1.6 - 10.7%). Although parameters were 
slightly different (AB serum concentration was 10% in table 20 and 50% in table 23) these 
results are more varied than would normally be expected. If normal control data is re-
analysed according to age (figure 21 ), it is possible to see that CD 152 increases gradually 
with age. Previous work also suggests that CD152 expression increases with age (Elliott 
SR et al 1999). The age range of normal controls used in table 20 is 37-45, and for table 
23, it is 23-63. Three normal controls (out of a total of six) were in their twenties and only 
one person was above 48. It is possible that one theory that could explain this variation in 
some of the normal control data is age of the subjects. Half of the controls with the low 
CD152 group were at the lower end of the age scale and this result could explain the large 
variation in patients results. 
6.1.2 Patient samples 
An intriguing finding in the experiments presented in this thesis have shown that there is 
often a case of high inter-assay variation amongst patient samples, as discussed in the 
results section. Cells cultured under identical conditions, but on different dates and from 
different patients, showed a wide variation in levels of expression of surface markers. In 
particular, tables 20 and 25 have cell populations treated in the same way. Both are 
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stimulated in the presence of OKT3 for 48 hours is the same culture medium, yet 
expression of CD28 ranges from a median 49.9% (range 10.3 - 61.5%) (table 20) to a 
median 62.7% (range 50.7 - 89.3%) (table 25). Similarly, results in table 20 show that 
CD152 expression also differs from those given in table 25, with a median 4.9% (range 3.1 
- 14.3%) (table 20) to a median 9.9% (range 7.6 - 17.7%) (table 25). Within these 
particular groups, all patients were in stage A. The age range was 57-78 for table 20 and 
55-70 for table 25. Prior treatment was similar; only 1 patient from each group had 
received prior treatment and in each case, treatment had consisted of chlorambucil + 
prednisolone. 
To try and explain this anomaly further, patient data from different experiments were 
grouped according to age, prior treatment and stage. Although patient numbers were small 
and statistical analysis of each individual sub-group was not possible, graphical display of 
this data allows for any trends to become apparent that may help to explain the differences 
observed. Three groups of results were analysed; CD25, CD28 and CD152 as one group, 
TCR and CD4 as a second group and LFA-1 and ICAM-1 as the third group. Each group 
was examined for the same parameters. 
6.1.2.1 Age 
When patient data is organised into age and compared both within the CLL population and 
also to normal controls, results show that, compared to normals, CLL patients show a 
much greater range of expression as age increases, with no discernible trends. CD25 and 
CD28 data have no correlation with age and constantly fluctuate from the ages of 48 to 85 
(figure 20). CD152 stays relatively constant across the same age group (figure 20). 
Replicative senescence (discussed in more depth in the next section) describes a continued 
decline in expression of both CD25 and CD28 as age increases. No such trend can be seen 
with CLL patient data that may explain the inter-assay variation. In comparison, graphical 
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data for normal controls, although not wholly constant, does show a trend of decreased 
expression ofCD25 and CD28 as age increases (figure 21). 
Previous work has shown that expression ofCD152 is greater in adults when compared to 
neonates and in fact increases with age (Elliott SR et a! 1999). CLL CD !52 expression 
remains constant with age (figure 20), whilst normal controls show a small decline and 
then a gradual increase as age increases (figure 21). 
Expression of TCR and CD4 generally increases with age in CLL patients (figure 22), 
whilst in normal controls, expression remains fairly constant (figure 23). CLL patients 
show an increase of expression ofiCAM-1 and a slight increase then decline of LF A-1 as 
age increases (figure 24). In comparison, normal controls have a constant expression of 
LFA-1 and a slight increase in ICAM-1 as age increases (figure 25). 
In summary, age does not seem to be a factor that affects surface marker expression in 
CLL and patients do not seem to follow normal -or expected - patterns of expression with 
age. 
6.1.2.2 Prior treatme11t 
When patients are grouped according to prior treatment regtmes and surface marker 
expression is compared between the treatment groups, there are interesting results. 
Chemotherapy-induced T cell function (discussed in more depth shortly) suggests that T 
cells and T cell function can be profoundly affected by chemotherapy. As a result, when 
patients are grouped according to treatment history, one might expect to see a reduced 
expression of surface markers from those patients who had received previous treatment 
compared to treatment free groups. There is, in fact, a wide variation in the results. When 
chlorambucil treated patients are compared to non-treated groups, expression of CD25, 
CD28, CD! 52 and LFA-1 is higher in the treated group (figures 26 and 28). In comparison, 
expression of CD4 and TCR is reduced on cells from chlorambucil treated patients 
compared to non-treated groups (figure 27). If patients who had previously received 
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chlorambucil and prednisolone are compared to non-treated groups, expression of CD28, 
CD4 and LFA-1 is higher in the treated groups (figures 26, 27 and 28). In comparison, 
CD25, TCR and ICAM-1 expression is reduced. Prednisolone treatment alone gives an 
increase in expression of TCR and a decrease in expression of CD25, CD28 and TCR 
compared to non-treated groups (figures 26 and 27), whilst treatment with 
cyclophosphamide gives an increase in expression of CD25 and CD4 and a decrease in 
CD28 (figures 26 and 27). 
Although this data gives some interesting results, there are no discernible trends that apply 
to each type of treatment regime and as a result, prior treatment is unlikely to cause the 
variation in patients results. 
6.1.2.3 Stage of disease. 
If patients are grouped according to the stage of their disease and expression of surface 
markers are re-analysed, more trends are discernible. In particular, expression ofCD25 and 
CD28 decrease from stage A to stage B (figure 29). Expression of CD152 also declines 
from stage A to stage B, but this difference is not as striking (figure 29). In addition, 
expression ofiCAM-1 and CD4 also decline as stage of disease progresses, whilst LFA-1 
expression increases and TCR expression remains constant as disease progresses (figures 
30 and 31 ). It is possible that some of the variability seen in patients samples could be due 
to stage of disease, although with reference to tables 20 and 25, where striking differences 
were seen, all patients were in stage A. 
6.2 Cbemotberapy-induced T cell dysfunction in previously treated patients 
39% (16 out of 41) patients in this study had received previous chemotherapy to treat CLL. 
Of these 16 patients, the type of treatment received is shown in table 29 and the time since 
last treatment is shown in table 30. 
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Table 29: Type of treatment received by patients 
Type of treatment Number of patients receiving 
treatment 
Chlorambucil 4 
Chlorambucil + Prednisolone 4 
Cyclophosphamide 1 
Cladribine 1 
Splenic radiotherapy I 
Prednisolone 3 
Combination (chlor, chlor + pred, purine 2 
analogues) 
Table showing the type of treatment received by CLL patients and the number of patients receiving that 
particular type of treatment 
Table 30: Length of time since last treatment regime 
Time since last treatment Number of patients 
10 years 1 
6 years 3 
5 years 1 
4 years 3 
3 years 2 
2 years 3 
1 year 3 
Table showing the time lapsed since last treatment regime and the number of patients who last received 
treatment at that time 
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Although treatment has not been shown to have any discernible effect when data is 
compared to none-treatment groups, it is important to discuss what effect chemotherapy 
may have on the T cell populations. 
One of the most prominent findings ofT cell response to chemotherapy is a reduction in 
total T cell numbers following treatment (Bemego MG et al 1984; Petrini B et al 1984; 
Emmendorffer CA and Pichler WJ 1985; Takamatsu Yet al 1993; Mackall CL et al 1997; 
Fagnoni FF et al 2002; Svane IM et al 2002). The T cell decline increases after each cycle 
of therapy, suggesting an accumulative effect of the drugs (Bemego MG et al) and the 
main cause of this decline is postulated to be CD4+ve T cells . In contrast, CD8 T cells are 
not affected in such a dramatic way and their regeneration after cessation of therapy is 
quicker than CD4 cells (Mackall CL et al 1997). This is believed to be because CD4 cells 
require a thymus dependent pathway for regeneration, whilst CD8 cells are capable of 
regeneration using a thymic-independent pathway. As a result of this, there is often a 
prolonged, inverse CD4/CD8 ratio and reduced total T cell numbers after chemotherapy, 
sometimes for as long as 2-3 years (Petrini B et al 1984). A reversed CD4/CD8 ratio is 
well documented in CLL (Kay NE et al 1979; Kay NE 1981; Semenzato Get al 1983; 
Totterman TH et al 1989; Kimby E et a11989; Janssen 0 et al 1989; Burger T et al 1990; 
Goolsby CL et al2000; Porakishvili Net al2001) and it is possible that earlier studies may 
not have taken into account prior treatment before assessing CD4/CD8 numbers. 
Older patients who are receiving chemotherapy may have a more pronounced T cell 
decline and take longer to recover CD4 numbers, as thymic function invariably decreases 
with age and an inverse relation between age and CD4 regeneration has been shown 
(Mackall CL et al 1995; Mackall CL et al 1997; Fagnoni FF et al 2002). If such theories 
are applied to CLL patients, one might expect to see a reduced expression of CD4 on 
previously treated patients compared to non-treated patients and also a more pronounced 
decrease in older patients who had received treatment. Within the patient group tested for 
CD4 expression in this study, one patient aged 76 had received cyclophosphamide 1 year 
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prior to test. CD4 expression was compared to a younger patient aged 56 who had received 
chlorambucil + prednisolone 4 years prior to test. Surprisingly, expression of CD4 was 
100% for the 76 year old patient and only 35.8% for the 56 year old patient. Unfortunately 
patient numbers were too small to further evaluate this finding, but it would suggest that, in 
this instance, chemotherapy-induced T cell dysfunction may not be responsible for these 
findings. In contrast, CD8 numbers are unchanged from the normal control population and 
this would fit with findings for chemotherapy-induced T cell dysfunction. 
Other important findings in patients treated with chemotherapy is the presence of cytokines 
produced in recovery phase after drug treatment. One study has shown that levels of IFN-y 
and GM-CSF in both cultures and plasma are higher compared to normal controls 
(Takamatsu Y et at 1993). This suggests that T cells may be activated in vivo to produce 
haemopoietic cytokines during haematological recovery and that they may be actively 
involved in the induction of haemopoiesis. When data from this study is re-analysed 
according to prior drug treatment, the patient whose cells produced the highest levels of 
IFN-y from a resting cell population had received chlorambucil 1 year prior to test and the 
amount of expression was almost double the amount produced by the next closest patient 
and five times higher than the lowest secreting patient. This suggests that in this 
experiment, the effects of chemotherapy may be in some part responsible for the results 
shown here. 
Whilst it is important to take into account the effects of chemotherapy on T cell function 
and also to note that some findings in this thesis correlate with the findings of others, 
chemotherapy-induced T cell dysfunction cannot wholly explain the results observed in 
previously treated patients. 
6.3 Immunosenescence or Replicative Senescence 
Immunosenescence, also called replicative senescence, is described as a generalised, age-
related decline in immune responses in the elderly (Gioberson A and Effros RB 2000), 
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which may lead to an increased susceptibility to infectious disease, cancer and auto immune 
phenomena (Solana A and Pawelec G 1998). It implies that, as lymphocytes age, they 
reach a point at which they cannot replicate (growth arrest) and as a result, their immune 
responses begin to diminish (Effros RB and Pawelec G 1997). This theory has recently 
been challenged because, while the immune system does show a reduced level of 
diminished response with age, it also undergoes dramatic restructuring that leads also to 
some enhanced functions (Globerson A and Effros RB 2000). It is possible that the results 
seen in this study may be further evidence of immunosenescence, as most patients who 
develop CLL are elderly. While every attempt was made to age match patients and normal 
controls, this was not always feasible as access to volunteers within the hospital was 
limited to those under retirement age. The majority of normal controls were between 30 
and 50 years, this being the typical range of age of the hospital workforce. Careful 
comparison of abnormalities described as immunosenescence and those found within this 
study is therefore necessary. 
6.3.1 CD25 and CD28 expression, /L-2 secretion 
Recent studies reporting replicative senescence have consistently described reduced 
surface expression of CD28 on T cells (Effros RB and Pawelec G 1997; Pawelec G and 
Solana R 1997; Boucher Net al 1998; Globerson A and Effros RB 2000; Pawelec G and 
Solana R 2001). The results of the investigation for this thesis also show reduced 
expression of CD28. The reduced CD28 expression described in the initial studies was 
found on CD8+ve T cells, and the CD8 subset ofT cells is expanded in both replicative 
senescence (Effros RB and Pawelec G 1997; Pawelec G and Solana R 1997; Boucher Net 
al 1998; Globerson A and Effros RB 2000; Pawelec G and Solana R 2001) and also in 
CLL (Kay NE et al 1979; Kay NE 1981; Semenzato Get al 1983; Totterman TH et al 
1989; Burger T et al 1990). Both of these findings suggest that replicative senescence may 
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be responsible for the observed reduction in T cells expressing CD28 and the observed 
increase in numbers of CD8+ T cells in CLL. 
CD28 plays a critical role in upregulating expression of both IL-2 and the IL-2 receptor, 
CD25 (Jenkins M et al1991; Powell ID et al1998; Boonen GJJC et al1999; Boulougouris 
G et al 1999; Holdorf AD et al 2000). As a possible consequence of this reduced CD28 
expression in replicative senescence, production of IL-2 and its receptor CD25 are reduced 
in the elderly (Antonaci S et a! 1991; Ginaldi L et al 1999). This thesis also reports a 
significantly reduced expression ofiL-2 from CLL T cells in the MLR. 
However, while cell surface expression of CD28 is decreased in both CLL and replicative 
senescence, the results from this thesis show that although intracellular levels of CD28 are 
significantly decreased in activated CLL T cells, there is no difference in intracellular 
expression in resting CLL T cells compared to normals. If the decrease in surface CD28 in 
CLL T cells was a result of immunosenescence, then levels of intracellular CD28 should 
also be decreased in both activated and resting cells. But, as there is no significant 
difference in expression of intracellular CD28 in resting T cells, the decrease seen after 
activation is presumably a dysfunctional response to T cell stimulation. 
Immunosenescence is also characterised by a decrease in surface expression of CD25. This 
thesis also shows a decrease in surface expression of CD25 on the T cells of patients with 
B-CLL. The combination of this reduced surface expression of CD25 with normal 
intracellular expression in activated T cells and the significant increase in expression of 
intracellular CD25 in resting T cells from these patients also suggests a dysfunctional 
response to T cell mitogens. This response cannot be explained on the basis of 
immunosenescence or replicative senescence alone. 
6.3.2 CD152, CD154 a11d LFA-1 expression 
One of the key findings described in this study was the reduced number of T cells 
expressing CD152 in CLL, with 50% of patients expressing no surface CD152. Studies 
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comparing key activation markers in neonates, children and adults have shown that 
expression of CD 152 is greater in adults and less in neonates. CD 152 expression increases 
with age (Elliott SR et al 1999). In older subjects, reduced expression of CD 154, the ligand 
for CD40, and increased expression of adhesion markers such as LFA-1 (CD11a) have 
been described (Franceschi C et al 1995; Ginaldi L et al 1999). In comparison, this thesis 
finds no difference in surface expression of CD154 and a significant decrease in surface 
expression of LF A-1 comparing T cells from CLL patients with those from normal 
controls. All the findings discussed in 6.3.1 and 6.3.2 also suggest that the theory of 
imrnunosenescence does not apply to B-CLL. 
6.3.3 HLA-DR expressiotr, JFN-ya11d TNF-a secreti01r 
In this study significantly more T cells from CLL patients expressed HLA-DR on the cell 
surface after activation. Similarly, lymphocytes in the aged population show an increased 
number ofT cells expressing HLA-DR, which is linked to an increase in serum secretion 
of TNF-a, IFN-y and soluble IL-2R (Rea IM et al 1999). Previous studies have reported 
that CLL patients also have an increase of TNF-a in both the serum (Hulkkonen J et al 
1998) and intracellularly (Mainou-Fowler T et al 2001). These results are all similar to the 
findings of T cell dysregulation presented in this thesis and those of other studies, and 
support the hypothesis that the T cell dysfunction may be one natural consequence of 
agemg. 
Whilst both CLL patients and aged subjects have greater numbers of T cells expressing 
surface HLA-DR, there is a significant difference in the numbers ofT cells that express 
HLA-DR. The highest number ofT cells expressing HLA-DR reported in normal aged 
subjects was 25% ofCD45RA T cells (Rea IM et all999). When HLA-DR expression was 
measured on CD4 and CD8 T cells, 27% of CD4 cells and 22% of CD8 cells expressed 
HLA-DR. This was a twofold increase compared to expression in younger subjects. In this 
thesis, an average of90.7% ofT cells from CLL patients expressed surface HLA-DR with 
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a range of expression from 63.1% to 100%, an increase in CLL which is unlikely to be the 
result of ageing or immunosenescence alone. This study also found an increased 
expression of the cytokine IFN-y from resting CLL T cells compared to norma is, whereas 
in contrast, IFN-y was not found to be increased in resting T cells in normal elderly 
subjects presumed to show immunosenescence (Rea IM et al 1999; Ginaldi L et a! 1999). 
6.3.4 T cell numbers 
During natural ageing, the absolute number of T cells decreases (Pawelec G et al 1995; 
Franceshi C et a1 1995; Pawelec G et a! 1999), whilst in CLL, the absolute number ofT 
cells increases and the CD8 subset expands (Catovsky D et a! 1974; Totterman H et al 
1989; Burger T et al 1990; Caligaris-Cappio F and Hamblin T 1999; Stark P et al 1999; 
Caligaris-Cappio F et a! 2001). The CD8 subset expands in both CLL and replicative 
senescence, but whilst CD4 absolute numbers have been observed to increase in CLL, a 
marked CD4 lymphopaenia is often observed in the elderly (Solana R and Pawelec G 
1998). The results presented in this thesis show that the number of CD4 expressing T cells 
from CLL patients are significantly variable, suggesting that there is no set pattern to CD4 
expression in the course of the disease. 
6.3.5 T cell response to mitogen 
The theory of replicative senescence is also based on the observation of an increase in the 
number of aged T cells unable to proliferate in response to known T cell mitogens 
(Boucher N et al 1998; Pawelec G et a! 1999). Whilst the work for this thesis did not 
include measurement of proliferation of T cells from B-CLL patients, the finding of 
reduced expression of activation markers suggests that these T cells were unable to 
proliferate as efficiently as those from normal controls, in much the same way that aged T 
cells are unable to proliferate in response to mitogens. 
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However, T cells that have reached a stage of immunosenescence cannot respond to 
antigenic re-stimulation or T cell mitogens including anti-C03 (Effros RB and Pawelec G 
1997), suggesting that they would not be able to upregulate any activation markers. The 
results in this thesis show that T cells from B-CLL patients are able to mount a partial 
response to anti-C03, distinguishing them from ageing immunosenescent T cells. 
6.3. 6 B cells 
In elderly, healthy subjects, there is a general increase in the number of B cells expressing 
surface COS and producing auto-antibodies (Gioberson A and Effros RB 2000). One of the 
key identifying factors of CLL is the expression of surface COS on the malignant B cell 
clone, the increase in production of autoantibodies and an increase in associated 
autoimmune clinical complications. Although the production of the auto-antibodies in CLL 
has not been directly linked to the malignant clone, the similarities that can be observed 
between a normal, healthy, elderly population and CLL are striking. It is possible that CLL 
may be a manifestation of an aged immune system which has perhaps undergone a higher 
than normal degree of challenge by external antigens resulting in a population of 
lymphocytes that have reached an immunosenescent end point. It is now quite normal for 
humans to live to at least 80 years or older and it is clear that the increase in COS 
expression and the production of autoantibodies in ageing is not entirely similar to the 
findings in CLL. Whilst there is an increase in COS expression on B cells with ageing, 
immunosenescence also results in a decrease in B cell numbers (Franceshi C et al 199S; 
Pawelec G et al 1999; Globerson A and Effros RB 2000). In contrast, in CLL there is a 
variable but often striking increase in B cell numbers. While the clonal malignant B cells 
also express COS, they are not thought to be responsible for the production of the 
autoantibodies (Kobayashi R et al 1992; Kneitz C et al 1999). Experiments with animal 
models have also shown that younger animals are more susceptible to the induction of 
autoimmune disease than the old (Globerson A and Effros RB 2000). 
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The evidence discussed here would suggest that while CLL patients T cells do share many 
characteristics with immunosenescent T lymphocytes, there are too many variables which 
cannot be explained by the ageing process alone (table 31 ). But, it is possible that ageing 
may have an effect on their ability to respond effectively to the malignant B-cell clone as 
the disease progresses so this theory cannot be dismissed as entirely inapplicable to the 
immune dysfuntion of CLL T cells. 
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Table 31: Differences and similarities between lymohocyte subsets in replicative 
senescence and CLL 
Cell status Replicative Senescence CLL 
T cell CD28 surface decreased decreased 
expression 
T cell CD28 intracellular decreased in activated cells decreased in activated cells 
expression decreased in resting cells no change in resting cells 
T cell CD25 surface decreased decreased 
expression 
T cell CD25 intracellular decreased in activated cells no change in activated cells 
expression decreased in resting cells increased in resting cells 
T cell CD I 52 surface increased decreased 
expression 
T cell CD154 surface decreased increased (not significant) 
expression 
LFA-1 expression decreased increased 
T cell HLA-DR expression increased increased 
mean no. ofT cells expressing 25% 90.7% 
HLA-DR 
T cell IFN-y production increased in activated cells increased in resting cells 
T cell TNF-a production increased increased 
T cell IL-2 production decreased decreased 
Total T cell numbers decreased increased 
Total B cell numbers decreased increased 
CD5 B cells increased increased 
autoantibody production increased increased 
CD5 B cell autoantibody yes no 
production 
T cell proliferative response to decreased decreased 
mitogen 
T cell activation response to no yes (partial) 
anti-CD3 
Table showing the difference and similarities in expression of T cell markers, cytokine secretion and 
lymphocyte subsets in both replicative senescence and CLL 
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6.4 Tolerance and clonal anergy 
Complete activation ofT cells requires two signals, one through the T cell receptor as the 
antigen binds, and the second through a costimulatory signal as the T cell interacts with the 
cell presenting the antigen. If the second signal is missing or reduced, the T cell is only 
able to make a partial response and will enter a state of unresponsiveness known as clonal 
anergy, in which the T cell is incapable of producing IL-2 on re-stimulation and becomes 
tolerant to activation signals (Schwartz RH 1990; Lechler R et al 2001; de St Groth BF 
2001). There are a number of similarities that can be seen between CLL T cells and T cells 
tolerant through clonal anergy which will be described here. 
6.4.1 CD28, CD25 and LFA-1 expression, /L-2 secretio11 
Recent evidence suggests that the critical second signal required from T cells to prevent 
their anergy and tolerance as a result of antigen presentation is expression of CD28 (Powell 
JD et al 1998). The evidence indicates that TCR engagement by antigen leads to 
progression of the cell cycle into G1 when further cell cycle progression can be blocked by 
cell cycle inhibitors. However, CD28 ligation with its co-receptors CD80 and CD86 on B 
cells and other antigen presenting cells (APC), leads to the up-regulation of autocrine IL-2 
production and the binding of IL-2 to its receptor down-regulates the cell cycle inhibitors 
so that the cell can progress through the rest of the cycle (Becker JC et al 1995). If, during 
antigen presentation, blocking antibodies to IL-2 are introduced in vitro, anergy will also 
be induced (DeSilva DR et al 1991 ). Without the CD28 second signal from ligation with 
CD80/CD86 on B cells and APCs, T cells will remain in a partially activated state and be 
unable to fully respond to any further signals. Further stimulation with antigens may fail to 
cause T cell proliferation or IL-2 production and the T cells may remain anergic (Jenkins 
MK and Schwartz RH 1987). 
The integrins such as LFA-1 and ICAM-1 have also been shown to have important roles in 
preventing anergy by promoting the adhesion between cells and facilitating the TCR signal 
189 
after antigen binding (Powell ID et al 1998). CLL T cells appear to be in a state similar to 
anergy and tolerance, with reduced surface expression of both CD28 and LFA-1, as 
described in this thesis. This reduced expression could explain the state of partial activation 
of the CLL T cells. If the T cells have become tolerized in vivo, their removal and 
subsequent activation with anti-CD3 in vitro would only result in a partial activation, due 
to the reduced expression of the second signal and their pre-existing tolerized state. In 
addition to the reduced expression of CD28 as the second signal and the reduced 
expression of LFA-1, this study has also shown that CLL T cells secrete less IL-2, another 
hallmark of the tolerized cell. 
However, the increased expression of intracellular CD25 and CD152 found in resting CLL 
T cells suggests that some kind of response is made by the T cells and that there are factors 
present either within the CLL serum or the microenvironment that prevent their expression 
on the cell surface. After activation, expression of intracellular CD25 is lower. Continual 
antigenic stimulation from the serum or microenvironment in vivo would repeatedly 
activate the T cells, even when in a resting state, and prevent a clear response when 
activated in vitro. 
This study has shown that when normal T cells are cultured in CLL AB serum, expression 
of CD25 is significantly higher than when cultured in normal AB serum, suggesting the 
presence of a serum factor from CLL patients that provides an activation signal. CLL T 
cells also have higher expression of CD25 when cultured in CLL AB serum compared to 
normal AB serum. While there is evidence of a tolerant state in the CLL T cells, it is 
possible that the in vivo environment may in some way be responsible for this. Evidence 
suggests that anergy also persists after the removal of the induction signal, as shown in this 
study. Removal of the malignant B cells and subsequent activation of the remaining pure T 
cell population still results in reduced expression ofCD28. 
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6.4.2 CD152 expressi011 
Fewer T cells in CLL express surface CD152 and more express intracellular CD152 in 
their resting state than do normal controls. CD152 plays a critical role in down-regulating 
the T cell response following activation (da Rocha Dias S and Rudd CE 2001). In the 
absence of CD152, or if expression of CD152 was significantly reduced once activation 
had occurred, T cells would not receive signals to stop and may continue in a partial state 
of activation, rendering them more susceptible to autoimmunity and increasing T cell 
numbers as they resist the normal signals for apoptosis. The role of CD152 can be 
observed clearly m CTLA-4 knock-out m1ce which develop splenomegaly, 
lymphadenopathy, multi-organ lymphocytic infiltration and tissue destruction, dying 
within 3-4 weeks of birth (Tivol EA et al 1995). These findings suggest that CTLA-4 plays 
a critical role in down-regulating T-cell activation and preventing autoimmunity. Blocking 
antibodies to CD152 during activation produce a 4 to 5 fold reduction in the level of 
expression of CD95 (FasL), which induces antigen-induced cell death (AICD), a process 
that ensures the deletion of self-reactive T cells (da Rocha Dias and Rudd CE 2001). This 
suggests that under normal conditions of CD152 expression during T cell activation, 
ligation of CD152 with CD80/CD86 induces termination of the immune response by 
reducing IL-2 and IL-2R production, arresting cell cycle progression and inducing AICD 
to prevent the initiation of autoimmunity. 
This reduced expression of CD 152, however, does not correlate with theories of tolerance. 
Previous studies have shown that CD152 negative mice are resistant to tolerance induction, 
as demonstrated by proliferative responses, IL-2 production and progression into the cell 
cycle (Greenwald RJ et al 2001), confirming earlier experiments with CD152 negative 
mice (Tivol EA et al 1995). However, CLL T cells do not show normal proliferative 
responses and have low IL-2 production, suggesting that the expression of surface CD152 
could be regulated by external factors, such as the serum factor referred to above. 
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Intracellular CD 152, like intracellular CD25, is expressed in more resting CLL T cells than 
in normal T cells. 
6.4.3 HLA-DR expression and IFN-ysecretion 
The increased number of activated CLL T cells expressing HLA-DR and the increased 
secretion of IFN-y from resting CLL T cells could be the result of long term, continual 
exposure to antigenic stimulation, resulting in a state of clonal anergy. IFN-y is produced 
in response to tumour cells (Ferrantini M and Belardelli F 2000). It is possible that the 
continued exposure to malignant B cells over long periods of time could result in a low 
grade but continued secretion of IFN-y as a response to the tumour cells. It has been 
suggested that 50% of CLL B cells express CD86, which is normally only up-regulated 
following activation and that expression of CD86 on these B cells can be further up-
regulated by IFN-y (Zheng Z et a! 1998). This IFN-y secretion, either as a response to the 
tumour or stimulated directly by the B cells, could either push the T cells into an anergic 
state or could simply be a result of pre-existing clonal anergy. Conversely, the B cells may 
produce a serum factor which causes the increased IFN-y response. CLL T cells appear to 
be able to increase IFN-y production and B cells benefit from this by reducing their 
susceptibility to apoptosis (Zaki M et al 2000) implying B cells may somehow be inducing 
the T cells into secreting cytokines that can directly aid their survival. The significantly 
higher number ofT cells in CLL expressing HLA-DR, reported both here and by others 
(Garci-Suarez J et al 1991) could be a result of the higher expression of CD86, among 
other markers, on the malignant B cells (Zheng Z et all998). 
Other evidence suggests that, at some point in the development of this disease, there may 
be a host T cell response directed against leukaemia-related antigens, demonstrated by the 
presence of clonal T cells (WenT et al 1990; Serrano D et all997). These clonal T cells 
may have arisen from early T cells that attempted to respond to the malignant clone and 
support the theory that there may be a continuous, low grade T cell activation in response 
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to this. High IFN-y secretion and increased numbers ofT cells expressing HLA-DR could 
also be a result of this low grade activation. 
6.5 Possible immunosuppression by CLL B cells 
It is possible that some of the T cell defects described in this thesis may be caused by 
immunosuppression by the CLL B cells. In a normal immune system, T cells are more 
abundant than B cells, particularly in the peripheral blood. In CLL, B cell numbers 
increase dramatically and "dilute" T cells, originally causing what appeared to be a 
reduced T cell population. This increase in B cells numbers, the surface markers expressed 
on them and the possible factors secreted by them could all have a direct or indirect effect 
on T cell function. This should be taken into account when considering the T cell 
dysfunction presented in this thesis. 
Key findings have shown that B cells are capable of suppressing the normal function ofT 
cells. When CLL T cells are cultured with CLL B cells, the T cells show a reduced ability 
to co-operate in the production of immunoglobulins, a possible cause for the 
hypogammaglobulinaemia common to CLL patients (Callery RT et al 1980). 
B cells may also suppress T cells by either absorbing or utilising cytokines essential for T 
cell function. If CLL T cells are cultured alone, they produce normal levels of IL-2. If CLL 
B cells are added to the system, levels of IL-2 produced are reduced and appear to be 
utilised by the B cells, suggesting a reversed immune control by B cells over the T cells 
(Zaknoen SL and Kay NE 1990). 
Other methods of immune control by the CLL B cells include an ability to force T cells to 
up-regulate surface markers that would otherwise not normally be expressed. If CLL T 
cells are activated in the presence of CLL B cells, the T cells up-regulate surface CD30 
(De Totero D et al 1999; Cerutti A et al 2001 ). This prevents up-regulation of CD40 on 
non-malignant B cells and prevents normal immunoglobulin production through T and B 
cell contact. 
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CLL B cells may also be capable of producing soluble factors that both suppress T cells 
and exert control over them. If T cells are cultured in the presence of supematants from 
CLL B cells, a variety ofT cell functions are inhibited, such as PHA-induced proliferation, 
PHA-stimulated entry ofT cells into the cell cycle and PHA-induced production of IL-2 
(Burton ID et al 1989). Control B cells and other malignant cell lines had little or no effect. 
Similarly, CLL B cells have been shown to secrete a protein called CCL22, which can 
actively induce the migration ofT cells towards the B cells (Ghia P et al 2002). These T 
cells can then induce a strong chemokine production by the leukaemic clone, creating a 
vicious cycle that allows the clone to accumulate. 
There is much evidence of CLL B cell control over T cells. Such facts should be taken into 
account when considering possible causes for the T cell dysfunction observed in this study. 
Even though the majority of experiments were carried out on T cell enriched populations, 
cell culture was only for 48 hours. It is possible that any suppression of the T cells by B 
cells may be long lasting, either as a prolonged down-regulation or in a partially activated 
state that prevents normal up-regulation of cell surface markers. 
6.6 Conclusions 
In CLL, T cells express an abnormal pattern of the normal activation and interaction 
markers. They do not respond to stimulation in the same way as normal T cells and more 
resting T cells express higher amounts of intracellular activation markers than activated T 
cells. The CLL T cell produces higher levels of the activation cytokine IFN-y when resting, 
and when activated produces reduced levels of the activation cytokine IL-2. A soluble 
factor found in CLL AB serum causes significantly more normal T cells to express the 
activation markers CD25 and CD152 than when they are activated in normal AB serum. 
The patient who had been in clinical remission for 6 years had a continued reduced 
expression of CD25, suggesting that the T cell defect may persist even if the leukaemia is 
in clinical and pathological remission. 
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Replicative senescence has much in common with the CLL T cell, yet does not explain all 
the abnormalities described in this thesis. Tolerance also provides some interesting 
theories, but again cannot account for all of the findings. CLL is a slowly progressing 
disease. Chemotherapy-induced T cell dysfunction cannot wholly explain the findings for 
previously treated patients. The T cell will find itself surrounded by increasing numbers of 
malignant cells that may cause immunosuppression and until more is known about the B 
cells avoidance of immune recognition, it is difficult to understand how B and T cells fail 
to interact to prevent this. B and T cell interaction is critical and what is clear from this 
study is the reduced capability of the CLL T cell to express the markers and the cytokines 
necessary to do this efficiently. This T cell dysfunction may explain the partial response of 
these cells to B cell antigen presented to them in vitro via dendritic cells (Goddard RV et al 
2001). Until ways are found to restore effective responsiveness, such attempts to use 
autologous T cells in adoptive immunotherapy will have only limited clinical value. 
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7.0 Future work 
There are a number of experiments that could further enhance the findings of this thesis. 
Replicative senescence of the aged could not explain all of the results described here but 
further study may distinguish to what extent the CLL T cell defects are related to either the 
leukaemic process or the age of the patient. Replicative senescence is associated with a 
decrease in telomere length. With each subsequent replication of a cell, the telomeres 
shorten as the chromosome divides and telomere length is therefore indicative of the cells 
replicative status. CLL B cells do not show a significant increase in telomerase activity 
compared to solid tumours or other haematological malignancies such as hairy cell 
leukaemia (Trentin Let al 1999). It would have been useful however, to have measured 
telomere length in CLL T cells to evaluate if they had reached a state of replicative 
senescence when compared to normal age matched controls. In addition, T cells that have 
reached immunosenescence are only able to undergo a certain number of population 
doublings (PDs). After they have undergone continued replication, they are unable to 
continue with any further replications. Measuring the ability of CLL T cells to undergo 
PDs in vitro would provide useful information about their replicative age and further 
determine how important a role ageing plays in the CLL T cell. 
The patient who had been in clinical remission for 6 years had a continued reduced 
expression of CD25, suggesting that the T cell defect may persist and be at least partly 
independent of the leukaemic process. Therefore, it may prove useful to study more 
patients in clinical remission with a greater array of monoclonals, in particular HLA-DR, 
as CLL patients have a significantly higher number ofT cells expressing surface HLA-DR, 
while the number of T cells expressing other activation markers were significantly 
reduced. Secretion ofiFN-y from resting T cells in patients in remission would also help to 
show if the malignant B cells were responsible for the increased IFN-y production by the T 
cells or if it is an independent CLL T cell phenomenon. 
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Determinants of IFN-y production and its consequences could also provide more 
information. More normal T cells expressed activation markers when cultured in CLL AB 
serum. It would be useful to measure IFN-y secretion from the resting T cells from the 
patient who supplied the AB serum. This may help to identify the serum factor that caused 
the increase in activation in normal T cells. Additional experiments to identify both the 
serum factor and the role of IFN-y could include the addition of neutralising antibodies to 
the cultures of normal T cells and CLL T cells in CLL AB serum. If IFN-y was present in 
the serum and did cause the increase in activation, neutralising antibodies would prevent 
this. HLA-DR expression has been associated with the presence of IFN-y. To ascertain if 
the increase in HLA-DR on CLL T cells is due to IFN-y, investigating the expression of 
HLA-DR on CLL T cells and normal T cells cultured in CLL AB serum with and without 
neutralising antibodies to IFN-y may prove interesting. Finally, repeating the initial 
experiments of cell surface expression of all antigens studied in both CLL patients and 
normal controls with CLL AB serum may show if the serum factor could mcrease 
expression ofthese in the same way it increased expression ofCD25 and CD152. 
These experiments would all help in understanding if there is a factor in CLL serum that 
prevents full activation of CLL T cells, the possible identity of this serum factor and the 
role it may play in controlling the T cells themselves in vivo. 
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FIGURE 13: Percentage of cells expressing surface antigens that were significantly different 
between patients and normals 
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FIGURE 15: Percentage of resting T cells expressing intracellular antigens in patients 
and normals 
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FIGURE 17: Percentage of CLL T ceUs expressing surface antigens after cell culture in 
CLL and normal AB serum 
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FIGURE 18: Secretion of cytokines in an MLR from patients' and normals'T cells 
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FIGURE 19: Secretion of IFN-g from resting patient and normal T cells 
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FIGURE 20: Age comparison of CD25, CD28 and CD152 expression in CLL patients 
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FIGURE 21: Age comparison of CD25, CD28 and CD152 expression in normal controls 
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FIGURE 22: Age comparison of TCR and CD4 expression in CLL patients 
100 
90 
80 
s::: 70 
0 
m 
m 60 Cl) 
... b:l c. >< Cl) 50 s::: .! 4 
'0 40 Cl) 
E 
~ 0 30 
20 
10 
0 
54 56 69 72 76 77 
Age 
Graph showing median expression of TCR and CD4 in CLL patients according to age. Although variable, data shows a subtle increase in expression of 
both with age 207 
FIGURE 23: Age comparison of TCR and CD4 expression in normal controls 
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FIGURE 24: Age comparison of LFA-1 and ICAM-1 expression in CLL patients 
100 
90 
80 
70 
c 
.2 
tn 60 tn 
C» 
.... 
Q. 
-+- LFA-1 )( 
C» 50 
c 
- ICAM-1 
.! 
"C 
C» 40 E 
~ 0 
30 
20 
10 
0 
57 65 66 76 80 
Age 
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FIGURE 25: Age comparison of LFA-1 and ICAM-1 expression in normal controls 
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FIGURE 26: Mean expression of CD25, CD28 and CD152 in CLL patients according to prior 
treatment 
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FIGURE 27: Mean expression of TCR and CD4 in CLL patients according to prior treatment 
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FIGURE 28: Mean expression of LFA-1 and ICAM-1 according to prior 
treatment 
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FIGURE 29: Mean expression of CD25, CD28 and CD152 in CLL patients according to stage 
of disease 
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FIGURE 30: Mean expression of TCR and CD4 in CLL patients according to stage of disease 
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FIGURE 31: Mean expression of LFA-1 and ICAM-1 according to stage of 
disease 
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9.0 Abbreviations 
AI CD 
AI HA 
AITP 
APC 
BCR 
bFGF 
CDK 
CDKI 
CMV 
CTLA-4 
DBM 
DC 
DLI 
EBV 
ECM 
EF 
FDC 
FISH 
FITC 
FMZ 
GC 
GM-CSF 
GVH 
GVL 
HLA-
antigen-induced cell death 
autoimmune haemolytic anaemia 
autoimmune thrombocytopenic purpura 
antigen presenting cell 
B-cell receptor 
basic fibroblast growth factor 
cyclin dependent kinase 
cyclin dependent kinase inhibitor 
cytomegalovirus 
Cytotoxic T lymphocyte antigen-4 
deleted in 8-cell malignancy 
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graft-versus-leukaemia 
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sCD8 soluble CD8 
SDF-1 stromal cell-derived factor- I 
SLVL splenic lymphoma with villous lymphocytes 
TdT terminal deoxynucleotidyl transferase 
Thl T helper 1 
TCR T cell receptor 
TECK thymus-expressed chemok.ine 
TFS treatment free survival 
TNFR tumour necrosis factor receptor 
lNF-a Tumour Necrosis Factor a 
TGF-~ Transforming growth factor I} 
TRM Transplant related mortality 
VLA very late antigen 
VCAM vascular cell adhesion molecule 
VEGF vascular endothelial growth factor 
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Summary. B-cell chronic lymphocytic leukaemia (B-CLL) is 
characterized by an accumulation of clonal malignant B 
cells. The intrinsic characteristics that permit this accumu-
lation have been extensively studied and described. How-
ever, it is possible that proliferation and survival of this 
malignant clone is facilitated by a disruption in the 
interaction between B and 1' cells that normally regulate 
the immune system. In this study. using now cytometry and 
cell culture techniques. marked abnormalities of the 
expression of certain key activation and interaction 
molecules on the peripheral blood 1' cells of patients with 
B-CLL were demonstrated. In particular, on comparison 
with normal controls, there was a marked reduction in the 
number of circulating 1' cells expressing C025 (interleukin 2 
B-cell chronic lymphocytic leukaemia (B-CLL) is character-
ized by the accumulation of malignant B cells In lymphoid 
tissue. the bone marrow and the peripheral blood. The 
pathogenesis of B-CLL is poorly understood and Is associated 
with a profound disturbance of immune regulation. In 
addition to the malignant B-cell clonal expansion, there is 
evidence that T-cell function is compromised. Morphological 
and functional abnormalities of the non-malignant T-cells 
have been confirmed in patients with B-CLL (Chiorazzi et al. 
1979; Kay et al, 1979; Han et al. 1981; Kay, 1981; Poa et a/, 
1985; Ayanlar-Batuman et al, 1986; Totterman et al. 1989; 
Peller & Kaufman, 1991; Antica et a/, 1993; Prieto et al, 
1993; Dianzani et a/, 1994; Rossi et al. 1996; Cantwell et al. 
1997; Mu et al. 199 7; Tinhofer et al. 1998; Hill et al. 1999). 
These abnormalities could theoretically be associated with 
an impaired ability to recognize and regulate normal and 
malignant B-cells. 
In the normal immune response, T-cell activation is 
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receptor) (P = 0·007). CD28 (I'= 0·01) and CD152 
(CTLA-4) (P = 0·001). There was also a reduction in the 
number of circulating T cells expressing CD4 (P = 0·03), 
COS (P = 0·05) and COlla (P = 0·01). There was no 
difference in the number expressing 1' -cell receptor ol3 
(P = 0·1), CD8 (I'= 0·4), C054 (I'= 0·4) and C0154 
(P = 0· 5), and the only marker expressed on a greater 
number of circulating T cells in B-CLL patients was HLA-DR 
(I'= 0·05). These results suggest that there is a profound T-
cell dysregulation that may contribute to the survival of the 
malignant B cells in patients with B-CLL and to the related 
autoimmune phenomena of the disease. 
Kcywonls: B-CLL, T cells, lmmunophenotyping. 
mediated by interactions between antigen presenting cells 
(APCs) such as B-cells and dendritic cells (DCs). These 
interactions involve a pathway of highly regulated events 
critical for specific activation and control of both B and T 
cells (Pig 1). A recent study has suggested that surface 
expression of C0154, the ligand for CD40. is reduced in the 
'normal' 1'-cell compartment of patients with B-CLL 
(Cantwell et al, 1997). This finding, if confirmed, would 
lend support to a role for impaired T-cell function in the 
pathogenesis of B-CLL proliferation and associated auto-
immunity. However. CD40 binding to CD 154 is only one in a 
complex series of events in T-cell activation and interaction 
with B-cells. 
When T cells encounter antigen in conjunction with 
AI'Cs. cell-cell contact is first established with these 
APCs via leucocyte function associated molecule-1 (LPA-1) 
(COlla) and inlercellular adhesion molecule-] (ICAM-1) 
(CD54) interaction, when cell binding is still non-specific 
and of low affinity as no antigen recognition has taken 
place. The LPA-1/ICAM-1 interaction is a major contributor 
to adhesion between T cells and other lymphoid cells 
(Makgoba et al. 1989; Figdo et al. 1990; Lub et al. 1995). 
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Pig I. Diugr-dm showing key hitcraction and· aCtivation markers 
betwecn-ll·and T cells. 
The binding of LFAc1 (CDHa)/lCAM-1 (CD54) allows the 
cells to· be brought into close enough contact for antigen 
recognition to take place·via the T-cell receptor (TCR)/CD3 
complex. 
The immune response continues via signalling between 
HLA antigens and the TCR. a process that.is facilitated by 
the CD3 complex and strengthened by CD4 (MHC cclass 11) 
or CD8 (MHC class I) binding. thus .triggering the T-cell 
activation cascade (llenjamini et al. 1996). Signalling 
through the TCR/CD3 complex leads to the initiation of 
key T-cell immune responses. including cytokine production 
and surface marker upregulation. The cell surface marker 
CD28 on the 'I' cells interacts with the CD80/CDS6 receptors 
on the B cells and upregulation of CD154 on the TceU leads 
to·hinding with its appropriate•ligand. ·CD40. on the ll-cell 
surface (Durie et al. 1994: Clark el al. 1996: Grewal & 
Flavell. 1996. 1997: Lenschow et al. 1996). Production of 
interleukin 2 (IL-2) is initiated and receptors for this 
cytokine (CD2 5!II,2R) are constitutively expressed approxi-
mately 4S· h post activation, facilitating recruitment of T 
cells and their .continued activation and clonal expansion 
(Waldmanri, 1986, 199.1: Taniguchi & Minami. 1993). The 
final key stage in this cascade is the ·expression of CTLA-4 
(CD152). believed to send a negative 'oiT' signal to•the Tcell 
and to control the immune response. either by terminating 
T-cell proliferation or by inducing apoptosis (Walunas 
et al. 1994: Krummel & Allison, 1995: Tivol et al. 1995: 
Schweitzcr & Sharpe, 1998). 
This study was therefore designed to examine; iJI·vitro. T · 
cells from the peripheral blood of patients with B-CLL, in five 
stages. The first was· to confirm a previous report of reduced 
T-cell CD154 expression (Cantwell et al. 1997). The second 
was .to examine expression of other key molecules involved 
in antigen recognition and T-cell activation: CD25 (IL-2R), 
CD28. CD152 (CTLA-4). TCRaJ3, CD4. CD5c-CD8 and HLA-
DR. The third was to examine the expression of the adhesion 
molecules critical for cell to cell contact'LFA-1 (CDlla) and 
ICAM-1 (CD54). The fourth stage Involved the removal. of 
the malignant ll-cell· done using magnetic bead separation 
and the subsequent stimulation of the remaining T cells for 
analysis of two key surface antigens. CD28 and CD152. The 
final stage involved depleting the B cells, stimulating with 
OKT3 and penneabillzing for analysis of internal CD25. 
CD28 and CD152. 
PATIENTS AND METHODS 
This study was approved by the local research ethics 
committee. 
Patierrls. Between September 1997 and November 1999, 
33 blood samples were taken with informed consent from 
27.patients with classic B-CLL who were either untreated or 
not treated for·the preceding 6 months (19 men and eight 
women. median age 72 years.•range 49-86 years). None of 
the patients had received purine analogues prior to this 
study. In addition. 26 control;sumples were taken from 13 
age-matched normal subjects, 
Cell isolatioJI. Peripheral blood mononuclear cells (PBMCs) 
were isolated from sodium heparin anticoagulated blood ;by 
density gradient centrifugation· with the lymphocyte separa-
tion medium Lymphoprep (Nycomed Amersham. Amer-
sham. UK). Thereafter, PBMCs were washed twice in.Roswell 
Park Memorial Institute (RPMI)-1640 medium (Gibco Life 
Technologies. Paisley, UK). counted. rcsuspended in RPMI-
1640 medium supplemented with 10% human AB sertiin 
(National Blood Transfusion Service,' llristol, UK), 
Cell culture. A controlled comparison between :the mito-
genic eiTects of phytohaemagglutinin (!'HA) and OKT3 
(anti-CD3) was carried.out for expression-of each of the cell 
surface markers. In these experiments, the most eiTective 
method of upregulating each marker was determined prior 
to data collection. PBMCs for CD28 and CD154 analysis 
were cultured for 4 h in RPMI,1640 medium (Gibco) with 
10% human AB serum at 3 7°C in 5% C02 . The culture 
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plates (Nycomed) were coated with OKT3 Oanssen-Cllag, 
High Wycombe, UK) for 2 h at room temperature at a 
concentration of 1 mg/ml in 500 ml of phosphate-buffered 
saline (PBS) per well and then washed five times in excess 
P8S prior to the addition of the cells at n concentration 
1 X 106 per well. 
P8MCs for CD25, C0152 and 1-ILA-OR analysis were 
cultured for 48 h in RPMI-1640 medium with 10% AB 
serum at 3 7"C in 5% C02• PHA (5 ~J-1) (Murex, Maidenhead, 
UK) was added to 1 x 106 cells at a final concentration of 
1 mg/ml for CD25 activation. OKT3 was used as described 
above for CD152 and HLA-OR analysis. 
B-cell depletion. Sodium heparin anticoagulated blood was 
added 1:1 with cold P8S and layered onto Lymphoprep 
as described above. Cells were resuspended in buffer 
(P8S + 2 mmol/1 EDTA: Sigma-Aldrich, Poole, UK) and 
0· 5% bovine serum albumin (8SA; Lorne Laboratories, 
Reading, UK). CD19 microbeads (Miltenyi-8iotec, 8ergisch 
Gladbach, Germany) were added at a cunccntration of 30 111 
per 1 x 107 total cells for normal controls. and between 
55 111 and 70 111 per 1 x 107 total cells for CLL patients, 
depending on the white cell count of the patient. After 
15 min at 4"C. cells were then washed in buffer and passed 
over two LS+ separation columns (Miltenyi Biotec). After 
washing. cells were plated for culture with RPMI + 10% 
human AB scrum on 24-well plates precoated with OKT3 
for 4 h and 41! h. as described above. 
Permeabiliwtion. 8 cells were depleted as described. After 
48 h activation with OKT3 as described. cells were 
harvested and washed in PBS. The cell pellet was 
resuspcnded and antibodies for the cell surface marker 
added and incubated in the dark at room temperature for 
25 min. DAKO lntrastain Reagent A (100 ~J-1) (Dako, Ely, 
UK) was added to each tube, vorlexed gently and incubated 
for 15 m in at room temperature. Cells were then washed in 
1 ml P8S. DAKO Intraslain Reagent B (100 11l) was added 
to each tube followed immediately by 10 111 of the relevant 
antibody for intracellular staining and incubated for 15 min 
In the dark at room temperature. Cells were then washed, 
resuspended in l ml P8S and analysed. 
Plow cutometru. All cells stained for antibody were 
pretreated with 20 111 of human lgG (Sigma-Aidrich) at a 
final concentration of 250 ~J.g/ml to prevent non-specific 
binding. Monocional antibody was used at 10 111 per 
1 x 106 total cells and incubated for 15 min in the dark 
at 22"C. All cells were analysed on a Coulter Epics nlite flow 
cytometer. P8MCs were stained with the pan T-cell marker 
fiuorescein isothiocyanate (FrfC)-conjugated CD2 (Serotcc, 
Kidlington. Oxford, IJK) for the analysis of phycoerythrin 
(PE)-conjugatcd CD28 (8eckman Coulter, High Wycombc. 
IJK), PE-conjugated CD154 (Ancell Corporation, Bingham, 
Nottingham, UK) or I'E-conjugated CD152 (Beckman 
Coulter). PE-con)ugated CD154 was also analysed in 
conjunction with the pan T-cell marker FITC--conjugatcd 
CD3 (Serotcc). following activation with the pan T-cell 
mitogen OKT3 (anti-CD3 antibody). I'BMCs were stained 
using the pan T-cell marker FITC-conjugated C03 (Serotec) 
for analysis of PE-conjugated CD25, HLA-DR, CD4, CDS. 
COB, LFA-1, ICAM-1 and TCRa~ (all Serotec). 
Table 1. llxpresston of cell surface markers that showed no 
significant difference between pallents and normals. 
B-CLL 
Cell type Cell marker (mean ± SD) 
CD3 
CD3 
CD3 
CD2 
TCR af\ 
CDB 
CD 54 
CD154 
77·6% ± 24·4 
(38·1- lOO%) 
34·8% ± 8·8 
(20·3-43·6%) 
41·2% ± 15·1 
(23·4-65·1 %) 
16·6% ± l4·1 
(3·6-51-4%) 
Normal 
(mean± SD) 
95·7% ± 2·2 
(93·6-98·6%) 
37·4% ± 4·3 
(32·6-42·8%) 
40·3% ± 11·9 
(19·9-54·6%) 
11·1% ± 4·5 
(5·5-18·5%) 
P-valuc 
0·1 
0·4 
0·4 
0·5 
The Mann-Whitney (Wilcoxon) comparison of medians 
was used for statistical analysis. 
RESULTS 
CD 154 expression on C/J2+ T cells 
A greater number of CD2+ T cells from patients with 8-CLL 
expressed the CD40 ligand CD1 54 than normals after 
stimulation (16·6% ± 14 vs. 11·1% ± 4. I'= 0·5), 
although this difference was not significant (Table I). The 
use of an anti-CD3 mitogen followed by an anti-C03 
monoclonal antibody may effect results previously described 
by others (Cantwcll et al. 1997). OKT3 triggers stimulation 
of T cells by binding to and occupying the CD3 receptor 
(Sgro, 199 5; Bonnefoy-Bcrard & Revillard, 1996; Reinkc 
et al. 199 7: 8rusa et al. 1998). We have shown that if a CD3 
monoclonal antibody is subsequently used to identify the T-
cell population, a false low number is obtained. OKT3 
rcccptor occupation will prevent and/or reduce C03 
monocional antibody (mAb) binding. We therefore used 
C02 as our pan T--cellmarker and subsequently showed that 
we were able to identify a greater number of T cells than 
with CD3 (81·2% ± 3·1 CD2 vs. 71·3% ± 5·6 CD3. 
p = 0·04). 
CIJ25. C/J28, C/Jl52, TCRa/3. C/J4, C/JS, C/J8 ami mA-/JR 
expression on C/J2+ T cells 
Significantly fewer T cells from B-CLL patients than normals 
expressed the markers CD25 (IL-2R) (30·7% ± 27 vs. 
76·5% ± 18. P = 0·007). CD28 (52·8% ± 23 vs. 
79·9% ± 12, I'= 0·01) and CD152 (CTLA-4) (1·9% ± 2 
vs. 15·5% ± 7. P = 0·001) after stimulation. l'ifty percent 
of 8-CLL patienls failed to express any surface CD152 
following OKT3 activation (range 0-7 · 5%), while the 
percentages of CD2+ T cells expressing C025 after activa-
tion varied greatly between patients (range 1·8-91·2%) 
(Table ll). 
In unstimulated T cells from patients with 8-CLL 
compared with those from normals, there was a significant 
reduction of the percentages of cells expressing I he cell 
surface markers CD4 (47·4% ± 27 vs. 66·2% ± 4, 
P = 0·03) and COS (85·0% ± 10 vs. 99·2% ± 1, 
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Table 11. Expression of cell surface markers U1at were significantly 
different between rmtienls am.linormuls. 
ll-CIJ, Normal 
Cell type Cell marker (mean± SIJ) (mean± SIJ) P-value 
CIJ3 HLA-IJR 90·7%.± 18·5 65·9% ± 18·7 0·05 
(63·1-100%) (6·8-89·2%) 
Cll3 CD4 47·4% ± 27·4 66·2% ± 4'9 ()-()3 
(16·6-JOO%) 58·7-71·3%) 
CD3 CD5 85·0% ± 10·4 99·2% ± 1·4 0·05 
(74·5-100%) 99·6-100%) 
CD3 CD25 30·7% ± 27·9 76·5% ± 18·4 0·007 
(I ·8-91· 2%) (43·0-95·1%) 
CD3 CD II a 77·9% ± 22·5 99·9% ± !HI8 O·U1 
(43·6-100·0%) (99·8-1 00·0% 
CD2 CD28 52·8% ± 23·2 79·9% ± 12·1 0·01 
(19·5-100%) (56·4-92·4%) 
CD2 CD152 1·9% ± 2·7 15·5% ± 7·6 0·001 
(0·0-7·5%) (fA-24-4%) 
I'= 0·05). with a wide range of expression between 
patients (Table 11). 
All hough percentages of unslimulated Cl)3+ cells from-B-
CLL patients expressing CD8 and TCI{oj3 were lower. these 
were not significant-differences (Table-1). 
In contrast. significantly greater numbers of stimulated 
CD3 + cells from B-CLL patients expressed HLA-DR com-
pared with normals (90·7% ± 18 vs. fi5·9% ± 18. 
I'= 0·05) (Table 11). 
Expression of mflresion molecules /.FA- I (CD I 1 a) wul /CAM- I 
(CD54) 
Significantly fewer T cells of patients with B-CLL expressed 
the adhesion molecule· Il'A-1 (CD 11 a) than nomwls 
(77·9% ± 22 vs. 99·9% ± 0·08. P = 0·01) (Table 11) in 
unstimulated •cells. Expression oriCAM-1 (CD 54) was not 
significantly different bet\Veen patients and nonnals 
(Table I). 
Expression of CD28 tuul CD I 52 on .,timulilled CIJ2< T cells 
after depletion of B cells 
T cells from patients with B-CLL continued to show a 
reduction in the expression of the two surface antigens 
CD28 ,(45·0% ± 19·3 vs. 88·3%:!: 8·6. I'= 0·01) and 
CD152 (6·8% ± 5·1 vs. 15·7%:!: 8·1, I'= 0·05) com-
pared with normal controls after depletion of the malignant 
CDI9+ B-cell population and stimulation.of the remaining 
cell .population (Table UI). CD19 cells were depleted from 
PBMCs and any remaining B cells were counted using 
CD20c The mean CD20 count after 13-ccll depletion was 
3 · 2% for 13-CLL patients and 2 · 3% for normal. controls. 
Expression• of intracellular CD25. CD28 wrd CD I 52 on 
stimulated nud rmstimulated CD2+ T cells after B-ceU depletiou 
After permeabilization of stimulated CIJ2+ cells. intra-
ccilular CD2H. was expressed in significantly fewer cells in 
B-CLL patients than in normals (46·2% :!: 18·0 vs. 
65·9% :!: 6·7. I'= 0·02) (Table IV). CD25 and CDl52 
Table Ill; Expression of cell surface markers on activated T cells 
following B-cell depletion. 
11-CLL Normal 
Cell type Cell marker (mean ± SD) (mean ± SD) /'-value 
CD2 
C02 
CD28 
CD152 
45·0% ± 19·3 88·3% ± 8·6 0·01 
6·8%±5·1 15·7% ± 8·1 0·05 
positivity were also reduced on stimulated T cells. hut riot 
significantly. In contrust, significantly more unstimulated 
CD2+ cells from CLL patients expressed intracellular CD25 
(7·3% ± 3·3 vs. 3·3%:!: 2·2, P = 0·01) and intracellular 
CD152 (9·2% ± 4·1 vs. 5·4% ± 2·6. P = 0·03) than 
normals. Intracellular CD2!! positivity was reduced in 
unstimulated C02 + cells from CLL patients. but this 
difference was not significant. 
When levels of intracellular CD25, CD28 and CD152 
were compared in activated and unactivated cells in 
nonnals and patients. there was a significant difference 
seen in the expression of CD25 and.CD152 after activation. 
In contrast. levels of CD28 were not significantly different in 
either patients or controls after activation. 
DISCUSSION 
These results suggest that the circulating T-cell compart-
ment in the peripheral blood is profoundly dysregulated in 
patients with B-CU,. Expression of key cell surface activation 
and interaction markers is markedly reduced after activa-
tion. with the exception of HLA-DR and CD154. the ligand 
for B-ccll CD40. Each of the key markers discussed here 
plays a major role in stimulating not only the T cell on 
which it is expressed. but also in the activation of and 
interaction \\~th many other key immune responders. The 
complete lack of expression 'of surface CD 152 (CTLA-4) ·on 
the circulating T cells of-half the patients with 13-Cf.J,. the 
persistence of its reduced expression after B-cell depletion 
and the increased intracellular expression in unstimulated 
cells are of interest. CDJ•52 plays a pivotal role in immune 
regulation by effectively providing a negative feedback 
("switch-oiT") signal to the T cell once an immune response 
has been initiated and completed (Walunas et al. 1994: 
Krumniel el al. 1995; Tivol et al, 1995: Schweilzer & 
Sharpe. 1998). 
The finding of increased expression intracellularly in 
unstimulated cells suggests that these T cells may be in a 
partial stale of activation. yet are unable to effectively 
express the antigen or signal externally. Without the 
external expression. failure to 'switch off" the T-cell 
compartment cotild lead to the 'survival of a clone of T 
cells in this partial slate 'or activation. able ·to make weak 
immune responses; 'possibly against self-antigen, yet unable 
to mount an effective response ·to known T-cell mitogens. 
CD 152 knock-out mice display a clinical and pathological 
syndrome that is similar to that seen in the B-CI.J, patient 
(Tivol.et al. 1995). This includes spontaneous lymphopro-
liferative disease with lymphocytic infiltrates in many 
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Table IV. Expression of Intracellular markers following B-cell 
depletion and penneabilixation. 
A. Stimulated cells 
B-CLL Normal 
Cell type Cell marker (mean ±SD) (mean ±SD) P-value 
CD2 CD25 46·8% ± 11·1 55·2% ± 17·9 0·2 
CD2 CD28 46·2% ± 18·0 65·9% ± 6·7 0·02 
CD2 CDI52 56·1% ± 14·4 67·3% ± 6·9 0·07 
B. Unstimulatcd cells 
B-CU. Normal 
Cell type Cell marker (mean ±SD) (mean± SD) P-vulue 
C02 CD25 7·3% ± 3·3 3·3% ± 2·2 0·01 
C02 CD28 44·4% ± 14·2 54·6% ± 18·5 0·1 
C02 CD I 52 9·2%±4·1 5·4% ± 2·6 0·03 
tissues. splenomegaly. lymphadenopathy and higher rates of 
autoimrnune phenomena than in C0152+ mice .. Pailure to 
complete aT-cell response or a continued partial response to 
malignant B-cell antigens could facilitate their proliferation 
in these mice and in human subjects. The lack of expression 
of CD152 may result in a failure to delete autoreactive 'I' 
cells or prevent antigen-specific apoptosis of activated T 
cells. Anderson et al (2000) have recently shown that, if T 
cells are not fully activated or the TCR signal is weak, 
blockade of CD152 paradoxically inhibits immune 
responses. The lack of expression of CD152 demonstrated 
in the CLL T cells may equate to blockade in this respect. 
Reduced expression of surface and intracellular CD28 
afier activation suggests a relative inability to interact 
effectively with any cell that expresses the CD28 ligands 
C080 and CD86, including B cells, and thus an impaired 
ability to promote antigen presentation and processing. 
Cell-cell adhesion may also be impaired because of reduced 
expression of LFA-1 (COlla). A reduced expression of 
surface CD25 after activation suggests a relative inability to 
respond to 11-2 and, thus. an impaired ability to control '1'-
cell activation. However. an increased expression of 
intracellular C025 in unstimulated 'I' cells correlates with 
the finding of increased internal CD152. Both results imply 
that the T cells are in a partially activated state. Reduced 
expression of C04 implies that the initial activation signal 
generated by MHC class fi antigen presentation through the 
CD3/TCR/CD4 complex on the T-cell surface may be 
weakened. although reduction in expression of TCRof3 is 
not statistically significant. CD4 plays an important role in 
both adhesion between B and T cells and also in generating 
unique and rapid signals to the cell nucleus for activation 
(Benjamini et al. 1996). A reduction or absence of this 
antigen may impair or prevent transmission of signals forT-
cell activation. 
In contrast to our findings of reduced expression of these 
markers and to the findings of others (Cantwell et al. 1997). 
we have shown that surface CD154 (CD40L) is expressed 
equally on T cells in normal subjects and B-CLL patients. By 
using CD2 as the pan T -cell marker afier activation instead 
of CD3. we may have included T cells that would not have 
been detected owing to CDJ receptor occupation by OKT3 or 
other anti-CD3 activators. OKT3 is believed to occupy and 
modulate the CD3 antigen and to either become endocy-
tosed into the cell or block the receptor, preventing antibody 
binding and thus reducing the total number of T cells that 
will stain positively with CD3 (Sgro. 1995; Bonnefoy-Berard 
& Revillard. 1996; Reinke et al, 1997; Brusa et al, 1998). 
We have also shown that HLA-DR is expressed on 
significantly more 'I' cells in B-CLL patients than in normal 
controls. This anomaly of normal or increased expression of 
CD154 and HLA-DR compared with reduced expression of 
the other antigens in the activation pathway requires 
further investigation. 
These abnormalities of cell surface antigen expression on 
B-CLL T cells are not altered by depletion of the malignant B-
cell clone. This implies that either the effect of the malignant 
cells is long-lived or that the T-cell abnormality is a primary 
one. The former explanation is the more probable. suggest-
ing a chronic but not necessarily irreversible dysfunction of 
the '1'-cell compartment. Studies are currently underway to 
address this question. 
ACKNOWLEDGMENTS 
This work was supported by grants from the Cornwall 
Leukaemia Trust and the Plymouth and District Leukaemia 
rund. We thank Dr Anton Kruger for his encouragement 
and support, Nick Hurlock for excellent technical assistance 
and Or Adrion Copplestone for patient selection. 
REFERENCES 
Anderson. D.E .. Biegnnowska. K.D .. Bar-Or. A .. Oliveira. H.M.L .. 
Carreno. B .. Collins. M. & Hafler. D.A. (2000) Paradoxical 
inhibition of T-cell function In response to CIT.A-4 blockade; 
heterogeneity within the human T-cell population. Nature 
Medicine. 6. 211-214. 
Antica. M .. Kusic, R .. Spaventi. R .. )aksic, B. & Vitale. B. (1993) 
Functional diiTerences of T cells in B-chronic lymphocytic 
leukaemia. l.eukemia ami Lymphoma. 9. 133-140. 
Ayanlar-Baluman. 0 .. llbert. H. & Hauptman. S. (1986) Defective 
interleukin-2 production and responsiveness toT cc.lls in patients 
with chronic lymphocytic leukaemia of ll ceU variety. Blood. 67. 
279-284. 
Beniamini. ll .. Sunshine. G. & Leskowitz. S. (1996) Immunology, 11 
Short Course. 3rd edn, pp. 199-202. Wiley-Liss. New York. 
Bonnefoy-llerard. N. & ReviUard. ).P. (1996) Mechanisms of 
immunosuppression induced by anllthymocyte globulins and 
OKT3. journal of 1/rart and l.wrg Tmnsplantatiorr. IS. 435-442. 
Urusa. 1~. Casullo. R .. Dosio, F .. Cattel. L .. Bcllramini. S .. Chiapctta. 
R .. Tosetti. L .. Andorno. ll. & Salizzoni. M. (1998) OKT3 
monitoring in the treatment or steroid-resistant acute rejection 
of hepatotransplanl recipients. lluropcan journal of Dnrg Metabt>-
lisrrr ami Pharrrrokinetlcs. 23. 301-306. 
CanlweU, M .. Hua. T .. Pappas. 1. & Kipps. T. (1997) Acquired CD40-
Iigand deficiency in chronic lymphocytic leukaemia. N11ture 
Mediciue. 3. 984-989. 
ChioraZ'll. N .. Pu. S.P .. Montazeri. G .. Kunkel. H.G .. Rai. K. & Gee. T. 
«:> 2001 Plymouth Postgraduate Medical School. llrillslr journal of llaematoloay 112: 959-964 
964 S. Scriveuer et al 
(1979) Tccll helper de[ect in patients "1th chronic lymphocytic 
leukaemia. ]ournal·of.lmnumoloml 122. 108 7 -109!i, 
Clark. L.B .. l'oy. 1: & Noclle, R.]. ( 1996) CD40 and its Ugand. 
Advances)n Im1111111Diom1 63. 43-78. 
Dianzani, U .. Omcde. P., Marmont. E. Dil'ranco, ll, Fusaro. D. & 
Jlragardo, M. ( 1994) l!xpansion o[ T cells expressing low CD4 or 
CD8. levels in B-ceU chronic lymphocyilc leukaemia:, correlation 
with disease status andlneoplaslic phenotype. Blood. 83, 2198-
2205. 
Durie. F.H .. Foy. T.M .. Masters. S.R .. Laman. ].D. & Noelle, R.J. 
( 1994) The role or CD40 in the regulation o[• humoral and cell-
mediated immunity. lllllllllllology Today. 15. 406-410. 
Figdo. C. G .. van Kooyk. Y. & Keizer. G. D. ( 1990) On the mode or 
action o[ U'A-1. Immunology Trnla11 11. 277-280. 
Poa. R .. Giovarelli, M .. Jemma, C .. l'icrro. M.T, Lusso. P .. Ferrando. 
M.L,, Laurio. E & Forni. G. (1985) lnterleukin-2 (JL 2) and 
iriter[eion-'Y production by T lymphorytcs [rom patients with B, 
chronic. lymphocytic. leukaemia: evidence that normally released 
JL-2 is absorbed .by the neoplastic ll cell population. lllood. fifi, 
614-618. 
Grewal. I.S' & Plavell. R.A. (1996) A central role o[·CD40 ligand in 
the regulation of CD4+ T-ccll· responses. lmrmmoloou 1'orlll!~ 17. 
410-414. 
Grcwal. I.S. & Flavell. R.A. (1997) The CD40 Ligand: at the centcr 
or the·imml:lne universe? ImmunolOIJic Rcsearcll. 16, 59!...70. 
Han. T. Ozer. 11., llenderson. ll.S .. Dadey. B .. Nussbaum-Biumen-
son. 1\. & Barcos. M. (1981) De[ective immunoregulatory in T-cell 
function in chronic lymphoq1ic leukaemia. Bloorl. 58, 1182-
1189. 
Hill. S.] .. Peters, S.H .. Aylillc. M.J .. Merceica, J. & Ransal. A.S. ( 1999) 
Reduced IIA and inter[eron--y (li'N-"() expression by Cll4 T cells 
in patients with chronicJiymphocytic leukaemia; ClirJiml E.rpcri-
rnenltll lmmwwlogy. 1117. H-11. 
Kay. N. (1981) Abnormal T-cell subpopulallon [unction in CLL: 
excessive suppressor ('I'"Y) and deficient helper (TfJ.) acti\•ity with 
respect to B-cell proll[erallon. Blood. 57. 418-420. 
Kay. N .. Johnson. ].D .. Stnnek. R. &. Douglas. S.D. (I '179) T-cell 
subpopulations In chronic lymphocytic leukaemia: abnomtalities 
in distribution and in vitro receptor matUralioil. Blood. 54. 540-
543. 
Krummel. M.P. & Allison, J.P. ( 1995) CD28 and Cll.A-4 have 
opposing-effects oD the response ofT cells to stimuletdon.fourrwl 
of llxJ>erimeuUrl Medieiue. 182, 459-465. 
Lenschow. D.] .. Walunas. 1:L. & lllucstonc, ]:A. (1990) CD28/B7 
system ofT cell costimulation. Ar~n1ml Review of Imniu1rology. 14, 
233-258: ' 
Lub. M .. van·Kooyk. Y. & Figdo, C.G. (1995) Ins and outs o[LFA-1. 
lnununology Todny. 16, 479-484. 
Makgoba, M.W:. Sanders. M.E. & Shaw. S. (1989) The CD2-'r.J.'A-3 
and LPA-1-ICAM-1 pathways: relevance to T-cell recognition. 
l1111mmology Todny. 10, 417-422. 
Mu. X .. Kay, N .. Gosland, M. & Jennings, C. (1997) Analysis o[blood 
T-ccU cylokinc expression lil B-chronic lymphocytic leukaemia: 
evidence for increased !cvcls of cytoplasmic lL-4 in resting and 
activated CD8 T cells, llrilisiJ ]mmml of llnemntology. 96. 733-
735. 
Pcller. S, & Kau[man, S. ( 1991) Decreased L'Ll45RA 'I' cells in ll-ccll 
chronic lymphatic leukaemia patients: correlation with disease 
stage. Blood: 78. 1569-1573. 
Prieto, A .. Garcia-Suarez. ],. Reyes. ll.. Lapcnn. P.. Hcrnandez. M, & 
Alvarez-Mon, ~L (1993) Diminished DNA synthesis in T cells 
from B chronic lymphocytic leukaemia afier phytohaemaggluti-
njn, anti·CDJ and phorbol myristate acetate mitogenic signals. 
l>.tperimeutnl He11111tology. 21. 15(,3-1569. 
Reinke. P., Schwimer. 11 .. Hontch. C .. Ode-llnkin. C .. Dockc. W.D .. 
I' rei. IJ. & Yolk. H.D. ( 199 7) Selective in vivo deletion or 
alloactivated TH I cells by OKT3 monoclonal antibody in acute 
rejection. lmnumology Lerters. 57. 151-153. 
Rnssi, E .. Matutcs. H .. Morilla. R .. Owusu-Ankomah. K .. Hellernan. 
A. & Catovsky. D. (1996) 7..cta chain and CD28 are poorly 
expressed on T lymphocytes from chronic lymphocytic leukac· 
mia, l.euk11enrin. 10. 494-497. 
Schweitzer. A.N. & Sharpc. A.H. (1998) The complexity o[ the B7-
CD28/t.ILA-4 eo- stimulatory pathway. Aycuts nml Actions 
Supplemcn!s. 49, 33-43. 
Sgro. C. (199 5) Side-<:ITects or a monoclonal antibody, muromonab 
CD3/ort hoclone OICI'3: bibliographic review. Toxicology. 105. 23-
29. 
'lomiguchi. T. & Minaml. Y. (1993) The'llr21llr2 rcceptor system: a 
.current overview. Cell. 73, 5-H. 
'l'inho[er. 1.. Marschitz. 1:, Kos. M .. Herm. '1' . .' Egle, A., Villunger. A. & 
Greil. R. (1998) Dillerential sensitivity o[ CD4+ w'd Cl)R+ T 
lympliocytes to· the killing, efficacy o[ Pas (Apo-I/CD9 5) ligand 
tumour cells in B chronic lymphocytic leukaemia. Blootl. 91. 
4273-4281. 
Tivol. E.A .. Borriello. F .. Schweitzer. A.N .. Lynch. W.P.. Bluestone. 
].A. & Sharpe. A.ll. ( 1989) lms o[ CI'I"'\-4 leads to massive 
lymphoprolireralion and rata! rp.ulti-orn•m tissue destruction. 
n;wcaling h critical ncgaHv~ regulatory role of CI'L.A-4. lnuiumUn. 
3. 541-547. 
Totterman. T.ll.. Carlsson. AL Simonsson. n.. llengtsson. ~t f!i. 
Nilsson. K. ( 1989) '1'-ccll activation and subset patterns are 
altered in B-CLL and correlate with the swge o[ the disease. lllood, 
2. ~86-ZY2. 
Waldmann, 'f, (1986) The structure. [unciion and expression or 
interleukln-2 receptors on nonnal and malignant lymphocytes. 
Science. 232. 727-732. 
Woldmann. 'I' (1991) The lnterleukin-2 receptor. ]ormuil of 
lliologiccrl Cl1mristry. 266. 2681-2684. 
Walunas. 't:L., Lenschow. D.] .. Bakker. C.Y .. Linsley. I~S .. Freeman. 
G.] .. Green, J.M .. Thompson. C.B: & Bluestone, I•A. (1994) Cl'LA-
4 can function as a. negative regulator of T cell activation. 
Immrmil!l I. 405-413. 
© 2001 Plymouth Postgraduate Medical School. ·British.]ormml of• Haematology 112: 959-964 
